Regulation of breast cancer metastasis signaling by miRNAs

1.

Vieira, A. F., & Schmitt, F. (2018). An update on breast cancer multigene prognostic tests—emergent clinical biomarkers. [Review]. Front Med (Lausanne), 5, 248. https://doi.org/10.3389/fmed.2018.00248.CrossRef

2.

Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: a review. JAMA, 321(3), 288–300. https://doi.org/10.1001/jama.2018.19323.CrossRefPubMed

3.

van Hellemond, I. E. G., Geurts, S. M. E., & Tjan-Heijnen, V. C. G. (2018). Current status of extended adjuvant endocrine therapy in early stage breast cancer. Curr Treat Options Oncol, 19(5), 26. https://doi.org/10.1016/j.ctrv.2017.02.005.CrossRefPubMedPubMedCentral

4.

Nourmoussavi, M., Pansegrau, G., Popesku, J., Hammond, G. L., Kwon, J. S., & Carey, M. S. (2017). Ovarian ablation for premenopausal breast cancer: a review of treatment considerations and the impact of premature menopause. Cancer Treat Rev, 55, 26–35. https://doi.org/10.1016/j.ctrv.2017.02.005.CrossRefPubMed

5.

Mathew, A., & Davidson, N. E. (2015). Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer. Breast, 24, S120–S125. https://doi.org/10.1016/j.breast.2015.07.027.CrossRefPubMed

6.

Burstein, H. J., Lacchetti, C., Anderson, H., Buchholz, T. A., Davidson, N. E., Gelmon, K. E., et al. (2016). Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol, 34(14), 1689–1701. https://doi.org/10.1200/JCO.2015.65.9573.CrossRefPubMed

7.

Steeg, P. S. (2016). Targeting metastasis. [Review article]. Nat Rev Cancer, 16, 201. https://doi.org/10.1038/nrc.2016.25.CrossRefPubMedPubMedCentral

8.

Clarke, R., Tyson, J. J., & Dixon, J. M. (2015). Endocrine resistance in breast cancer – an overview and update. Molecular and Cellular Endocrinology., 418(Part 3), 220–234. https://doi.org/10.1016/j.mce.2015.09.035.

9.

Ignatov, A., Ignatov, T., Roessner, A., Costa, S., & Kalinski, T. (2010). Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat, 123(1), 87–96. https://doi.org/10.1007/s10549-009-0624-6.CrossRefPubMed

10.

Muluhngwi, P., & Klinge, C. M. (2015). Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer, 22(5), R279–R300. https://doi.org/10.1530/erc-15-0355.CrossRefPubMedPubMedCentral

11.

Muluhngwi, P., & Klinge, C. M. (2017). Identification of miRNAs as biomarkers for acquired endocrine resistance in breast cancer. Mol Cell Endocrinol, 456, 76–86. https://doi.org/10.1016/j.mce.2017.02.004.CrossRefPubMed

12.

Jeselsohn, R., De Angelis, C., Brown, M., & Schiff, R. (2017). The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer. Curr Oncol Rep, 19(5), 35. https://doi.org/10.1007/s11912-017-0591-8.CrossRefPubMed

13.

Toy, W., Weir, H., Razavi, P., Lawson, M., Goeppert, A. U., Mazzola, A. M., et al. (2017). Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov, 7(3), 277–287. https://doi.org/10.1158/2159-8290.cd-15-1523.CrossRefPubMed

14.

Chandarlapaty, S., Chen, D., He, W., et al. (2016). Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the bolero-2 clinical trial. JAMA Oncol, 2, 1310–1315. https://doi.org/10.1001/jamaoncol.2016.1279.CrossRefPubMedPubMedCentral

15.

Xu, G., Chhangawala, S., Cocco, E., Razavi, P., Cai, Y., Otto, J. E., et al. (2020). ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer. Nat Genet. https://doi.org/10.1038/s41588-019-0554-0.

16.

BenAyed-Guerfali, D., Dabbèche-Bouricha, E., Ayadi, W., Trifa, F., Charfi, S., Khabir, A., et al. (2019). Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer. Mol Biol Rep, 46(3), 3247–3255. https://doi.org/10.1007/s11033-019-04784-w.CrossRefPubMed

17.

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., et al. (2016). Palbociclib and letrozole in advanced breast cancer. N Engl J Med, 375(20), 1925–1936. https://doi.org/10.1056/NEJMoa1607303.CrossRefPubMed

18.

Ayyagari, R., Tang, D., Patterson-Lomba, O., Zhou, Z., Xie, J., Chandiwana, D., et al. (2018). Progression-free survival with first-line endocrine-based therapies among postmenopausal women with HR+/HER2− metastatic breast cancer: a network meta-analysis. Clin Ther, 40(4), 628–639.e623. https://doi.org/10.1016/j.clinthera.2018.03.004.CrossRefPubMed

19.

Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., et al. (2018). Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102. J Clin Oncol. https://doi.org/10.1200/JCO.2017.76.9331.

20.

Rugo, H. S., Turner, N. C., Finn, R. S., Joy, A. A., Verma, S., Harbeck, N., et al. (2018). Palbociclib plus endocrine therapy in older women with HR+/HER2− advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies. Eur J Cancer, 101, 123–133. https://doi.org/10.1016/j.ejca.2018.05.017.CrossRefPubMed

21.

Giuliano, M., Schettini, F., Rognoni, C., Milani, M., Jerusalem, G., Bachelot, T., et al. (2019). Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol, 20(10), 1360–1369. https://doi.org/10.1016/s1470-2045(19)30420-6.CrossRefPubMed

22.

Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., et al. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med, 380(20), 1929–1940. https://doi.org/10.1056/NEJMoa1813904.CrossRefPubMed

23.

Markham, A. (2019). Alpelisib: first global approval. Drugs, 79(11), 1249–1253. https://doi.org/10.1007/s40265-019-01161-6.CrossRefPubMed

24.

O'Shaughnessy, J., Thaddeus Beck, J., & Royce, M. (2018). Everolimus-based combination therapies for HR+, HER2− metastatic breast cancer. Cancer Treat Rev, 69, 204–214. https://doi.org/10.1016/j.ctrv.2018.07.013.CrossRefPubMed

25.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., et al. (2019). Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor-positive metastatic breast cancer: the MANTA phase 2 randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.2526.

26.

Klinge, C. M. (2018). Non-coding RNAs in breast cancer: intracellular and intercellular communication. Noncoding RNA, 4(4), 40. https://doi.org/10.3390/ncrna4040040.CrossRefPubMedCentral

27.

Klinge, C. M. (2018). Non-coding RNAs: long non-coding RNAs and microRNAs in endocrine-related cancers. Endocr Relat Cancer, 25(4), R259–R282. https://doi.org/10.1530/ERC-17-0548.CrossRefPubMed

28.

Cech, T. R., & Steitz, J. A. (2014). The noncoding RNA revolution—trashing old rules to forge new ones. Cell, 157(1), 77–94. https://doi.org/10.1016/j.cell.2014.03.008.CrossRefPubMed

29.

Meldolesi, J. (2018). Exosomes and ectosomes in intercellular communication. Curr Biol, 28(8), R435–R444. https://doi.org/10.1016/j.cub.2018.01.059.CrossRefPubMed

30.

Sun, Z., Yang, S., Zhou, Q., Wang, G., Song, J., Li, Z., et al. (2018). Emerging role of exosome-derived long non-coding RNAs in tumor microenvironment. Mol Cancer, 17(1), 82. https://doi.org/10.1186/s12943-018-0831-z.CrossRefPubMedPubMedCentral

31.

Madak-Erdogan, Z., Band, S., Zhao, Y. C., Smith, B. P., Kulkoyluoglu-Cotul, E., Zuo, Q., et al. (2019). Free fatty acids rewire cancer metabolism in obesity-associated breast cancer via estrogen receptor and mTOR signaling. Cancer Res, 79(10), 2494. https://doi.org/10.1158/0008-5472.CAN-18-2849.CrossRefPubMed

32.

Walsh, H. R., Cruickshank, B. M., Brown, J. M., & Marcato, P. (2019). The flick of a switch: conferring survival advantage to breast cancer stem cells through metabolic plasticity. Front Oncol, 9, 753. https://doi.org/10.3389/fonc.2019.00753.CrossRefPubMedPubMedCentral

33.

San-Millán, I., Julian, C. G., Matarazzo, C., Martinez, J., & Brooks, G. A. (2020). Is lactate an oncometabolite? Evidence supporting a role for lactate in the regulation of transcriptional activity of cancer-related genes in MCF7 breast cancer cells. [Original research]. Front Oncol, 9, 1536. https://doi.org/10.3389/fonc.2019.01536.CrossRefPubMedPubMedCentral

34.

Blücher, C., & Stadler, S. C. (2017). Obesity and breast cancer: current insights on the role of fatty acids and lipid metabolism in promoting breast cancer growth and progression. [Mini review]. Front Endocrinol, 8, 293. https://doi.org/10.3389/fendo.2017.00293.CrossRef

35.

Kozomara, A., & Griffiths-Jones, S. (2014). miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res, 42(Database issue), D68–D73. https://doi.org/10.1093/nar/gkt1181.CrossRefPubMed

36.

Alles, J., Fehlmann, T., Fischer, U., Backes, C., Galata, V., Minet, M., et al. (2019). An estimate of the total number of true human miRNAs. Nucleic Acids Res, 47(7), 3353–3364. https://doi.org/10.1093/nar/gkz097.CrossRefPubMedPubMedCentral

37.

Watanabe, T., & Lin, H. (2014). Posttranscriptional regulation of gene expression by Piwi proteins and piRNAs. Mol Cell, 56(1), 18–27. https://doi.org/10.1016/j.molcel.2014.09.012.CrossRefPubMedPubMedCentral

38.

Friedman, R. C., Farh, K. K., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome Res, 19(1), 92–105. https://doi.org/10.1101/gr.082701.CrossRefPubMedPubMedCentral

39.

Drusco, A., & Croce, C. M. (2017). Chapter one - microRNAs and cancer: a long story for short RNAs. In C. M. Croce & P. B. Fisher (Eds.), Advances in cancer research (135th ed., pp. 1–24). Cambridge: Academic.

40.

Saini, H. K., Griffiths-Jones, S., & Enright, A. J. (2007). Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci, 104(45), 17719–17724. https://doi.org/10.1073/pnas.0703890104.CrossRefPubMedPubMedCentral

41.

Wang, Z.-Y., & Yin, L. (2015). Estrogen receptor alpha-36 (ER-α36): a new player in human breast cancer. Mol Cell Endocrinol, 418, 193–206. https://doi.org/10.1016/j.mce.2015.04.017.CrossRefPubMed

42.

Li, X., Liu, X., Xu, W., Zhou, P., Gao, P., Jiang, S., et al. (2013). c-MYC-regulated miR-23a/24-2/27a cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting Sprouty2. J Biol Chem, 288(25), 18121–18133. https://doi.org/10.1074/jbc.M113.478560.CrossRefPubMedPubMedCentral

43.

Almeida, M. I., Reis, R. M., & Calin, G. A. (2010). MYC-microRNA-9-metastasis connection in breast cancer. Cell Res, 20(6), 603–604.PubMed

44.

Daugaard, I., & Hansen, T. B. (2017). Biogenesis and function of Ago-associated RNAs. Trends Genet, 33(3), 208–219. https://doi.org/10.1016/j.tig.2017.01.003.CrossRefPubMed

45.

Klinge, C. M. (2015). miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets. Mol Cell Endocrinol, 418, 273–297. https://doi.org/10.1016/j.mce.2015.01.035.CrossRefPubMedPubMedCentral

46.

Sheng, P., Fields, C., Aadland, K., Wei, T., Kolaczkowski, O., Gu, T., et al. (2018). Dicer cleaves 5′-extended microRNA precursors originating from RNA polymerase II transcription start sites. Nucleic Acids Res, 46(11), 5737–5752. https://doi.org/10.1093/nar/gky306.CrossRefPubMedPubMedCentral

47.

Khan, S., Greco, D., Michailidou, K., Milne, R. L., Muranen, T. A., Heikkinen, T., et al. (2014). MicroRNA related polymorphisms and breast cancer risk. PLoS One, 9(11), e109973. https://doi.org/10.1371/journal.pone.0109973.CrossRefPubMedPubMedCentral

48.

Hata, A., & Kashima, R. (2016). Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol, 51(3), 121–134. https://doi.org/10.3109/10409238.2015.1117054.CrossRefPubMed

49.

Alarcón, C. R., Goodarzi, H., Lee, H., Liu, X., Tavazoie, S., & Tavazoie, S. F. (2015). HNRNPA2B1 is a mediator of m6A-dependent nuclear RNA processing events. Cell, 162(6), 1299–1308. https://doi.org/10.1016/j.cell.2015.08.011.CrossRefPubMedPubMedCentral

50.

Alarcón, C. R., Lee, H., Goodarzi, H., Halberg, N., & Tavazoie, S. F. (2015). N6-methyladenosine marks primary microRNAs for processing. [Letter]. Nature, 519(7544), 482–485. https://doi.org/10.1038/nature14281.CrossRefPubMedPubMedCentral

51.

Hock, J., & Meister, G. (2008). The Argonaute protein family. Genome Biol, 9(2), 210. https://doi.org/10.1186/gb-2008-9-2-210.CrossRefPubMedPubMedCentral

52.

Pitchiaya, S., Heinicke, L. A., Park, J. I., Cameron, E. L., & Walter, N. G. (2017). Resolving subcellular miRNA trafficking and turnover at single-molecule resolution. Cell Rep, 19(3), 630–642. https://doi.org/10.1016/j.celrep.2017.03.075.CrossRefPubMedPubMedCentral

53.

Kobayashi, H., & Tomari, Y. (2016). RISC assembly: coordination between small RNAs and Argonaute proteins. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1859(1), 71–81. https://doi.org/10.1016/j.bbagrm.2015.08.007.CrossRef

54.

Kourtidis, A., & Anastasiadis, P. Z. (2018). Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol, 54, 30–36. https://doi.org/10.1016/j.ceb.2018.03.001.CrossRefPubMedPubMedCentral

55.

Meyer, K. D., & Jaffrey, S. R. (2014). The dynamic epitranscriptome: N6-methyladenosine and gene expression control. [Review]. Nat Rev Mol Cell Biol, 15(5), 313–326. https://doi.org/10.1038/nrm3785.CrossRefPubMedPubMedCentral

56.

Licht, K., & Jantsch, M. F. (2016). Rapid and dynamic transcriptome regulation by RNA editing and RNA modifications. J Cell Biol, 213(1), 15–22. https://doi.org/10.1083/jcb.201511041.CrossRefPubMedPubMedCentral

57.

Wu, L., Wu, D., Ning, J., Liu, W., & Zhang, D. (2019). Changes of N6-methyladenosine modulators promote breast cancer progression. BMC Cancer, 19(1), 326. https://doi.org/10.1186/s12885-019-5538-z.CrossRefPubMedPubMedCentral

58.

Zhou, J., Allred, D. C., Avis, I., Martinez, A., Vos, M. D., Smith, L., et al. (2001). Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat, 66(3), 217–224. https://doi.org/10.1023/a:1010631915831.CrossRefPubMed

59.

Hu, Y., Sun, Z., Deng, J., Hu, B., Yan, W., Wei, H., et al. (2017). Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway. Tumour Biol, 39(3), 1010428317694318. https://doi.org/10.1177/1010428317694318.CrossRefPubMed

60.

Gyorffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., et al. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat, 123(3), 725–731. https://doi.org/10.1007/s10549-009-0674-9.CrossRefPubMed

61.

Klinge, C. M., Piell, K. M., Tooley, C. S., & Rouchka, E. C. (2019). HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells. Sci Rep, 9(1), 9430. https://doi.org/10.1038/s41598-019-45636-8.CrossRefPubMedPubMedCentral

62.

Pawłowska, E., Szczepanska, J., & Blasiak, J. (2017). The long noncoding RNA HOTAIR in breast cancer: does autophagy play a role? Int J Mol Sci, 18(11), 2317. https://doi.org/10.3390/ijms18112317.CrossRefPubMedCentral

63.

Meredith, E. K., Balas, M. M., Sindy, K., Haislop, K., & Johnson, A. M. (2016). An RNA matchmaker protein regulates the activity of the long noncoding RNA HOTAIR. RNA, 22(7), 995–1010. https://doi.org/10.1261/rna.055830.115.CrossRefPubMedPubMedCentral

64.

Liu, Y., Li, H., Liu, F., Gao, L.-B., Han, R., Chen, C., et al. (2020). Heterogeneous nuclear ribonucleoprotein A2/B1 is a negative regulator of human breast cancer metastasis by maintaining the balance of multiple genes and pathways. EBioMedicine, 51, 102583. https://doi.org/10.1016/j.ebiom.2019.11.044.CrossRefPubMedPubMedCentral

65.

Zhang, X., Wu, M., Chong, Q.-Y., Zhang, W., Qian, P., Yan, H., et al. (2018). Amplification of hsa-miR-191/425 locus promotes breast cancer proliferation and metastasis by targeting DICER1. Carcinogenesis, 39(2), 1506–1516. https://doi.org/10.1093/carcin/bgy102.CrossRefPubMed

66.

Nagpal, N., Ahmad, H. M., Molparia, B., & Kulshreshtha, R. (2013). MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis, 34(8), 1889–1899. https://doi.org/10.1093/carcin/bgt107.CrossRefPubMed

67.

Nagpal, N., Ahmad, H. M., Chameettachal, S., Sundar, D., Ghosh, S., & Kulshreshtha, R. (2015). HIF-inducible miR-191 promotes migration in breast cancer through complex regulation of TGFβ-signaling in hypoxic microenvironment. Sci Rep, 13(5), 9650. https://doi.org/10.1038/srep09650.CrossRef

68.

Rodriguez-Barrueco, R., Nekritz, E. A., Bertucci, F., Yu, J., Sanchez-Garcia, F., Zeleke, T. Z., et al. (2017). miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes Dev, 31(6), 553–566. https://doi.org/10.1101/gad.292318.116.CrossRefPubMedPubMedCentral

69.

Selever, J., Gu, G., Lewis, M. T., Beyer, A., Herynk, M. H., Covington, K. R., et al. (2011). Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res, 17(20), 6510–6521. https://doi.org/10.1158/1078-0432.ccr-11-1403.CrossRefPubMedPubMedCentral

70.

Conger, A. K., Martin, E. C., Yan, T. J., Rhodes, L. V., Hoang, V. T., La, J., et al. (2016). Argonaute 2 expression correlates with a luminal B breast cancer subtype and induces estrogen receptor alpha isoform variation. Noncoding RNA, 2(3), 8. https://doi.org/10.3390/ncrna2030008.CrossRefPubMedCentral

71.

Casey, M. C., Prakash, A., Holian, E., McGuire, A., Kalinina, O., Shalaby, A., et al. (2019). Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer. BMC Cancer, 19(1), 712. https://doi.org/10.1186/s12885-019-5884-x.CrossRefPubMedPubMedCentral

72.

Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y., & Deuel, T. F. (2005). Identification, cloning, and expression of human estrogen receptor-[alpha]36, a novel variant of human estrogen receptor-[alpha]66. Biochem Biophys Res Commun, 336(4), 1023–1027. https://doi.org/10.1016/j.bbrc.2005.08.226.CrossRefPubMed

73.

Omarjee, S., Jacquemetton, J., Poulard, C., Rochel, N., Dejaegere, A., Chebaro, Y., et al. (2017). The molecular mechanisms underlying the ER[alpha]-36-mediated signaling in breast cancer. [Original article]. Oncogene, 36(18), 2503–2514. https://doi.org/10.1038/onc.2016.415.CrossRefPubMed

74.

Wang, Q., Jiang, J., Ying, G., Xie, X.-Q., Zhang, X., Xu, W., et al. (2018). Tamoxifen enhances stemness and promotes metastasis of ERα36+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res, 28, 336. https://doi.org/10.1038/cr.2018.15.CrossRefPubMedPubMedCentral

75.

Thiebaut, C., Chesnel, A., Merlin, J. L., Chesnel, M., Leroux, A., Harle, A., et al. (2019). Dual epigenetic regulation of ERalpha36 expression in breast cancer cells. Int J Mol Sci, 20(11), 2637. https://doi.org/10.3390/ijms20112637.CrossRefPubMedCentral

76.

Poulard, C., Jacquemetton, J., Tredan, O., Cohen, P. A., Vendrell, J., Ghayad, S. E., et al. (2019). Oestrogen non-genomic signalling is activated in tamoxifen-resistant breast cancer. Int J Mol Sci, 20(11), 2773. https://doi.org/10.3390/ijms20112773.CrossRefPubMedCentral

77.

Welch, D. R., & Hurst, D. R. (2019). Defining the hallmarks of metastasis. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-19-0458.

78.

Bohl, C., Harihar, S., Denning, W., Sharma, R., & Welch, D. (2014). Metastasis suppressors in breast cancers: mechanistic insights and clinical potential. J Mol Med, 92(1), 13–30. https://doi.org/10.1007/s00109-013-1109-y.CrossRefPubMed

79.

Abba, M., Patil, N., & Allgayer, H. (2014). MicroRNAs in the regulation of MMPs and metastasis. Cancers (Basel), 6(2), 625–645. https://doi.org/10.3390/cancers6020625.CrossRef

80.

Acerbi, I., Cassereau, L., Dean, I., Shi, Q., Au, A., Park, C., et al. (2015). Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol, 7(10), 1120–1134. https://doi.org/10.1039/c5ib00040h.CrossRef

81.

Annis, M. G., Ouellet, V., Rennhack, J. P., L’Esperance, S., Rancourt, C., Mes-Masson, A.-M., et al. (2018). Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion. Breast Cancer Res, 20(1), 9. https://doi.org/10.1186/s13058-018-0936-8.CrossRefPubMedPubMedCentral

82.

Han, B., Nakamura, M., Mori, I., Nakamura, Y., & Kakudo, K. (2005). Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep, 14(1), 105–112.PubMed

83.

Cosentino, G., Plantamura, I., Cataldo, A., & Iorio, M. V. (2019). MicroRNA and oxidative stress interplay in the context of breast cancer pathogenesis. Int J Mol Sci, 20(20), 5143. https://doi.org/10.3390/ijms20205143.CrossRefPubMedCentral

84.

Cheung, K. J., & Ewald, A. J. (2016). A collective route to metastasis: Seeding by tumor cell clusters. Science, 352(6282), 167–169. https://doi.org/10.1126/science.aaf6546.CrossRefPubMedPubMedCentral

85.

Franklin, R. A., & Li, M. O. (2016). Ontogeny of tumor-associated macrophages and its implication in cancer regulation. Trends Cancer, 2(1), 20–34. https://doi.org/10.1016/j.trecan.2015.11.004.CrossRefPubMedPubMedCentral

86.

Yang, M., McKay, D., Pollard, J. W., & Lewis, C. E. (2018). Diverse functions of macrophages in different tumor microenvironments. Cancer Res, 78(19), 5492. https://doi.org/10.1158/0008-5472.CAN-18-1367.CrossRefPubMedPubMedCentral

87.

Williams, C. B., Yeh, E. S., & Soloff, A. C. (2016). Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. NPJ Breast Cancer, 2, 15025. https://doi.org/10.1038/npjbcancer.2015.25.CrossRefPubMedPubMedCentral

88.

Hermano, E., Goldberg, R., Rubinstein, A. M., Sonnenblick, A., Maly, B., Nahmias, D., et al. (2019). Heparanase accelerates obesity-associated breast cancer progression. Cancer Res, 79(20), 5342. https://doi.org/10.1158/0008-5472.CAN-18-4058.CrossRefPubMed

89.

Clements, M. E., & Johnson, R. W. (2019). Breast cancer dormancy in bone. Curr Osteoporos Rep, 17(5), 353–361. https://doi.org/10.1007/s11914-019-00532-y.CrossRefPubMedPubMedCentral

90.

Amit, M., Na'ara, S., & Gil, Z. (2016). Mechanisms of cancer dissemination along nerves. Nat Rev Cancer, 16, 399. https://doi.org/10.1038/nrc.2016.38.CrossRefPubMed

91.

Venkatesh, H., & Monje, M. (2017). Neuronal activity in ontogeny and oncology. Trends Cancer, 3(2), 89–112. https://doi.org/10.1016/j.trecan.2016.12.008.CrossRefPubMedPubMedCentral

92.

Pundavela, J., Roselli, S., Faulkner, S., Attia, J., Scott, R. J., Thorne, R. F., et al. (2015). Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer. Mol Oncol, 9(8), 1626–1635. https://doi.org/10.1016/j.molonc.2015.05.001.CrossRefPubMedPubMedCentral

93.

Celià-Terrassa, T., & Kang, Y. (2016). Distinctive properties of metastasis-initiating cells. Genes Dev, 30(8), 892–908. https://doi.org/10.1101/gad.277681.116.CrossRefPubMedPubMedCentral

94.

Fluegen, G., Avivar-Valderas, A., Wang, Y., Padgen, M. R., Williams, J. K., Nobre, A. R., et al. (2017). Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. [Article]. Nat Cell Biol, 19, 120. https://doi.org/10.1038/ncb3465.CrossRefPubMedPubMedCentral

95.

Borgen, E., Rypdal, M. C., Sosa, M. S., Renolen, A., Schlichting, E., Lønning, P. E., et al. (2018). NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Res, 20(1), 120. https://doi.org/10.1186/s13058-018-1049-0.CrossRefPubMedPubMedCentral

96.

Terrigno, M., Bertacchi, M., Pandolfini, L., Baumgart, M., Calvello, M., Cellerino, A., et al. (2018). The microRNA miR-21 is a mediator of FGF8 action on cortical COUP-TFI translation. Stem Cell Reports, 11(3), 756–769. https://doi.org/10.1016/j.stemcr.2018.08.002.CrossRefPubMedPubMedCentral

97.

Sanger, N., Effenberger, K. E., Riethdorf, S., Van Haasteren, V., Gauwerky, J., Wiegratz, I., et al. (2011). Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer, 129(10), 2522–2526. https://doi.org/10.1002/ijc.25895.CrossRefPubMed

98.

Marjanovic, N. D., Weinberg, R. A., & Chaffer, C. L. (2013). Cell plasticity and heterogeneity in cancer. Clin Chem, 59(1), 168. https://doi.org/10.1373/clinchem.2012.184655.CrossRefPubMed

99.

Grosselin, K., Durand, A., Marsolier, J., Poitou, A., Marangoni, E., Nemati, F., et al. (2019). High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer. Nat Genet, 51(6), 1060–1066. https://doi.org/10.1038/s41588-019-0424-9.CrossRefPubMed

100.

Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., et al. (2017). Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. [Article]. Nat Genet, 49, 708. https://doi.org/10.1038/ng.3818.CrossRefPubMed

101.

Yates, L. R. (2017). Intratumoral heterogeneity and subclonal diversification of early breast cancer. Breast, 34(Suppl 1), S36–s42. https://doi.org/10.1016/j.breast.2017.06.025.CrossRefPubMed

102.

Janiszewska, M., Tabassum, D. P., Castaño, Z., Cristea, S., Yamamoto, K. N., Kingston, N. L., et al. (2019). Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol, 21(7), 879–888. https://doi.org/10.1038/s41556-019-0346-x.CrossRefPubMedPubMedCentral

103.

Karagiannis, G. S., Condeelis, J. S., & Oktay, M. H. (2018). Chemotherapy-induced metastasis: mechanisms and translational opportunities. Clin Exp Metastasis, 35(4), 269–284. https://doi.org/10.1007/s10585-017-9870-x.CrossRefPubMedPubMedCentral

104.

Shibue, T., & Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol, 14, 611. https://doi.org/10.1038/nrclinonc.2017.44.CrossRefPubMedPubMedCentral

105.

Alferez, D. G., Simoes, B. M., Howell, S. J., & Clarke, R. B. (2018). The role of steroid hormones in breast and effects on cancer stem cells. Curr Stem Cell Rep, 4(1), 81–94. https://doi.org/10.1007/s40778-018-0114-z.CrossRefPubMedPubMedCentral

106.

Thery, L., Meddis, A., Cabel, L., Proudhon, C., Latouche, A., Pierga, J. Y., et al. (2019). Circulating tumor cells in early breast cancer. JNCI Cancer Spectr, 3(2), pkz026. https://doi.org/10.1093/jncics/pkz026.CrossRefPubMedPubMedCentral

107.

Liu, Y., & Cao, X. (2016). Characteristics and significance of the pre-metastatic niche. Cancer Cell, 30(5), 668–681. https://doi.org/10.1016/j.ccell.2016.09.011.CrossRefPubMed

108.

Clements, M. E., & Johnson, R. W. (2019). PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells. Oncogene. https://doi.org/10.1038/s41388-019-1064-3.

109.

Yao, Y., Liu, R., Gao, C., Zhang, T., Qi, L., Liu, G., et al. (2019). Identification of prognostic biomarkers for breast cancer based on miRNA and mRNA co-expression network. J Cell Biochem, 120(9), 15378–15388. https://doi.org/10.1002/jcb.28805.CrossRefPubMed

110.

Chiodoni C, Cancila V, Renzi TA, Perrone M, Tomirotti AM, Sangaletti S, et al. (2019). Transcriptional profiles and stromal changes reveal bone marrow adaptation to early breast cancer in association with deregulated circulating microRNAs. Cancer Res, canres.1425.2019, doi:https://doi.org/10.1158/0008-5472.CAN-19-1425.

111.

Ma, F., Li, W., Liu, C., Li, W., Yu, H., Lei, B., et al. (2017). MiR-23a promotes TGF-beta1-induced EMT and tumor metastasis in breast cancer cells by directly targeting CDH1 and activating Wnt/beta-catenin signaling. Oncotarget. https://doi.org/10.18632/oncotarget.18422.

112.

Wang, L., & Wang, J. (2012). MicroRNA-mediated breast cancer metastasis: from primary site to distant organs. Oncogene, 31(20), 2499–2511.PubMed

113.

Zhang, H., Li, Y., & Lai, M. (2010). The microRNA network and tumor metastasis. Oncogene, 29(7), 937–948.PubMed

114.

Weidle, U. H., Dickopf, S., Hintermair, C., Kollmorgen, G., Birzele, F., & Brinkmann, U. (2018). The role of micro RNAs in breast cancer metastasis: preclinical validation and potential therapeutic targets. Cancer Genomics Proteomics, 15(1), 17–39. https://doi.org/10.21873/cgp.20062.CrossRefPubMed

115.

Fridrichova, I., & Zmetakova, I. (2019). MicroRNAs contribute to breast cancer invasiveness. Cells, 8(11), 1361. https://doi.org/10.3390/cells8111361.CrossRefPubMedCentral

116.

Kim, J., Yao, F., Xiao, Z., Sun, Y., & Ma, L. (2018). MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastasis Rev, 37(1), 5–15. https://doi.org/10.1007/s10555-017-9712-y.CrossRefPubMedPubMedCentral

117.

Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009). Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res, 69(4), 1279–1283. https://doi.org/10.1158/0008-5472.can-08-3559.CrossRefPubMedPubMedCentral

118.

Hurst, D. R., Edmonds, M. D., & Welch, D. R. (2009). Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res, 69(19), 7495–7498. https://doi.org/10.1158/0008-5472.can-09-2111.CrossRefPubMedPubMedCentral

119.

Hsu, S.-D., Tseng, Y.-T., Shrestha, S., Lin, Y.-L., Khaleel, A., Chou, C.-H., et al. (2014). miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res, 42(D1), D78–D85. https://doi.org/10.1093/nar/gkt1266.CrossRefPubMed

120.

Ma, L., Young, J., Prabhala, H., Pan, E., Mestdagh, P., Muth, D., et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol, 12, 247–256. https://doi.org/10.1038/ncb2024.CrossRefPubMedPubMedCentral

121.

Chen, D., Sun, Y., Wei, Y., Zhang, P., Rezaeian, A. H., Teruya-Feldstein, J., et al. (2012). LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med, 18(10), 1511–1517. https://doi.org/10.1038/nm.2940.CrossRefPubMedPubMedCentral

122.

Cheng, C. W., Yu, J. C., Hsieh, Y. H., Liao, W. L., Shieh, J. C., Yao, C. C., et al. (2018). Increased cellular levels of microRNA-9 and microRNA-221 correlate with cancer stemness and predict poor outcome in human breast cancer. Cell Physiol Biochem, 48(5), 2205–2218.PubMed

123.

Iyevleva, A., Kuligina, E., Mitiushkina, N., Togo, A., Miki, Y., & Imyanitov, E. (2011). High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. Breast Cancer Res Treat, 131(3), 1–11. https://doi.org/10.1007/s10549-011-1845-z.CrossRef

124.

Gwak, J. M., Kim, H. J., Kim, E. J., Chung, Y. R., Yun, S., Seo, A. N., et al. (2014). MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat, 147(1), 39–49. https://doi.org/10.1007/s10549-014-3069-5.CrossRefPubMed

125.

Barbano, R., Pasculli, B., Rendina, M., Fontana, A., Fusilli, C., Copetti, M., et al. (2017). Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in oestrogen regulated pathways in breast cancer patients. Sci Rep, 7(1), 45283. https://doi.org/10.1038/srep45283.CrossRefPubMedPubMedCentral

126.

Negrini, M., & Calin, G. A. (2008). Breast cancer metastasis: a microRNA story. Breast Cancer Res, 10(2), 203. https://doi.org/10.1186/bcr1867.CrossRefPubMedPubMedCentral

127.

Kim, J., Siverly, A. N., Chen, D., Wang, M., Yuan, Y., Wang, Y., et al. (2016). Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways. Cancer Res, 76(21), 6424.PubMedPubMedCentral

128.

Zhang, J., Yang, J., Zhang, X., Xu, J., Sun, Y., & Zhang, P. (2018). MicroRNA-10b expression in breast cancer and its clinical association. PLoS One, 13(2), e0192509. https://doi.org/10.1371/journal.pone.0192509.CrossRefPubMedPubMedCentral

129.

Lu, Z., Liu, M., Stribinskis, V., Klinge, C. M., Ramos, K. S., Colburn, N. H., et al. (2008). MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene, 27(31), 4373–4379.PubMed

130.

Wickramasinghe, N., Manavalan, T., Dougherty, S., Riggs, K., Li, Y., & Klinge, C. (2009). Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res, 37(8), 2584–2595.PubMedPubMedCentral

131.

Hannafon, B., Sebastiani, P., de las Morenas, A., Lu, J., & Rosenberg, C. (2011). Expression of microRNAs and their gene targets are dysregulated in pre-invasive breast cancer. Breast Cancer Res, 13(2), R24.PubMedPubMedCentral

132.

Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007). MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem, 282(19), 14328–14336. https://doi.org/10.1074/jbc.M611393200.CrossRefPubMed

133.

Queiros, A. M., Eschen, C., Fliegner, D., Kararigas, G., Dworatzek, E., Westphal, C., et al. (2013). Sex- and estrogen-dependent regulation of a miRNA network in the healthy and hypertrophied heart. Int J Cardiol, 169(5), 331–338. https://doi.org/10.1016/j.ijcard.2013.09.002.CrossRefPubMed

134.

Kanwal, R., Plaga, A. R., Liu, X., Shukla, G. C., & Gupta, S. (2017). MicroRNAs in prostate cancer: functional role as biomarkers. Cancer Lett, 407(Supplement C), 9–20. https://doi.org/10.1016/j.canlet.2017.08.011.CrossRefPubMed

135.

Petrovic, N. (2016). miR-21 might be involved in breast cancer promotion and invasion rather than in initial events of breast cancer development. Mol Diagn Ther, 20(2), 97–110. https://doi.org/10.1007/s40291-016-0186-3.CrossRefPubMed

136.

Wang, H., Tan, Z., Hu, H., Liu, H., Wu, T., Zheng, C., et al. (2019). microRNA-21 promotes breast cancer proliferation and metastasis by targeting LZTFL1. BMC Cancer, 19(1), 738. https://doi.org/10.1186/s12885-019-5951-3.CrossRefPubMedPubMedCentral

137.

Liu, L.-Z., Li, C., Chen, Q., Jing, Y., Carpenter, R., Jiang, Y., et al. (2011). MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One, 6(4), e19139. https://doi.org/10.1371/journal.pone.0019139.CrossRefPubMedPubMedCentral

138.

Iliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010). STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell, 39(4), 493–506. https://doi.org/10.1016/j.molcel.2010.07.023.CrossRefPubMedPubMedCentral

139.

Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., et al. (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65(16), 7065–7070.PubMed

140.

Markou, A., Yousef, G. M., Stathopoulos, E., Georgoulias, V., & Lianidou, E. (2014). Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Clin Chem, 60(1), 197–205. https://doi.org/10.1373/clinchem.2013.210542.CrossRefPubMed

141.

De Mattos-Arruda, L., Bottai, G., Nuciforo, P. G., Di Tommaso, L., Giovannetti, E., Peg, V., et al. (2015). MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 6(35), 37269–37280. https://doi.org/10.18632/oncotarget.5495.CrossRefPubMedPubMedCentral

142.

Chang, L., Zhang, D., Shi, H., Bian, Y., & Guo, R. (2017). MiR-143 inhibits endometrial cancer cell proliferation and metastasis by targeting MAPK1. Oncotarget, 8(48), 84384-84395, doi:10.18632/oncotarget.21037.

143.

Zhang, Q., Feng, Y., Liu, P., & Yang, J. (2017). MiR-143 inhibits cell proliferation and invasion by targeting DNMT3A in gastric cancer. Tumour Biol, 39(7), 1010428317711312. https://doi.org/10.1177/1010428317711312.CrossRefPubMed

144.

Wang, J. H., Wang, X. W., Qu, D., Sun, J. W., Guo, F. X., & Lu, D. (2017). Upregulation of microRNA-143 reverses drug resistance in human breast cancer cells via inhibition of cytokine-induced apoptosis inhibitor 1. Oncol Lett, 13(6), 4695–4700. https://doi.org/10.3892/ol.2017.6078.CrossRefPubMedPubMedCentral

145.

Ma, Z., Luo, Y., & Qiu, M. (2017). miR-143 induces the apoptosis of prostate cancer LNCap cells by suppressing Bcl-2 expression. Med Sci Monit, 23, 359–365.PubMedPubMedCentral

146.

Wang, S., Liu, J. C., Ju, Y., Pellecchia, G., Voisin, V., Wang, D. Y., et al. (2017). microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer. JCI Insight, 2(15), 93313. https://doi.org/10.1172/jci.insight.93313.CrossRefPubMed

147.

Adhami, M., Haghdoost, A. A., Sadeghi, B., & Malekpour Afshar, R. (2018). Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer, 25, 198–205. https://doi.org/10.1007/s12282-017-0814-8.CrossRefPubMed

148.

Toda, H., Seki, N., Kurozumi, S., Shinden, Y., Yamada, Y., Nohata, N., et al. (2019). RNA-sequence-based microRNA expression signature in breast cancer: tumor-suppressive miR-101-5p regulates molecular pathogenesis. Mol Oncol. https://doi.org/10.1002/1878-0261.12602.

149.

Yang, F., Zhang, W., Shen, Y., & Guan, X. (2015). Identification of dysregulated microRNAs in triple-negative breast cancer (review). Int J Oncol, 46(3), 927–932. https://doi.org/10.3892/ijo.2015.2821.CrossRefPubMed

150.

Fite, K., & Gomez-Cambronero, J. (2016). Down-regulation of microRNAs (MiRs) 203, 887, 3619 and 182 prevents vimentin-triggered, phospholipase D (PLD)-mediated cancer cell invasion. J Biol Chem, 291(2), 719–730. https://doi.org/10.1074/jbc.M115.686006.CrossRefPubMed

151.

Zhan, Y., Li, X., Liang, X., Li, L., Cao, B., Wang, B., et al. (2016). MicroRNA-182 drives colonization and macroscopic metastasis via targeting its suppressor SNAI1 in breast cancer. Oncotarget, 8(3), 4629–4641. https://doi.org/10.18632/oncotarget.13542.CrossRefPubMedCentral

152.

Sang, Y., Chen, B., Song, X., Li, Y., Liang, Y., Han, D., et al. (2019). CircRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther - Nucleic Acids, 27(9), 1638–1652. https://doi.org/10.1016/j.omtn.2019.05.005.CrossRef

153.

Eichelser, C., Stuckrath, I., Muller, V., Milde-Langosch, K., Wikman, H., Pantel, K., et al. (2014). Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 5(20), 9650–9663.PubMedPubMedCentral

154.

Huang, Q., Gumireddy, K., Schrier, M., le Sage, C., Nagel, R., Nair, S., et al. (2008). The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 10(2), 202–210.PubMed

155.

Yan, G. R., Xu, S. H., Tan, Z. L., Liu, L., & He, Q. Y. (2011). Global identification of miR-373-regulated genes in breast cancer by quantitative proteomics. Proteomics, 11(5), 912–920. https://doi.org/10.1002/pmic.201000539.CrossRefPubMed

156.

Keklikoglou, I., Koerner, C., Schmidt, C., Zhang, J. D., Heckmann, D., Shavinskaya, A., et al. (2012). MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-[kappa]B and TGF-[beta] signaling pathways. Oncogene, 31(37), 4150–4163. https://doi.org/10.1038/onc.2011.571.CrossRefPubMed

157.

Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K., & Schwarzenbach, H. (2013). Deregulated serum concentrations of circulating cell–free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem, 59(10), 1489–1496. https://doi.org/10.1373/clinchem.2013.205161.CrossRefPubMed

158.

Tang, C. P., Zhou, H. J., Qin, J., Luo, Y., & Zhang, T. (2017). MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer. Oncol Rep, 38(5), 3144–3152. https://doi.org/10.3892/or.2017.5968.CrossRefPubMed

159.

Farazi, T. A., Horlings, H. M., ten Hoeve, J. J., Mihailovic, A., Halfwerk, H., Morozov, P., et al. (2011). MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res, 71(13), 4443–4453. https://doi.org/10.1158/0008-5472.can-11-0608.CrossRefPubMedPubMedCentral

160.

Muluhngwi, P., Krishna, A., Vittitow, S. L., Napier, J. T., Richardson, K. M., Ellis, M., et al. (2017). Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells. Cancer Lett, 388, 230–238. https://doi.org/10.1016/j.canlet.2016.12.007.CrossRefPubMed

161.

Muluhngwi, P., Alizadeh-Rad, N., Vittitow, S. L., Kalbfleisch, T. S., & Klinge, C. M. (2017). The miR-29 transcriptome in endocrine-sensitive and resistant breast cancer cells. Sci Rep, 7(1), 5205. https://doi.org/10.1038/s41598-017-05727-w.CrossRefPubMedPubMedCentral

162.

Jiang, H., Zhang, G., Wu, J. H., & Jiang, C. P. (2014). Diverse roles of miR-29 in cancer (review). Oncol Rep, 31(4), 1509–1516. https://doi.org/10.3892/or.2014.3036.CrossRefPubMed

163.

Milevskiy, M. J. G., Sandhu, G. K., Wronski, A., Korbie, D., Brewster, B. L., Shewan, A., et al. (2018). MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer. Oncotarget, 9(71), 33577–33588. https://doi.org/10.18632/oncotarget.26094.CrossRefPubMedPubMedCentral

164.

Scott, G. K., Mattie, M. D., Berger, C. E., Benz, S. C., & Benz, C. C. (2006). Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res, 66(3), 1277–1281.PubMed

165.

Guttilla, I. K., & White, B. A. (2009). Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem, 284(35), 23204–23216. https://doi.org/10.1074/jbc.M109.031427.CrossRefPubMedPubMedCentral

166.

Jiang, G., Shi, W., Fang, H., & Zhang, X. (2018). miR-27a promotes human breast cancer cell migration by inducing EMT in a FBXW7 dependent manner. Mol Med Rep, 18(6), 5417–5426. https://doi.org/10.3892/mmr.2018.9587.CrossRefPubMedPubMedCentral

167.

Tsuchiya, Y., Nakajima, M., Takagi, S., Taniya, T., & Yokoi, T. (2006). MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res, 66(18), 9090–9098. https://doi.org/10.1158/0008-5472.can-06-1403.CrossRefPubMed

168.

Vimalraj, S., Miranda, P. J., Ramyakrishna, B., & Selvamurugan, N. (2013). Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers, 35(5), 369–387. https://doi.org/10.1155/2013/451248.CrossRefPubMedPubMedCentral

169.

Yu, Z., Wang, C., Wang, M., Li, Z., Casimiro, M. C., Liu, M., et al. (2008). A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol, 182(3), 509–517. https://doi.org/10.1083/jcb.200801079.CrossRefPubMedPubMedCentral

170.

Yang, J., Zhang, Z., Chen, C., Liu, Y., Si, Q., Chuang, T. H., et al. (2013). MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene, 33, 3014. https://doi.org/10.1038/onc.2013.258.CrossRefPubMed

171.

Ouchida, M., Kanzaki, H., Ito, S., Hanafusa, H., Jitsumori, Y., Tamaru, S., et al. (2012). Novel direct targets of miR-19a identified in breast cancer cells by a quantitative proteomic approach. PLoS One, 7(8), e44095. https://doi.org/10.1371/journal.pone.0044095.CrossRefPubMedPubMedCentral

172.

Wu, J., Jiang, Y., Cao, W., Li, X., Xie, C., Geng, S., et al. (2018). miR-19 targeting of PTEN mediates butyl benzyl phthalate-induced proliferation in both ER(+) and ER(−) breast cancer cells. Toxicol Lett, 295, 124–133. https://doi.org/10.1016/j.toxlet.2018.05.040.CrossRefPubMed

173.

Mogilyansky, E., Clark, P., Quann, K., Zhou, H., Londin, E., Jing, Y., et al. (2016). Post-transcriptional regulation of BRCA2 through interactions with miR-19a and miR-19b. Front Genet, 7, 143. https://doi.org/10.3389/fgene.2016.00143.CrossRefPubMedPubMedCentral

174.

Yin, R., Guo, L., Gu, J., Li, C., & Zhang, W. (2018). Over expressing miR-19b-1 suppress breast cancer growth by inhibiting tumor microenvironment induced angiogenesis. Int J Biochem Cell Biol, 97, 43–51. https://doi.org/10.1016/j.biocel.2018.02.005.CrossRefPubMed

175.

Sochor, M., Basova, P., Pesta, M., Dusilkova, N., Bartos, J., Burda, P., et al. (2014). Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer, 14, 448. https://doi.org/10.1186/1471-2407-14-448.CrossRefPubMedPubMedCentral

176.

Thorne, J. L., Battaglia, S., Baxter, D. E., Hayes, J. L., Hutchinson, S. A., Jana, S., et al. (2018). MiR-19b non-canonical binding is directed by HuR and confers chemosensitivity through regulation of P-glycoprotein in breast cancer. Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 1861(11), 996–1006. https://doi.org/10.1016/j.bbagrm.2018.08.005.CrossRef

177.

Li, C., Zhang, J., Ma, Z., Zhang, F., & Yu, W. (2018). miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway. Onco Targets Ther, 11, 4087–4095. https://doi.org/10.2147/ott.S171043.CrossRefPubMedPubMedCentral

178.

Zhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., Ma, X., et al. (2008). MicroRNA-221/222 negatively regulates ERalpha and associates with tamoxifen resistance in breast cancer. J Biol Chem, 283(45), 31079–31086. https://doi.org/10.1074/jbc.M806041200.CrossRefPubMedPubMedCentral

179.

Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., et al. (2008). MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27(Kip1). J Biol Chem, 283(44), 29897–29903. https://doi.org/10.1074/jbc.M804612200.CrossRefPubMedPubMedCentral

180.

Lu, Y., Roy, S., Nuovo, G., Ramaswamy, B., Miller, T., Shapiro, C., et al. (2011). Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem, 286(49), 42292–42302. https://doi.org/10.1074/jbc.M111.270926.CrossRefPubMedPubMedCentral

181.

Dentelli, P., Rosso, A., Orso, F., Olgasi, C., Taverna, D., & Brizzi, M. F. (2010). microRNA-222 controls neovascularization by regulating signal transducer and activator of transcription 5A expression. Arterioscler Thromb Vasc Biol, 30(8), 1562–1568. https://doi.org/10.1161/atvbaha.110.206201.CrossRefPubMed

182.

Zhang, Y., Lin, X., Zhang, L., Hong, W., & Zeng, K. (2018). MicroRNA-222 regulates the viability of fibroblasts in hypertrophic scars via matrix metalloproteinase 1. Exp Ther Med, 15(2), 1803–1808. https://doi.org/10.3892/etm.2017.5634.CrossRefPubMed

183.

Li, Y., Liang, C., Ma, H., Zhao, Q., Lu, Y., Xiang, Z., et al. (2014). miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules, 19(6), 7122–7137. https://doi.org/10.3390/molecules19067122.CrossRefPubMedPubMedCentral

184.

Chatterjee, A., Jana, S., Chatterjee, S., Wastall, L. M., Mandal, G., Nargis, N., et al. (2019). MicroRNA-222 reprogrammed cancer-associated fibroblasts enhance growth and metastasis of breast cancer. Br J Cancer, 121(8), 679–689. https://doi.org/10.1038/s41416-019-0566-7.CrossRefPubMedPubMedCentral

185.

Wu, Q., Lu, Z., Li, H., Lu, J., Guo, L., & Ge, Q. (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol, 2011, 597145. https://doi.org/10.1155/2011/597145.CrossRefPubMedPubMedCentral

186.

Kim, C., Go, E. J., & Kim, A. (2018). Recurrence prediction using microRNA expression in hormone receptor positive breast cancer during tamoxifen treatment. Biomarkers, 23(8), 84–811. https://doi.org/10.1080/1354750x.2018.1499131.CrossRef

187.

Shibahara, Y., Miki, Y., Onodera, Y., Hata, S., Chan, M. S., Yiu, C. C., et al. (2012). Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol, 227(3), 357–366. https://doi.org/10.1002/path.4019.CrossRefPubMed

188.

Mattie, M. D., Benz, C. C., Bowers, J., Sensinger, K., Wong, L., Scott, G. K., et al. (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5(24), 24.PubMedPubMedCentral

189.

Blenkiron, C., Goldstein, L. D., Thorne, N. P., Spiteri, I., Chin, S. F., Dunning, M. J., et al. (2007). MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol, 8(10), R214.PubMedPubMedCentral

190.

Oztemur, Y., Bekmez, T., Aydos, A., Yulug, I. G., Bozkurt, B., & Dedeoglu, B. G. (2015). A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer. PLoS One, 10(5), e0126837. https://doi.org/10.1371/journal.pone.0126837.CrossRefPubMedPubMedCentral

191.

Humphries, B., & Yang, C. (2015). The microRNA-200 family: small molecules with novel roles in cancer development, progression and therapy. Oncotarget, 6(9), 6472–6498. https://doi.org/10.18632/oncotarget.3052.CrossRefPubMedPubMedCentral

192.

Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S., et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep, 9(6), 582–589.PubMedPubMedCentral

193.

Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol, 10(5), 593–601.PubMed

194.

Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y.-J., Volinia, S., et al. (2011). p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2. J Exp Med, 208(5), 875–883. https://doi.org/10.1084/jem.20110235.CrossRefPubMedPubMedCentral

195.

Menschikowski, M., Hagelgans, A., Nacke, B., Jandeck, C., Sukocheva, O., & Siegert, G. (2015). Epigenetic control of phospholipase A2 receptor expression in mammary cancer cells. BMC Cancer, 15, 971. https://doi.org/10.1186/s12885-015-1937-y.CrossRefPubMedPubMedCentral

196.

Yao, Y. S., Qiu, W. S., Yao, R. Y., Zhang, Q., Zhuang, L. K., Zhou, F., et al. (2015). miR-141 confers docetaxel chemoresistance of breast cancer cells via regulation of EIF4E expression. Oncol Rep, 33(5), 2504–2512. https://doi.org/10.3892/or.2015.3866.CrossRefPubMed

197.

Abedi, N., Mohammadi-Yeganeh, S., Koochaki, A., Karami, F., & Paryan, M. (2015). miR-141 as potential suppressor of beta-catenin in breast cancer. Tumour Biol, 36(12), 9895–9901. https://doi.org/10.1007/s13277-015-3738-y.CrossRefPubMed

198.

Li, P., Xu, T., Zhou, X., Liao, L., Pang, G., Luo, W., et al. (2017). Downregulation of miRNA-141 in breast cancer cells is associated with cell migration and invasion: involvement of ANP32E targeting. Cancer Med, 6(3), 662–672. https://doi.org/10.1002/cam4.1024.CrossRefPubMedPubMedCentral

199.

Chen, L., Li, Y., Fu, Y., Peng, J., Mo, M.-H., Stamatakos, M., et al. (2013). Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One, 8(1), e54213. https://doi.org/10.1371/journal.pone.0054213.CrossRefPubMedPubMedCentral

200.

Antolin, S., Calvo, L., Blanco-Calvo, M., Santiago, M. P., Lorenzo-Patino, M. J., Haz-Conde, M., et al. (2015). Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. BMC Cancer, 15, 297. https://doi.org/10.1186/s12885-015-1238-5.CrossRefPubMedPubMedCentral

201.

Debeb, B. G., Lacerda, L., Anfossi, S., Diagaradjane, P., Chu, K., Bambhroliya, A., et al. (2016). miR-141-mediated regulation of brain metastasis from breast cancer. JNCI: Journal of the National Cancer Institute, 108(8), djw026. https://doi.org/10.1093/jnci/djw026.CrossRefPubMedCentral

202.

Zhang, G., Zhang, W., Li, B., Stringer-Reasor, E., Chu, C., Sun, L., et al. (2017). MicroRNA-200c and microRNA-141 are regulated by a FOXP3-KAT2B axis and associated with tumor metastasis in breast cancer. Breast Cancer Res, 19(1), 73. https://doi.org/10.1186/s13058-017-0858-x.CrossRefPubMedPubMedCentral

203.

Finlay-Schultz, J., Cittelly, D. M., Hendricks, P., Patel, P., Kabos, P., Jacobsen, B. M., et al. (2015). Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. [Original article]. Oncogene, 34(28), 3676–3687. https://doi.org/10.1038/onc.2014.298.CrossRefPubMed

204.

Li, X. F., Yan, P. J., & Shao, Z. M. (2009). Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene, 28(44), 3937–3948. https://doi.org/10.1038/onc.2009.245.CrossRefPubMed

205.

Leivonen, S.-K., Rokka, A., Östling, P., Kohonen, P., Corthals, G. L., Kallioniemi, O., et al. (2011). Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol Cell Proteomics, 10(7), M110 005322. https://doi.org/10.1074/mcp.M110.005322.CrossRefPubMedPubMedCentral

206.

Hurteau, G. J., Carlson, J. A., Spivack, S. D., & Brock, G. J. (2007). Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res, 67(17), 7972–7976. https://doi.org/10.1158/0008-5472.can-07-1058.CrossRefPubMed

207.

Bracken, C. P., Gregory, P. A., Kolesnikoff, N., Bert, A. G., Wang, J., Shannon, M. F., et al. (2008). A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res, 68(19), 7846–7854. https://doi.org/10.1158/0008-5472.can-08-1942.CrossRefPubMed

208.

Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009). MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Mol Cancer Ther, 8(5), 1055–1066. https://doi.org/10.1158/1535-7163.mct-08-1046.CrossRefPubMedPubMedCentral

209.

Sossey-Alaoui, K., Bialkowska, K., & Plow, E. F. (2009). The miR200 family of microRNAs regulates WAVE3-dependent cancer cell invasion. J Biol Chem, 284(48), 33019–33029. https://doi.org/10.1074/jbc.M109.034553.CrossRefPubMedPubMedCentral

210.

Cochrane, D., Cittelly, D., Howe, E., Spoelstra, N., McKinsey, E., LaPara, K., et al. (2010). MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Hormones and Cancer, 1(6), 306–319. https://doi.org/10.1007/s12672-010-0043-5.CrossRefPubMed

211.

Chen, Y., & Zhang, L. (2017). Members of the microRNA-200 family are promising therapeutic targets in cancer. Exp Ther Med, 14(1), 10–17. https://doi.org/10.3892/etm.2017.4488.CrossRefPubMedPubMedCentral

212.

Yahya, S. M. M., & Elsayed, G. H. (2015). A summary for molecular regulations of miRNAs in breast cancer. Clin Biochem, 48(6), 388–396. https://doi.org/10.1016/j.clinbiochem.2014.12.013.CrossRefPubMed

213.

De Cola, A., Volpe, S., Budani, M. C., Ferracin, M., Lattanzio, R., Turdo, A., et al. (2015). miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis, 6, e1823. https://doi.org/10.1038/cddis.2015.192.CrossRefPubMedPubMedCentral

214.

Greene, S. B., Herschkowitz, J. I., & Rosen, J. M. (2010). The ups and downs of miR-205: identifying the roles of miR-205 in mammary gland development and breast cancer. RNA Biol, 7(3), 300–304.PubMed

215.

Chao, C.-H., Chang, C.-C., Wu, M.-J., Ko, H.-W., Wang, D., Hung, M.-C., et al. (2014). MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest, 124(7), 3093–3106. https://doi.org/10.1172/JCI73351.CrossRefPubMedPubMedCentral

216.

Xiao, Y., Li, Y., Tao, H., Humphries, B., Li, A., Jiang, Y., et al. (2018). Integrin α5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway. Cancer Lett, 433(1), 199–209. https://doi.org/10.1016/j.canlet.2018.06.037.CrossRefPubMed

217.

Hasegawa, T., Adachi, R., Iwakata, H., Takeno, T., Sato, K., & Sakamaki, T. (2017). ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras/Raf/MEK/ERK pathway in breast cancer. FEBS Open Bio, 7(8), 1154–1165. https://doi.org/10.1002/2211-5463.12256.CrossRefPubMedPubMedCentral

218.

Zhang, H., Li, B., Zhao, H., & Chang, J. (2015). The expression and clinical significance of serum miR-205 for breast cancer and its role in detection of human cancers. Int J Clin Exp Med, 8(2), 3034–3043.PubMedPubMedCentral

219.

Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem, 283(22), 14910–14914. https://doi.org/10.1074/jbc.C800074200.CrossRefPubMedPubMedCentral

220.

Uhlmann, S., Zhang, J. D., Schwager, A., Mannsperger, H., Riazalhosseini, Y., Burmester, S., et al. (2010). miR-200bc/429 cluster targets PLC[gamma]1 and differentially regulates proliferation and EGF-driven invasion than miR-200a/141 in breast cancer. Oncogene, 29(30), 4297–4306. https://doi.org/10.1038/onc.2010.201.CrossRefPubMed

221.

Castilla, M. Á., Díaz-Martín, J., Sarrió, D., Romero-Pérez, L., López-García, M. Á., Vieites, B., et al. (2012). MicroRNA-200 family modulation in distinct breast cancer phenotypes. PLoS One, 7(10), e47709. https://doi.org/10.1371/journal.pone.0047709.CrossRefPubMedPubMedCentral

222.

Liu, Q., Wang, W., Yang, X., Zhao, D., Li, F., & Wang, H. (2016). MicroRNA-146a inhibits cell migration and invasion by targeting RhoA in breast cancer. Oncol Rep, 36(1), 189–196. https://doi.org/10.3892/or.2016.4788.CrossRefPubMedPubMedCentral

223.

Song, G., Zhang, Y., & Wang, L. (2009). MicroRNA-206 targets notch3, activates apoptosis, and inhibits tumor cell migration and focus formation. J Biol Chem, 284(46), 31921–31927. https://doi.org/10.1074/jbc.M109.046862.CrossRefPubMedPubMedCentral

224.

Tavazoie, S. F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175), 147–152.PubMedPubMedCentral

225.

Heyn, H., Engelmann, M., Schreek, S., Ahrens, P., Lehmann, U., Kreipe, H., et al. (2011). MicroRNA miR-335 is crucial for the BRCA1 regulatory cascade in breast cancer development. Int J Cancer, 129(12), 2797–2806. https://doi.org/10.1002/ijc.25962.CrossRefPubMed

226.

Kasinski, A. L., & Slack, F. J. (2011). MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer, 11(12), 849–864.PubMedPubMedCentral

227.

Martin, E. C., Conger, A. K., Yan, T. J., Hoang, V. T., Miller, D. F. B., Buechlein, A., et al. (2017). MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Lett, 591(2), 382–392. https://doi.org/10.1002/1873-3468.12538.CrossRefPubMedPubMedCentral

228.

Augoff, K., Das, M., Bialkowska, K., McCue, B., Plow, E. F., & Sossey-Alaoui, K. (2011). miR-31 is a broad regulator of β1-integrin expression and function in cancer cells. Mol Cancer Res, 9(11), 1500. https://doi.org/10.1158/1541-7786.mcr-11-0311.CrossRefPubMedPubMedCentral

229.

Chan, Y. T., Lin, Y. C., Lin, R. J., Kuo, H. H., Thang, W. C., Chiu, K. P., et al. (2013). Concordant and discordant regulation of target genes by miR-31 and its isoforms. PLoS One, 8(3), e58169. https://doi.org/10.1371/journal.pone.0058169.CrossRefPubMedPubMedCentral

230.

Luo, L.-J., Yang, F., Ding, J.-J., Yan, D.-L., Wang, D.-D., Yang, S.-J., et al. (2016). MiR-31 inhibits migration and invasion by targeting SATB2 in triple negative breast cancer. Gene, 594(1), 47–58. https://doi.org/10.1016/j.gene.2016.08.057.CrossRefPubMed

231.

Valastyan, S., Reinhardt, F., Benaich, N., Calogrias, D., Szász, A. M., Wang, Z. C., et al. (2009). RETRACTED: a pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell, 137(6), 1032–1046. https://doi.org/10.1016/j.cell.2009.03.047.CrossRefPubMedPubMedCentral

232.

Soon, P. S., Provan, P. J., Kim, E., Pathmanathan, N., Graham, D., Clarke, C. L., et al. (2018). Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Clin Exp Metastasis, 35(1), 3–13. https://doi.org/10.1007/s10585-017-9868-4.CrossRefPubMed

233.

Ouyang, M., Li, Y., Ye, S., Ma, J., Lu, L., Lv, W., et al. (2014). MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PLoS One, 9(5), e96228. https://doi.org/10.1371/journal.pone.0096228.CrossRefPubMedPubMedCentral

234.

Riaz, M., van Jaarsveld, M. T., Hollestelle, A., Prager-van der Smissen, W. J., Heine, A. A., Boersma, A. W., et al. (2013). miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res, 15(2), R33. https://doi.org/10.1186/bcr3415.CrossRefPubMedPubMedCentral

235.

Viré, E., Curtis, C., Davalos, V., Git, A., Robson, S., Villanueva, A., et al. (2014). The breast cancer oncogene EMSY represses transcription of antimetastatic microRNA miR-31. Mol Cell, 53(5), 806–818.PubMedPubMedCentral

236.

Mulrane, L., Gallagher, W. M., & O’Connor, D. P. (2014). A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer. Breast Cancer Res, 16(6), 467. https://doi.org/10.1186/s13058-014-0467-x.CrossRefPubMedPubMedCentral

237.

Kedmi, M., Ben-Chetrit, N., Körner, C., Mancini, M., Ben-Moshe, N. B., Lauriola, M., et al. (2015). EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci Signal, 8(368), ra29. https://doi.org/10.1126/scisignal.2005866.CrossRefPubMed

238.

Zhao, C., Wang, G., Zhu, Y., Li, X., Yan, F., Zhang, C., et al. (2016). Aberrant regulation of miR-15b in human malignant tumors and its effects on the hallmarks of cancer. Tumor Biol, 37(1), 177–183. https://doi.org/10.1007/s13277-015-4269-2.CrossRef

239.

Polytarchou, C., Iliopoulos, D., & Struhl, K. (2012). An integrated transcriptional regulatory circuit that reinforces the breast cancer stem cell state. Proc Natl Acad Sci, 109(36), 14470–14475. https://doi.org/10.1073/pnas.1212811109.CrossRefPubMedPubMedCentral

240.

Kratassiouk, G., Pritchard, L. L., Cuvellier, S., Vislovukh, A., Meng, Q., Groisman, R., et al. (2016). The WEE1 regulators CPEB1 and miR-15b switch from inhibitor to activators at G2/M. Cell Cycle, 15(5), 667–677. https://doi.org/10.1080/15384101.2016.1147631.CrossRefPubMedPubMedCentral

241.

Rivas, M. A., Venturutti, L., Huang, Y.-W., Schillaci, R., Huang, T. H.-M., & Elizalde, P. V. (2012). Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res, 14(3), R77. https://doi.org/10.1186/bcr3187.CrossRefPubMedPubMedCentral

242.

Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., et al. (2005). miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci, 102(39), 13944–13949. https://doi.org/10.1073/pnas.0506654102.CrossRefPubMedPubMedCentral

243.

Liang, H., Fu, Z., Jiang, X., Wang, N., Wang, F., Wang, X., et al. (2015). miR-16 promotes the apoptosis of human cancer cells by targeting FEAT. BMC Cancer, 15(1), 448. https://doi.org/10.1186/s12885-015-1458-8.CrossRefPubMedPubMedCentral

244.

Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J., Newell, J., & Kerin, M. J. (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg, 251(3), 499–505. https://doi.org/10.1097/SLA.0b013e3181cc939f.CrossRefPubMed

245.

Rinnerthaler, G., Hackl, H., Gampenrieder, S. P., Hamacher, F., Hufnagl, C., Hauser-Kronberger, C., et al. (2016). miR-16-5p is a stably-expressed housekeeping microRNA in breast cancer tissues from primary tumors and from metastatic sites. Int J Mol Sci, 17(2), 156. https://doi.org/10.3390/ijms17020156.CrossRefPubMedCentral

246.

Li, Z., Peng, Z., Gu, S., Zheng, J., Feng, D., Qin, Q., et al. (2017). Global analysis of miRNA-mRNA interaction network in breast cancer with brain metastasis. Anticancer Res, 37(8), 4455–4468. https://doi.org/10.21873/anticanres.11841.CrossRefPubMed

247.

Stuckrath, I., Rack, B., Janni, W., Jager, B., Pantel, K., & Schwarzenbach, H. (2015). Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients. Oncotarget, 6(15), 13387–13401. https://doi.org/10.18632/oncotarget.3874.CrossRefPubMedPubMedCentral

248.

Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci, 103(7), 2257–2261. https://doi.org/10.1073/pnas.0510565103.CrossRefPubMedPubMedCentral

249.

Sylvestre, Y., De Guire, V., Querido, E., Mukhopadhyay, U. K., Bourdeau, V., Major, F., et al. (2007). An E2F/miR-20a autoregulatory feedback loop. J Biol Chem, 282(4), 2135–2143. https://doi.org/10.1074/jbc.M608939200.CrossRefPubMed

250.

Yu, Z., Willmarth, N. E., Zhou, J., Katiyar, S., Wang, M., Liu, Y., et al. (2010). microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci, 107(18), 8231–8236. https://doi.org/10.1073/pnas.1002080107.CrossRefPubMedPubMedCentral

251.

Kim, K., Chadalapaka, G., Lee, S. O., Yamada, D., Sastre-Garau, X., Defossez, P. A., et al. (2012). Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 31(8), 1034–1044. https://doi.org/10.1016/j.toxlet.2018.05.040.CrossRefPubMed

252.

Liu, L., He, J., Wei, X., Wan, G., Lao, Y., Xu, W., et al. (2017). MicroRNA-20a-mediated loss of autophagy contributes to breast tumorigenesis by promoting genomic damage and instability. [Original article]. Oncogene, 36(42), 5874–5884. https://doi.org/10.1038/onc.2017.193.CrossRefPubMedPubMedCentral

253.

Bai, X., Han, G., Liu, Y., Jiang, H., & He, Q. (2018). MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3. Biomed Pharmacother, 103, 1482–1489. https://doi.org/10.1016/j.biopha.2018.04.165.CrossRefPubMed

254.

Zhao, W., Geng, D., Li, S., Chen, Z., & Sun, M. (2018). LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med, 7(3), 842–855. https://doi.org/10.1002/cam4.1353.CrossRefPubMedPubMedCentral

255.

Moi, L., Braaten, T., Al-Shibli, K., Lund, E., & Busund, L.-T. R. (2019). Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study. J Transl Med, 17(1), 334. https://doi.org/10.1186/s12967-019-2086-x.CrossRefPubMedPubMedCentral

256.

Braicu, C., Raduly, L., Morar-Bolba, G., Cojocneanu, R., Jurj, A., Pop, L.-A., et al. (2018). Aberrant miRNAs expressed in HER-2 negative breast cancers patient. J Exp Clin Cancer Res, 37(1), 257. https://doi.org/10.1186/s13046-018-0920-2.CrossRefPubMedPubMedCentral

257.

Castellano, L., Giamas, G., Jacob, J., Coombes, R. C., Lucchesi, W., Thiruchelvam, P., et al. (2009). The estrogen receptor-alpha induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci USA, 106(37), 15732–15737. https://doi.org/10.1073/pnas.0906947106.CrossRefPubMedPubMedCentral

258.

Giraud-Triboult, K., Rochon-Beaucourt, C., Nissan, X., Champon, B., Aubert, S., & Piétu, G. (2011). Combined mRNA and microRNA profiling reveals that miR-148a and miR-20b control human mesenchymal stem cell phenotype via EPAS1. Physiol Genomics, 43(2), 77–86. https://doi.org/10.1152/physiolgenomics.00077.2010.CrossRefPubMed

259.

Ao, X., Nie, P., Wu, B., Xu, W., Zhang, T., Wang, S., et al. (2016). Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis, 7, e2463. https://doi.org/10.1038/cddis.2016.367.CrossRefPubMedPubMedCentral

260.

Li, D., Ilnytskyy, Y., Kovalchuk, A., Khachigian, L. M., Bronson, R. T., Wang, B., et al. (2013). Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. Oncotarget, 4(9), 1373–1387. https://doi.org/10.18632/oncotarget.1165.CrossRefPubMedPubMedCentral

261.

Landais, S., Landry, S., Legault, P., & Rassart, E. (2007). Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. Cancer Res, 67(12), 5699–5707. https://doi.org/10.1158/0008-5472.can-06-4478.CrossRefPubMed

262.

Xue, T. M., Tao, L. D., Zhang, M., Zhang, J., Liu, X., Chen, G. F., et al. (2015). Clinicopathological significance of microRNA-20b expression in hepatocellular carcinoma and regulation of HIF-1alpha and VEGF Effect on cell biological behaviour. Dis Markers, 2015, 325176. https://doi.org/10.1155/2015/325176.CrossRefPubMedPubMedCentral

263.

He, J., Zhang, J. F., Yi, C., Lv, Q., Xie, W. D., Li, J. N., et al. (2010). miRNA-mediated functional changes through co-regulating function related genes. PLoS One, 5(10), e13558. https://doi.org/10.1371/journal.pone.0013558.CrossRefPubMedPubMedCentral

264.

Wang, W., Feng, L., Zhang, H., Hachy, S., Satohisa, S., Laurent, L. C., et al. (2012). Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta. J Clin Endocrinol Metab, 97(6), E1051–E1059. https://doi.org/10.1210/jc.2011-3131.CrossRefPubMedPubMedCentral

265.

Wang, B., Yang, J., & Xiao, B. (2016). MicroRNA-20b (miR-20b) promotes the proliferation, migration, invasion, and tumorigenicity in esophageal cancer cells via the regulation of phosphatase and tensin homologue expression. PLoS One, 11(10), e0164105. https://doi.org/10.1371/journal.pone.0164105.CrossRefPubMedPubMedCentral

266.

Hong, S., Yu, S., Li, J., Yin, Y., Liu, Y., Zhang, Q., et al. (2016). MiR-20b displays tumor-suppressor functions in papillary thyroid carcinoma by regulating the MAPK/ERK signaling pathway. Thyroid, 26(12), 1733–1743. https://doi.org/10.1089/thy.2015.0578.CrossRefPubMed

267.

Pérez-Rivas, L. G., Jerez, J. M., Carmona, R., de Luque, V., Vicioso, L., Claros, M. G., et al. (2014). A microRNA signature associated with early recurrence in breast cancer. PLoS One, 9(3), e91884. https://doi.org/10.1371/journal.pone.0091884.CrossRefPubMedPubMedCentral

268.

Li, M., Zhou, Y., Xia, T., Zhou, X., Huang, Z., Zhang, H., et al. (2018). Circulating microRNAs from the miR-106a–363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer. Breast Cancer Res Treat, 170(2), 257–270. https://doi.org/10.1007/s10549-018-4757-3.CrossRefPubMedPubMedCentral

269.

Valastyan, S., Chang, A., Benaich, N., Reinhardt, F., & Weinberg, R. A. (2015). Retraction: concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res, 75(13), 2760. https://doi.org/10.1158/0008-5472.Can-15-1251.CrossRefPubMedCentral

270.

Sporn, J. C., Katsuta, E., Yan, L., & Takabe, K. (2019). Expression of microRNA-9 is associated with overall survival in breast cancer patients. J Surg Res, 233, 426–435. https://doi.org/10.1016/j.jss.2018.08.020.CrossRefPubMed

271.

Medina, P. P., Nolde, M., & Slack, F. J. (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nat Adv Online Publ. https://doi.org/10.1038/nature09284.

272.

Donnarumma E, Fiore D, Nappa M, Roscigno G, Adamo A, Iaboni M, et al. (2017). Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer. Oncotarget.

273.

Li, S., Yang, X., Yang, J., Zhen, J., & Zhang, D. (2016). Serum microRNA-21 as a potential diagnostic biomarker for breast cancer: a systematic review and meta-analysis. Clin Exp Med, 16(1), 29–35. https://doi.org/10.1007/s10238-014-0332-3.CrossRefPubMed

274.

Dituri, F., Cossu, C., Mancarella, S., & Giannelli, G. (2019). The interactivity between TGFbeta and BMP signaling in organogenesis, fibrosis, and cancer. Cells, 8(10). https://doi.org/10.3390/cells8101130.

275.

Yu, X., Li, R., Shi, W., Jiang, T., Wang, Y., Li, C., et al. (2016). Silencing of microRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells. Biomed Pharmacother, 77, 37–44. https://doi.org/10.1016/j.biopha.2015.11.005.CrossRefPubMed

276.

Larcher, L. M., Wang, T., & Veedu, R. N. (2019). Development of novel antimiRzymes for targeted inhibition of miR-21 expression in solid cancer cells. Molecules, 24(13), 2489. https://doi.org/10.3390/molecules24132489.CrossRefPubMedCentral

277.

Patutina, O. A., Miroshnichenko, S. K., Mironova, N. L., Sen’kova, A. V., Bichenkova, E. V., Clarke, D. J., et al. (2019). Catalytic knockdown of miR-21 by artificial ribonuclease: biological performance in tumor model. [Original research]. Front Pharmacol, 10, 879. https://doi.org/10.3389/fphar.2019.00879.CrossRefPubMedPubMedCentral

278.

Fang, Y., Wang, J., Wu, F., Song, Y., Zhao, S., & Zhang, Q. (2017). Long non-coding RNA HOXA-AS2 promotes proliferation and invasion of breast cancer by acting as a miR-520c-3p sponge. Oncotarget, 8(28), 46090–46103. https://doi.org/10.18632/oncotarget.17552.CrossRefPubMedPubMedCentral

279.

Wu, X., Chen, S., & Lu, C. (2019). Amyloid precursor protein promotes the migration and invasion of breast cancer cells by regulating the MAPK signaling pathway. Int J Mol Med. https://doi.org/10.3892/ijmm.2019.4404.

280.

Ding, W., Fan, X.-L., Xu, X., Huang, J.-Z., Xu, S.-H., Geng, Q., et al. (2015). Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. PLoS One, 10(8), e0135128. https://doi.org/10.1371/journal.pone.0135128.CrossRefPubMedPubMedCentral

281.

Chen, D., Dang, B. L., Huang, J. Z., Chen, M., Wu, D., Xu, M. L., et al. (2015). MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget, 6(32), 32701–32712. https://doi.org/10.18632/oncotarget.4702.CrossRefPubMedPubMedCentral

282.

Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet, 40(1), 43–50. https://doi.org/10.1038/ng.2007.30.CrossRefPubMed

283.

Eyholzer, M., Schmid, S., Wilkens, L., Mueller, B. U., & Pabst, T. (2010). The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML. Br J Cancer, 103(2), 275–284. https://doi.org/10.1038/sj.bjc.6605751.CrossRefPubMedPubMedCentral

284.

Mott, J. L., Kurita, S., Cazanave, S., Bronk, S. F., Werneburg, N. W., & Fernandez-Zapico, M. E. (2010). Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, Hedgehog, and NF-kappaB. J Cell Biochem, 110(5), 1155–1164. https://doi.org/10.1002/jcb.22630.CrossRefPubMedPubMedCentral

285.

Kriegel, A. J., Liu, Y., Fang, Y., Ding, X., & Liang, M. (2012). The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics, 44(4), 237–244. https://doi.org/10.1152/physiolgenomics.00141.2011.CrossRefPubMedPubMedCentral

286.

Mishmar, D., Rahat, A., Scherer, S. W., Nyakatura, G., Hinzmann, B., Kohwi, Y., et al. (1998). Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci U S A, 95(14), 8141–8146.PubMedPubMedCentral

287.

Chou, J., Lin, J. H., Brenot, A., Kim, J.-W., Provot, S., & Werb, Z. (2013). GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. [10.1038/ncb2672]. Nat Cell Biol, 15(2), 201–213. https://doi.org/10.1038/ncb2672.CrossRefPubMedPubMedCentral

288.

Kuhnert, F., Campagnolo, L., Xiong, J.-W., Lemons, D., Fitch, M. J., Zou, Z., et al. (2005). Dosage-dependent requirement for mouse Vezf1 in vascular system development. Dev Biol, 283(1), 140–156. https://doi.org/10.1016/j.ydbio.2005.04.003.CrossRefPubMedPubMedCentral

289.

Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., et al. (2011). MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene, 30(9), 1082–1097. https://doi.org/10.1038/onc.2010.487.CrossRefPubMed

290.

Balzeau, J., Menezes, M. R., Cao, S., & Hagan, J. P. (2017). The LIN28/let-7 pathway in cancer. [Review]. Front Genet, 8, 31. https://doi.org/10.3389/fgene.2017.00031.CrossRefPubMedPubMedCentral

291.

Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial–mesenchymal transition. Nat Rev Mol Cell Biol, 15(3), 178–196. https://doi.org/10.1038/nrm3758.CrossRefPubMedPubMedCentral

292.

Deblois, G., Smith, H. W., Tam, I. S., Gravel, S.-P., Caron, M., Savage, P., et al. (2016). ERR[alpha] mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nat Commun, 7, 12156. https://doi.org/10.1038/ncomms12156.CrossRefPubMedPubMedCentral

293.

Cicek, M., Fukuyama, R., Welch, D. R., Sizemore, N., & Casey, G. (2005). Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-{kappa}B activity. Cancer Res, 65(9), 3586–3595. https://doi.org/10.1158/0008-5472.CAN-04-3139.CrossRefPubMed

294.

Hurst, D. R., Xie, Y., Vaidya, K. S., Mehta, A., Moore, B. P., Accavitti-Loper, M. A., et al. (2008). Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem, 283(12), 7438–7444. https://doi.org/10.1074/jbc.M709446200.CrossRefPubMed

295.

Qiu, R., Shi, H., Wang, S., Leng, S., Liu, R., Zheng, Y., et al. (2018). BRMS1 coordinates with LSD1 and suppresses breast cancer cell metastasis. Am J Cancer Res, 8(10), 2030–2045.PubMedPubMedCentral

296.

Bhaumik, D., Scott, G. K., Schokrpur, S., Patil, C. K., Campisi, J., & Benz, C. C. (2008). Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells. Oncogene, 27(42), 5643–5647. https://doi.org/10.1038/onc.2008.171.CrossRefPubMedPubMedCentral

297.

Hashemi, Z. S., Forouzandeh Moghadam, M., Khalili, S., Ghavami, M., Salimi, F., & Sadroddiny, E. (2019). Additive effect of metastamiR-193b and breast cancer metastasis suppressor 1 as an anti-metastatic strategy. Breast Cancer, 26(2), 215–228. https://doi.org/10.1007/s12282-018-0915-z.CrossRefPubMed

298.

Stevic, I., Müller, V., Weber, K., Fasching, P. A., Karn, T., Marmé, F., et al. (2018). Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med, 16(1), 179. https://doi.org/10.1186/s12916-018-1163-y.CrossRefPubMedPubMedCentral

299.

Luengo-Gil, G., Gonzalez-Billalabeitia, E., Perez-Henarejos, S. A., Navarro Manzano, E., Chaves-Benito, A., Garcia-Martinez, E., et al. (2018). Angiogenic role of miR-20a in breast cancer. PLoS One, 13(4), e0194638. https://doi.org/10.1371/journal.pone.0194638.CrossRefPubMedPubMedCentral

300.

Chan, M., Liaw, C. S., Ji, S. M., Tan, H. H., Wong, C. Y., Thike, A. A., et al. (2013). Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res, 19(16), 4477–4487. https://doi.org/10.1158/1078-0432.ccr-12-3401.CrossRefPubMed

301.

Guo, L., Zhu, Y., Li, L., Zhou, S., Yin, G., Yu, G., et al. (2019). Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med, 8(12), 5687–5701. https://doi.org/10.1002/cam4.2454.CrossRefPubMedPubMedCentral

302.

Bottani, M., Banfi, G., & Lombardi, G. (2019). Circulating miRNAs as diagnostic and prognostic biomarkers in common solid tumors: focus on lung, breast, prostate cancers, and osteosarcoma. J Clin Med, 8(10), 1661. https://doi.org/10.3390/jcm8101661.CrossRefPubMedCentral

303.

Parr, C., & Jiang, W. G. (2009). Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer, 45(9), 1673–1683. https://doi.org/10.1016/j.ejca.2009.02.019.CrossRefPubMed

304.

Lee, J. H., & Welch, D. R. (1997). Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res, 57(12), 2384–2387.PubMed

305.

Yoshida, B. A., Sokoloff, M. M., Welch, D. R., & Rinker-Schaeffer, C. W. (2000). Metastasis-suppressor genes: a review and perspective on an emerging field. J Natl Cancer Inst, 92(21), 1717–1730.PubMed

306.

Hurst DR, & Welch DR (2011). Chapter three - metastasis suppressor genes: at the interface between the environment and tumor cell growth. In K. W. Jeon (Ed.), International review of cell and molecular biology (Vol. 286, pp. 107-180): Academic.

307.

Li, G., Li, L., Sun, Q., Wu, J., Ge, W., Lu, G., et al. (2018). MicroRNA-3200-5p promotes osteosarcoma cell invasion via suppression of BRMS1. Mol Cell, 41(6), 523–531. https://doi.org/10.14348/molcells.2018.2200.CrossRef

308.

Guo, Z., Li, J., Sun, J., Sun, L., Zhou, Y., & Yu, Z. (2018). miR-346 promotes HCC progression by suppressing breast cancer metastasis suppressor 1 expression. Oncol Res, 26(7), 1073–1081. https://doi.org/10.3727/096504017x15145088802439.CrossRefPubMedPubMedCentral

309.

Meehan, W. J., Samant, R. S., Hopper, J. E., Carrozza, M. J., Shevde, L. A., Workman, J. L., et al. (2004). breast cancer metastasis suppressor 1 (BRMS1) FORMS COMPLEXES WITH RETINOBLASTOMA-BINDING Protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem, 279(2), 1562–1569.PubMed

310.

Hicks, D. G., Yoder, B. J., Short, S., Tarr, S., Prescott, N., Crowe, J. P., et al. (2006). Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients. Clin Cancer Res, 12(22), 6702–6708. https://doi.org/10.1158/1078-0432.ccr-06-0635.CrossRefPubMedPubMedCentral

311.

Li, Q.-J., Zhou, L., Yang, F., Wang, G.-X., Zheng, H., Wang, D.-S., et al. (2012). MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biol, 33(5), 1455–1465. https://doi.org/10.1007/s13277-012-0396-1.CrossRef

312.

Katoh, M. (2014). Cardio-miRNAs and onco-miRNAs: circulating miRNA-based diagnostics for non-cancerous and cancerous diseases. Front Cell Dev Biol, 2, 61. https://doi.org/10.3389/fcell.2014.00061.CrossRefPubMedPubMedCentral

313.

Minami, A., Shimono, Y., Mizutani, K., Nobutani, K., Momose, K., Azuma, T., et al. (2013). Reduction of the ST6 β-galactosamide α-2,6-sialyltransferase 1 (ST6GAL1)-catalyzed sialylation of nectin-like molecule 2/cell adhesion molecule 1 and enhancement of ErbB2/ErbB3 signaling by microRNA-199a. J Biol Chem, 288(17), 11845–11853. https://doi.org/10.1074/jbc.M112.405993.CrossRefPubMedPubMedCentral

314.

Takahashi, Y., Iwai, M., Kawai, T., Arakawa, A., Ito, T., Sakurai-Yageta, M., et al. (2012). Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer, 19(3), 242–252. https://doi.org/10.1007/s12282-011-0272-7.CrossRefPubMed

315.

Derfoul, A., Juan, A. H., Difilippantonio, M. J., Palanisamy, N., Ried, T., & Sartorelli, V. (2011). Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis, 32(11), 1607–1614. https://doi.org/10.1093/carcin/bgr184.CrossRefPubMedPubMedCentral

316.

Ulasov, I. V., Borovjagin, A. V., Timashev, P., Cristofanili, M., & Welch, D. R. (2019). KISS1 in breast cancer progression and autophagy. Cancer Metastasis Rev. https://doi.org/10.1007/s10555-019-09814-4.

317.

Martin, T. A., Watkins, G., & Jiang, W. G. (2005). KiSS-1 expression in human breast cancer. Clin Exp Metastasis, 22(6), 503–511. https://doi.org/10.1007/s10585-005-4180-0.CrossRefPubMed

318.

Kaverina, N., Borovjagin, A. V., Kadagidze, Z., Baryshnikov, A., Baryshnikova, M., Malin, D., et al. (2017). Astrocytes promote progression of breast cancer metastases to the brain via a KISS1-mediated autophagy. Autophagy, 13(11), 1905–1923. https://doi.org/10.1080/15548627.2017.1360466.CrossRefPubMedPubMedCentral

319.

Zhong, X.-Y., Yu, J.-H., Zhang, W.-G., Wang, Z.-D., Dong, Q., Tai, S., et al. (2012). MicroRNA-421 functions as an oncogenic miRNA in biliary tract cancer through down-regulating farnesoid X receptor expression. Gene, 493(1), 44–51. https://doi.org/10.1016/j.gene.2011.11.028.CrossRefPubMed

320.

Krattinger, R., Bostrom, A., Schioth, H. B., Thasler, W. E., Mwinyi, J., & Kullak-Ublick, G. A. (2016). microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol, 310(11), G1044–G1051. https://doi.org/10.1152/ajpgi.00297.2015.CrossRefPubMed

321.

Garcia, M., Thirouard, L., Sedès, L., Monrose, M., Holota, H., Caira, F., et al. (2018). Nuclear receptor metabolism of bile acids and xenobiotics: a coordinated detoxification system with impact on health and diseases. Int J Mol Sci, 19(11), 3630.PubMedCentral

322.

Barone, I., Vircillo, V., Giordano, C., Gelsomino, L., Győrffy, B., Tarallo, R., et al. (2018). Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts. Cancer Lett, 437, 89–99. https://doi.org/10.1016/j.canlet.2018.08.026.CrossRefPubMed

323.

Ma, Y., Qin, H., & Cui, Y. (2013). MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun, 441(4), 958–963. https://doi.org/10.1016/j.bbrc.2013.11.010.CrossRefPubMed

324.

Jiménez, A., López-Ornelas, A., Estudillo, E., González-Mariscal, L., González, R. O., & Segovia, J. (2014). A soluble form of GAS1 inhibits tumor growth and angiogenesis in a triple negative breast cancer model. Exp Cell Res, 327(2), 307–317. https://doi.org/10.1016/j.yexcr.2014.06.016.CrossRefPubMed

325.

Zhou, M., Hou, Y., Yang, G., Zhang, H., Tu, G., Du, Y. E., et al. (2016). LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of hedgehog signaling pathway. Stem Cells, 34(1), 55–66. https://doi.org/10.1002/stem.2219.CrossRefPubMed

326.

Mine, M., Yamaguchi, K., Sugiura, T., Chigita, S., Yoshihama, N., Yoshihama, R., et al. (2015). miR-203 inhibits Frizzled-2 expression via CD82/KAI1 expression in human lung carcinoma cells. PLoS One, 10(7), e0131350. https://doi.org/10.1371/journal.pone.0131350.CrossRefPubMedPubMedCentral

327.

Xu, L., Hou, Y., Tu, G., Chen, Y., Du, Y.-E., Zhang, H., et al. (2017). Nuclear Drosha enhances cell invasion via an EGFR-ERK1/2-MMP7 signaling pathway induced by dysregulated miRNA-622/197 and their targets LAMC2 and CD82 in gastric cancer. Cell Death Dis, 8, e2642. https://doi.org/10.1038/cddis.2017.5.CrossRefPubMedPubMedCentral

328.

Miller, J., Dreyer, T. F., Bacher, A. S., Sinner, E. K., Heinrich, C., Benge, A., et al. (2018). Differential tumor biological role of the tumor suppressor KAI1 and its splice variant in human breast cancer cells. Oncotarget, 9(5), 6369–6390. https://doi.org/10.18632/oncotarget.23968.CrossRefPubMedPubMedCentral

329.

Yang, X., Wei, L., Tang, C., Slack, R., Montgomery, E., & Lippman, M. (2000). KAI1 protein is down-regulated during the progression of human breast cancer. Clin Cancer Res, 6(9), 3424–3429.PubMed

330.

Wang, J., Song, C., Tang, H., Zhang, C., Tang, J., Li, X., et al. (2017). miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer. Breast Cancer Res, 19(1), 72. https://doi.org/10.1186/s13058-017-0865-y.CrossRefPubMedPubMedCentral

331.

Hergovich, A. (2012). YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer. Breast Cancer Res, 14(6), 326. https://doi.org/10.1186/bcr3349.CrossRefPubMedPubMedCentral

332.

Nilsson, E. M., Laursen, K. B., Whitchurch, J., McWilliam, A., Odum, N., Persson, J. L., et al. (2015). MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Oncotarget, 6(34), 35710–35725. https://doi.org/10.18632/oncotarget.5958.CrossRefPubMedPubMedCentral

333.

Yang, H., Li, Q., Zhao, W., Yuan, D., Zhao, H., & Zhou, Y. (2014). miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett, 588(1), 192–197. https://doi.org/10.1016/j.febslet.2013.11.036.CrossRefPubMed

334.

Ma, L., Ma, S., Zhao, G., Yang, L., Zhang, P., Yi, Q., et al. (2016). miR-708/LSD1 axis regulates the proliferation and invasion of breast cancer cells. Cancer Med, 5(4), 684–692. https://doi.org/10.1002/cam4.623.CrossRefPubMedPubMedCentral

335.

Yang, G. J., Lei, P. M., Wong, S. Y., Ma, D. L., & Leung, C. H. (2018). Pharmacological inhibition of LSD1 for cancer treatment. Molecules, 23(12), 3194. https://doi.org/10.3390/molecules23123194.CrossRefPubMedCentral

336.

Derr, R. S., van Hoesel, A. Q., Benard, A., Goossens-Beumer, I. J., Sajet, A., Dekker-Ensink, N. G., et al. (2014). High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer, 14(1), 604. https://doi.org/10.1186/1471-2407-14-604.CrossRefPubMedPubMedCentral

337.

Grieb, B. C., Gramling, M. W., Arrate, M. P., Chen, X., Beauparlant, S. L., Haines, D. S., et al. (2014). Oncogenic protein MTBP interacts with MYC to promote tumorigenesis. Cancer Res, 74(13), 3591. https://doi.org/10.1158/0008-5472.CAN-13-2149.CrossRefPubMedPubMedCentral

338.

Grieb, B. C., Chen, X., & Eischen, C. M. (2014). MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res, 12(9), 1216. https://doi.org/10.1158/1541-7786.MCR-14-0069.CrossRefPubMedPubMedCentral

339.

Mundt, F., Rajput, S., Li, S., Ruggles, K. V., Mooradian, A. D., Mertins, P., et al. (2018). Mass spectrometry–based proteomics reveals potential roles of NEK9 and MAP2K4 in resistance to PI3K inhibition in triple-negative breast cancers. Cancer Res, 78(10), 2732. https://doi.org/10.1158/0008-5472.CAN-17-1990.CrossRefPubMedPubMedCentral

340.

Liu, S., Huang, J., Zhang, Y., Liu, Y., Zuo, S., & Li, R. (2019). MAP2K4 interacts with vimentin to activate the PI3K/AKT pathway and promotes breast cancer pathogenesis. Aging (Albany NY), 11(22), 10697–10710. https://doi.org/10.18632/aging.102485.CrossRef

341.

Abba, M. C., Gong, T., Lu, Y., Lee, J., Zhong, Y., Lacunza, E., et al. (2015). A molecular portrait of high-grade ductal carcinoma in situ (DCIS). Cancer Res. https://doi.org/10.1158/0008-5472.can-15-0506.

342.

Lefebvre, C., Bachelot, T., Filleron, T., Pedrero, M., Campone, M., Soria, J. C., et al. (2016). Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med, 13(12), e1002201. https://doi.org/10.1371/journal.pmed.1002201.CrossRefPubMedPubMedCentral

343.

De Mattos-Arruda, L., Ng, C. K. Y., Piscuoglio, S., Gonzalez-Cao, M., Lim, R. S., De Filippo, M. R., et al. (2018). Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 9(29), 20617–20630. https://doi.org/10.18632/oncotarget.25041.CrossRefPubMedPubMedCentral

344.

Lopez-Knowles, E., Pearson, A., Schuster, G., Gellert, P., Ribas, R., Yeo, B., et al. (2019). Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations. Br J Cancer, 120(2), 247–255. https://doi.org/10.1038/s41416-018-0345-x.CrossRefPubMed

345.

Luo, E.-C., Chang, Y.-C., Sher, Y.-P., Huang, W.-Y., Chuang, L.-L., Chiu, Y.-C., et al. (2014). MicroRNA-769-3p down-regulates NDRG1 and enhances apoptosis in MCF-7 cells during reoxygenation. Sci Rep, 4(1), 5908. https://doi.org/10.1038/srep05908.CrossRefPubMedPubMedCentral

346.

Liu, R., Li, J., Teng, Z., Zhang, Z., & Xu, Y. (2013). Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One, 8(7), e68982. https://doi.org/10.1371/journal.pone.0068982.CrossRefPubMedPubMedCentral

347.

Wu, A.-Y., Hu, Y., Cang, W., Li, D., Wang, W.-J., Tian, Q., et al. (2019). Suppressive effect of microRNA-449a on the NDRG1/PTEN/AKT axis regulates endometrial cancer growth and metastasis. Exp Cell Res, 382(2), 111468. https://doi.org/10.1016/j.yexcr.2019.06.013.CrossRefPubMed

348.

Sevinsky, C. J., Khan, F., Kokabee, L., Darehshouri, A., Maddipati, K. R., & Conklin, D. S. (2018). NDRG1 regulates neutral lipid metabolism in breast cancer cells. Breast Cancer Res, 20(1), 55. https://doi.org/10.1186/s13058-018-0980-4.CrossRefPubMedPubMedCentral

349.

Jiao, G.-J., Zhang, S.-J., Li, Y., Wu, W.-L., & Liu, H.-C. (2018). MicroRNA-645 promotes metastasis of osteosarcoma via targeting tumor suppressor NM23 nucleoside diphosphate kinase 2. Clin Exp Pharmacol Physiol, 45(12), 1317–1324. https://doi.org/10.1111/1440-1681.13006.CrossRefPubMed

350.

Hartsough, M. T., Clare, S. E., Mair, M., Elkahloun, A. G., Sgroi, D., Osborne, C. K., et al. (2001). Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res, 61(5), 2320–1878.PubMed

351.

Radpour, R., Kohler, C., Haghighi, M. M., Fan, A. X. C., Holzgreve, W., & Zhong, X. Y. (2009). Methylation profiles of 22 candidate genes in breast cancer using high-throughput MALDI-TOF mass array. Oncogene, 28(33), 2969–2978.PubMed

352.

Xue, R., Peng, Y., Han, B., Li, X., Chen, Y., & Pei, H. (2019). Metastasis suppressor NME1 promotes non-homologous end joining of DNA double-strand breaks. DNA Repair, 77, 27–35. https://doi.org/10.1016/j.dnarep.2019.03.003.CrossRefPubMed

353.

Curtis, C. D., Likhite, V. S., McLeod, I. X., Yates, J. R., & Nardulli, A. M. (2007). Interaction of the tumor metastasis suppressor nonmetastatic protein 23 homologue H1 and estrogen receptor {alpha} alters estrogen-responsive gene Expression. Cancer Res, 67(21), 10600–10607. https://doi.org/10.1158/0008-5472.can-07-0055.CrossRefPubMed

354.

Romani, P., Ignesti, M., Gargiulo, G., Hsu, T., & Cavaliere, V. (2018). Extracellular NME proteins: a player or a bystander? Lab Investig, 98(2), 248–257. https://doi.org/10.1038/labinvest.2017.102.CrossRefPubMed

355.

Smagghe, B. J., Stewart, A. K., Carter, M. G., Shelton, L. M., Bernier, K. J., Hartman, E. J., et al. (2013). MUC1* ligand, NM23-H1, is a novel growth factor that maintains human stem cells in a more naïve state. PLoS One, 8(3), e58601. https://doi.org/10.1371/journal.pone.0058601.CrossRefPubMedPubMedCentral

356.

Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Horschowski, N., et al. (1998). Prognostic significance of Nm23/NDPK expression in breast carcinoma, assessed on 10-year follow-up by automated and quantitative immunocytochemical assays. J Pathol, 184(4), 401–407. https://doi.org/10.1002/(sici)1096-9896(199804)184:4<401::Aid-path1220>3.0.Co;2-u.CrossRefPubMed

357.

Ribeiro, M. A., Estill, M. S., Fernandez, G. J., Moraes, L. N., Krawetz, S. A., & Scarano, W. R. (2018). Integrative transcriptome and microRNome analysis identifies dysregulated pathways in human Sertoli cells exposed to TCDD. Toxicology, 409, 112–118. https://doi.org/10.1016/j.tox.2018.08.001.CrossRefPubMed

358.

Insel, P. A., Sriram, K., Wiley, S. Z., Wilderman, A., Katakia, T., McCann, T., et al. (2018). GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Front Pharmacol, 9, 431. https://doi.org/10.3389/fphar.2018.00431.CrossRefPubMedPubMedCentral

359.

Fan, P., Liu, L., Yin, Y., Zhao, Z., Zhang, Y., Amponsah, P. S., et al. (2016). MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett, 373(1), 130–137. https://doi.org/10.1016/j.canlet.2016.01.038.CrossRefPubMed

360.

Zhang, Y.-W., Jones, T. L., Martin, S. E., Caplen, N. J., & Pommier, Y. (2009). Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. J Biol Chem, 284(27), 18085–18095. https://doi.org/10.1074/jbc.M109.003020.CrossRefPubMedPubMedCentral

361.

Xu, Y. C., Zhang, F. C., Li, J. J., Dai, J. Q., Liu, Q., Tang, L., et al. (2015). RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: difference between mRNA and protein expression in predicting prognosis of breast cancer patients. Oncol Rep, 34(4), 1883–1894. https://doi.org/10.3892/or.2015.4183.CrossRefPubMed

362.

Jørgensen, C. L. T., Ejlertsen, B., Bjerre, K. D., Balslev, E., Nielsen, D. L., & Nielsen, K. V. (2013). Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. BMC Cancer, 13(1), 541. https://doi.org/10.1186/1471-2407-13-541.CrossRefPubMedPubMedCentral

363.

Dorman, S. N., Baranova, K., Knoll, J. H. M., Urquhart, B. L., Mariani, G., Carcangiu, M. L., et al. (2016). Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning. Mol Oncol, 10(1), 85–100. https://doi.org/10.1016/j.molonc.2015.07.006.CrossRefPubMed

364.

Jones, D. Z., Schmidt, M. L., Suman, S., Hobbing, K. R., Barve, S. S., Gobejishvili, L., et al. (2018). Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells. BMC Cancer, 18(1), 421. https://doi.org/10.1186/s12885-018-4258-0.CrossRefPubMedPubMedCentral

365.

Xia, W., Ni, J., Zhuang, J., Qian, L., Wang, P., & Wang, J. (2016). MiR-103 regulates hepatocellular carcinoma growth by targeting AKAP12. Int J Biochem Cell Biol, 71, 1–11. https://doi.org/10.1016/j.biocel.2015.11.017.CrossRefPubMed

366.

Gelman, I. H. (2012). Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. [Journal article]. Cancer Metastasis Rev, 31(3), 493–500. https://doi.org/10.1007/s10555-012-9360-1.CrossRefPubMedPubMedCentral

367.

Soh, R. Y. Z., Lim, J. P., Samy, R. P., Chua, P. J., & Bay, B. H. (2018). A-kinase anchor protein 12 (AKAP12) inhibits cell migration in breast cancer. Exp Mol Pathol, 105(3), 364–370. https://doi.org/10.1016/j.yexmp.2018.10.010.CrossRefPubMed

368.

Kioulafa, M., Balkouranidou, I., Sotiropoulou, G., Kaklamanis, L., Mavroudis, D., Georgoulias, V., et al. (2009). Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer, 125(12), 2887–2892. https://doi.org/10.1002/ijc.24686.CrossRefPubMed

369.

Roll, J. D., Rivenbark, A. G., Sandhu, R., Parker, J. S., Jones, W. D., Carey, L. A., et al. (2013). Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Exp Mol Pathol, 95(3), 276–287. https://doi.org/10.1016/j.yexmp.2013.09.001.CrossRefPubMed

370.

Chimonidou, M., Strati, A., Malamos, N., Kouneli, S., Georgoulias, V., & Lianidou, E. (2017). Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. Oncotarget, 8(42), 72054–72068. https://doi.org/10.18632/oncotarget.18679.CrossRefPubMedPubMedCentral

371.

Li, Q., Zheng, Z.-C., Ni, C.-J., Jin, W.-X., Jin, Y.-X., Chen, Y., et al. (2018). Correlation of cystatin E/M with clinicopathological features and prognosis in triple-negative breast cancer. Ann Clin Lab Sci, 48(1), 40–44.PubMed

372.

Clarke, M. R., Imhoff, F. M., & Baird, S. K. (2015). Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase-1 and -2. Mol Carcinog, 54(10), 1214–1219. https://doi.org/10.1002/mc.22178.CrossRefPubMed

373.

Daniele, A., Abbate, I., Oakley, C., Casamassima, P., Savino, E., Casamassima, A., et al. (2016). Clinical and prognostic role of matrix metalloproteinase-2, -9 and their inhibitors in breast cancer and liver diseases: a review. Int J Biochem Cell Biol, 77, 91–101. https://doi.org/10.1016/j.biocel.2016.06.002.CrossRefPubMed

374.

Liu, J., Shi, W., Wu, C., Ju, J., & Jiang, J. (2014). miR-181b as a key regulator of the oncogenic process and its clinical implications in cancer (Review). Biomed Rep, 2(1), 7–11. https://doi.org/10.3892/br.2013.199.CrossRefPubMed

375.

Song, B., Wang, C., Liu, J., Wang, X., Lv, L., Wei, L., et al. (2010). MicroRNA-21 regulates breast cancer invasion partly by targeting tissue inhibitor of metalloproteinase 3 expression. J Exp Clin Cancer Res, 29(1), 29. https://doi.org/10.1186/1756-9966-29-29.CrossRefPubMedPubMedCentral

376.

Gan, R., Yang, Y., Yang, X., Zhao, L., Lu, J., & Meng, Q. H. (2014). Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3. [Original article]. Cancer Gene Ther, 21(7), 290–296. https://doi.org/10.1038/cgt.2014.29.CrossRefPubMed

377.

Bachman, K. E., Herman, J. G., Corn, P. G., Merlo, A., Costello, J. F., Cavenee, W. K., et al. (1999). Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers. Cancer Res, 59(4), 798–802.PubMed

378.

Janiak, M., Paskal, W., Rak, B., Garbicz, F., Jarema, R., Sikora, K., et al. (2017). TIMP4 expression is regulated by miR-200b-3p in prostate cancer cells. APMIS, 125(2), 101–105. https://doi.org/10.1111/apm.12638.CrossRefPubMed

379.

Boufraqech, M., Zhang, L., Nilubol, N., Sadowski, S. M., Kotian, S., Quezado, M., et al. (2016). Lysyl oxidase (LOX) transcriptionally regulates SNAI2 expression and TIMP4 secretion in human cancers. Clin Cancer Res, 22(17), 4491–4504. https://doi.org/10.1158/1078-0432.Ccr-15-2461.CrossRefPubMedPubMedCentral

380.

Morrison Joly, M., Williams, M. M., Hicks, D. J., Jones, B., Sanchez, V., Young, C. D., et al. (2017). Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res, 19(1), 74. https://doi.org/10.1186/s13058-017-0868-8.CrossRefPubMedPubMedCentral

381.

Franssen, D., & Tena-Sempere, M. (2018). The kisspeptin receptor: a key G-protein-coupled receptor in the control of the reproductive axis. Best Pract Res Clin Endocrinol Metab, 32(2), 107–123. https://doi.org/10.1016/j.beem.2018.01.005.CrossRefPubMed

382.

Shen, Z. L., Wang, B., Jiang, K. W., Ye, C. X., Cheng, C., Yan, Y. C., et al. (2016). Downregulation of miR-199b is associated with distant metastasis in colorectal cancer via activation of SIRT1 and inhibition of CREB/KISS1 signaling. Oncotarget, 7(23), 35092–35105. https://doi.org/10.18632/oncotarget.9042.CrossRefPubMedPubMedCentral

383.

Journe, F., Durbecq, V., Chaboteaux, C., Rouas, G., Laurent, G., Nonclercq, D., et al. (2009). Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients. Breast Cancer Res Treat, 115(3), 523–535. https://doi.org/10.1007/s10549-008-0094-2.CrossRefPubMed

384.

Bandyopadhyay, S., Zhan, R., Chaudhuri, A., Watabe, M., Pai, S. K., Hirota, S., et al. (2006). Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med, 12(8), 933–938. https://doi.org/10.1038/nm1444.CrossRefPubMed

385.

Viswanadhapalli, S., Luo, Y., Sareddy, G. R., Santhamma, B., Zhou, M., Li, M., et al. (2019). EC359: a first-in-class small-molecule inhibitor for targeting oncogenic LIFR signaling in triple-negative breast cancer. Mol Cancer Ther, 18(8), 1341. https://doi.org/10.1158/1535-7163.MCT-18-1258.CrossRefPubMed

386.

Pollock, J. A., Larrea, M. D., Jasper, J. S., McDonnell, D. P., & McCafferty, D. G. (2012). Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and -independent manners. ACS Chem Biol, 7(7), 1221–1231. https://doi.org/10.1021/cb300108c.CrossRefPubMedPubMedCentral

387.

Hu, X., Xiang, D., Xie, Y., Tao, L., Zhang, Y., Jin, Y., et al. (2019). LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression. Oncogene, 38(44), 7017–7034. https://doi.org/10.1038/s41388-019-0923-2.CrossRefPubMedPubMedCentral

388.

Liu, J., Feng, J., Li, L., Lin, L., Ji, J., Lin, C., et al. (2019). Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep, 21(2), e48597. https://doi.org/10.15252/embr.201948597.CrossRefPubMedPubMedCentral

389.

Bi, Q., Ranjan, A., Fan, R., Agarwal, N., Welch, D. R., Weinman, S. A., et al. (2015). MTBP inhibits migration and metastasis of hepatocellular carcinoma. Clin Exp Metastasis, 32(4), 301–311. https://doi.org/10.1007/s10585-015-9706-5.CrossRefPubMedPubMedCentral

390.

Sehgal, V., & Ram, P. T. (2013). Network motifs in JNK signaling. Genes Cancer, 4(9-10), 409–413. https://doi.org/10.1177/1947601913507577.CrossRefPubMedPubMedCentral

391.

Xue, Z., Vis, D. J., Bruna, A., Sustic, T., van Wageningen, S., Batra, A. S., et al. (2018). MAP3K1 and MAP2K4 mutations are associated with sensitivity to MEK inhibitors in multiple cancer models. Cell Res, 28(7), 719–729. https://doi.org/10.1038/s41422-018-0044-4.CrossRefPubMedPubMedCentral

392.

Wangpu, X., Lu, J., Xi, R., Yue, F., Sahni, S., Park, K. C., et al. (2016). Targeting the metastasis suppressor, N-Myc downstream regulated gene-1, with novel di-2-pyridylketone thiosemicarbazones: suppression of tumor cell migration and cell-collagen adhesion by inhibiting focal adhesion kinase/paxillin signaling. Mol Pharmacol, 89(5), 521. https://doi.org/10.1124/mol.115.103044.CrossRefPubMedPubMedCentral

393.

Pietiäinen, V., Vassilev, B., Blom, T., Wang, W., Nelson, J., Bittman, R., et al. (2013). NDRG1 functions in LDL receptor trafficking by regulating endosomal recycling and degradation. J Cell Sci, 126(17), 3961–3971. https://doi.org/10.1242/jcs.128132.CrossRefPubMed

394.

Kinlaw, W. B., Baures, P. W., Lupien, L. E., Davis, W. L., & Kuemmerle, N. B. (2016). Fatty acids and breast cancer: make them on site or have them delivered. J Cell Physiol, 231(10), 2128–2141. https://doi.org/10.1002/jcp.25332.CrossRefPubMedPubMedCentral

395.

Luo, X., Cheng, C., Tan, Z., Li, N., Tang, M., Yang, L., et al. (2017). Emerging roles of lipid metabolism in cancer metastasis. Mol Cancer, 16(1), 76. https://doi.org/10.1186/s12943-017-0646-3.CrossRefPubMedPubMedCentral

396.

Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., et al. (2018). JAK/STAT3-regulated fatty acid β-oxidation is critical for breast cancer stem cell self-renewal and chemoresistance. Cell Metab, 27(1), 136–150.e135. https://doi.org/10.1016/j.cmet.2017.11.001.CrossRefPubMed

397.

Lin, H. C., Yeh, C. C., Chao, L. Y., Tsai, M. H., Chen, H. H., Chuang, E. Y., et al. (2018). The hypoxia-responsive lncRNA NDRG-OT1 promotes NDRG1 degradation via ubiquitin-mediated proteolysis in breast cancer cells. Oncotarget, 9(12), 10470–10482. https://doi.org/10.18632/oncotarget.23732.CrossRefPubMed

398.

Valastyan, S. (2012). Endogenous anticancer mechanisms: metastasis. Front Biosci (Elite Ed), 4, 1888–1897. https://doi.org/10.2741/510.CrossRef

399.

Smith, S. C., & Theodorescu, D. (2009). Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer, 9(4), 253–264. https://doi.org/10.1038/nrc2594.CrossRefPubMedPubMedCentral

400.

Horak, C. E., Lee, J. H., Elkahloun, A. G., Boissan, M., Dumont, S., Maga, T. K., et al. (2007). Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2. Cancer Res, 67(15), 7238–7246. https://doi.org/10.1158/0008-5472.can-07-0962.CrossRefPubMed

401.

Peeney, D., Fan, Y., Nguyen, T., Meerzaman, D., & Stetler-Stevenson, W. G. (2019). Matrisome-associated gene expression patterns correlating with TIMP2 in cancer. Sci Rep, 9(1), 20142. https://doi.org/10.1038/s41598-019-56632-3.CrossRefPubMedPubMedCentral

402.

Baum, B., Settleman, J., & Quinlan, M. P. (2008). Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol, 19(3), 294–308. https://doi.org/10.1016/j.semcdb.2008.02.001.CrossRefPubMed

403.

Derynck, R., & Weinberg, R. A. (2019). EMT and cancer: more than meets the eye. Dev Cell, 49(3), 313–316. https://doi.org/10.1016/j.devcel.2019.04.026.CrossRefPubMedPubMedCentral

404.

Imani, S., Hosseinifard, H., Cheng, J., Wei, C., & Fu, J. (2016). Prognostic value of EMT-inducing transcription factors (EMT-TFs) in metastatic breast cancer: a systematic review and meta-analysis. Sci Rep, 6(1), 28587. https://doi.org/10.1038/srep28587.CrossRefPubMedPubMedCentral

405.

Creighton, C. J., Gibbons, D. L., & Kurie, J. M. (2013). The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res, 5, 187–195. https://doi.org/10.2147/cmar.S35171.CrossRefPubMedPubMedCentral

406.

Dongre, A., & Weinberg, R. A. (2019). New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol, 20(2), 69–84. https://doi.org/10.1038/s41580-018-0080-4.CrossRefPubMed

407.

Vandewalle, C., Van Roy, F., & Berx, G. (2009). The role of the ZEB family of transcription factors in development and disease. [Journal article]. Cell Mol Life Sci, 66(5), 773–787. https://doi.org/10.1007/s00018-008-8465-8.CrossRefPubMed

408.

Zhao, M., Liu, Y., Zheng, C., & Qu, H. (2019). dbEMT 2.0: an updated database for epithelial-mesenchymal transition genes with experimentally verified information and precalculated regulation information for cancer metastasis. J Gen Genomics. https://doi.org/10.1016/j.jgg.2019.11.010.

409.

Aydoğdu, E., Katchy, A., Tsouko, E., Lin, C.-Y., Haldosén, L.-A., Helguero, L., et al. (2012). MicroRNA-regulated gene networks during mammary cell differentiation are associated with breast cancer. Carcinogenesis, 33(8), 1502–1511. https://doi.org/10.1093/carcin/bgs161.CrossRefPubMed

410.

Miao, H., & Wang, B. (2012). EphA receptor signaling—complexity and emerging themes. Semin Cell Dev Biol, 23(1), 16–25. https://doi.org/10.1016/j.semcdb.2011.10.013.CrossRefPubMed

411.

Sato, M., Kadota, M., Tang, B., Yang, H. H., Yang, Y.-A., Shan, M., et al. (2014). An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-β in human breast cancer. Breast Cancer Res, 16(3), R57. https://doi.org/10.1186/bcr3668.CrossRefPubMedPubMedCentral

412.

Gökmen-Polar, Y., Toroni, R. A., Hocevar, B. A., Badve, S., Zhao, Q., Shen, C., et al. (2011). Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. [Journal article]. Breast Cancer Res Treat, 127(2), 375–384. https://doi.org/10.1007/s10549-010-1004-y.CrossRefPubMed

413.

Youngblood, V. M., Kim, L. C., Edwards, D. N., Hwang, Y., Santapuram, P. R., Stirdivant, S. M., et al. (2016). The Ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer. Cancer Res, 76(7), 1825–1836. https://doi.org/10.1158/0008-5472.can-15-0847.CrossRefPubMedPubMedCentral

414.

Bronisz, A., Godlewski, J., Wallace, J. A., Merchant, A. S., Nowicki, M. O., Mathsyaraja, H., et al. (2012). Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320. Nat Cell Biol, 14(2), 159–167. https://doi.org/10.1038/ncb2396.CrossRef

415.

Hannafon, B. N., Carpenter, K. J., Berry, W. L., Janknecht, R., Dooley, W. C., & Ding, W. Q. (2015). Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA). Mol Cancer, 14, 133. https://doi.org/10.1186/s12943-015-0400-7.CrossRefPubMedPubMedCentral

416.

Lindemann, R. K., Ballschmieter, P., Nordheim, A., & Dittmer, J. (2001). Transforming growth factor β regulates parathyroid hormone-related protein expression in MDA-MB-231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem, 276(49), 46661–46670. https://doi.org/10.1074/jbc.M105816200.CrossRefPubMed

417.

Buggy, Y., Maguire, T. M., McDermott, E., Hill, A. D. K., O’Higgins, N., & Duffy, M. J. (2006). Ets2 transcription factor in normal and neoplastic human breast tissue. Eur J Cancer, 42(4), 485–491. https://doi.org/10.1016/j.ejca.2005.10.018.CrossRefPubMed

418.

McBryan, J., Theissen, S. M., Byrne, C., Hughes, E., Cocchiglia, S., Sande, S., et al. (2012). Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1. Cancer Res, 72(2), 548–559. https://doi.org/10.1158/0008-5472.can-11-2073.CrossRefPubMed

419.

Liu, F., Sang, M., Meng, L., Gu, L., Liu, S., Li, J., et al. (2018). miR-92b promotes autophagy and suppresses viability and invasion in breast cancer by targeting EZH2. Int J Oncol, 53(4), 1505–1515. https://doi.org/10.3892/ijo.2018.4486.CrossRefPubMedPubMedCentral

420.

Sander, S., Bullinger, L., Klapproth, K., Fiedler, K., Kestler, H. A., Barth, T. F. E., et al. (2008). MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood, 112(10), 4202–4212. https://doi.org/10.1182/blood-2008-03-147645.CrossRefPubMed

421.

Lawrence, C. L., & Baldwin, A. S. (2016). Non-canonical EZH2 transcriptionally activates RelB in triple negative breast cancer. PLoS One, 11(10), e0165005. https://doi.org/10.1371/journal.pone.0165005.CrossRefPubMedPubMedCentral

422.

Valencia, A. M., & Kadoch, C. (2019). Chromatin regulatory mechanisms and therapeutic opportunities in cancer. Nat Cell Biol, 21(2), 152–161. https://doi.org/10.1038/s41556-018-0258-1.CrossRefPubMedPubMedCentral

423.

Su, Y., Hopfinger, N. R., Nguyen, T. D., Pogash, T. J., Santucci-Pereira, J., & Russo, J. (2018). Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res, 37(1), 314. https://doi.org/10.1186/s13046-018-0988-8.CrossRefPubMedPubMedCentral

424.

Ding, L., Erdmann, C., Chinnaiyan, A. M., Merajver, S. D., & Kleer, C. G. (2006). Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res, 66(8), 4095–4099. https://doi.org/10.1158/0008-5472.can-05-4300.CrossRefPubMed

425.

Yang, W. S., Chadalapaka, G., Cho, S. G., Lee, S. O., Jin, U. H., Jutooru, I., et al. (2014). The transcriptional repressor ZBTB4 regulates EZH2 through a microRNA-ZBTB4-specificity protein signaling axis. Neoplasia, 16(12), 1059–1069. https://doi.org/10.1016/j.neo.2014.09.011.CrossRefPubMedPubMedCentral

426.

Gonzalez, M. E., Moore, H. M., Li, X., Toy, K. A., Huang, W., Sabel, M. S., et al. (2014). EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci, 111(8), 3098–3103. https://doi.org/10.1073/pnas.1308953111.CrossRefPubMedPubMedCentral

427.

Myatt, S. S., Wang, J., Monteiro, L. J., Christian, M., Ho, K.-K., Fusi, L., et al. (2010). Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res, 70(1), 367–377. https://doi.org/10.1158/0008-5472.can-09-1891.CrossRefPubMed

428.

Zou, Y., Lin, X., Bu, J., Lin, Z., Chen, Y., Qiu, Y., et al. (2019). Timeless-stimulated miR-5188-FOXO1/β-catenin-c-Jun feedback loop promotes stemness via ubiquitination of β-catenin in breast cancer. Mol Ther. https://doi.org/10.1016/j.ymthe.2019.08.015.

429.

Coomans de Brachène, A., & Demoulin, J.-B. (2016). FOXO transcription factors in cancer development and therapy. [Journal article]. Cell Mol Life Sci, 73(6), 1159–1172. https://doi.org/10.1007/s00018-015-2112-y.CrossRefPubMed

430.

Zhao, L., & Zheng, X. Y. (2016). MicroRNA-490 inhibits tumorigenesis and progression in breast cancer. Onco Targets Ther, 9, 4505–4516. https://doi.org/10.2147/ott.S100037.CrossRefPubMedPubMedCentral

431.

Chandra Mangalhara, K., Manvati, S., Saini, S. K., Ponnusamy, K., Agarwal, G., Abraham, S. K., et al. (2017). ERK2-ZEB1-miR-101-1 axis contributes to epithelial–mesenchymal transition and cell migration in cancer. Cancer Lett, 391, 59–73. https://doi.org/10.1016/j.canlet.2017.01.016.CrossRefPubMed

432.

Mohammadi-Yeganeh, S., Hosseini, V., & Paryan, M. (2019). Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. J Cell Physiol, 234(10), 18317–18328. https://doi.org/10.1002/jcp.28465.CrossRefPubMed

433.

Bourguignon, L. Y. W., Wong, G., Earle, C., Krueger, K., & Spevak, C. C. (2010). Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem, 285(47), 36721–36735. https://doi.org/10.1074/jbc.M110.162305.CrossRefPubMedPubMedCentral

434.

Lamouille, S., Connolly, E., Smyth, J. W., Akhurst, R. J., & Derynck, R. (2012). TGF-beta-induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion. J Cell Sci, 125(Pt 5), 1259–1273. https://doi.org/10.1242/jcs.095299.CrossRefPubMedPubMedCentral

435.

Pronina, I. V., Loginov, V. I., Burdennyy, A. M., Fridman, M. V., Kazubskaya, T. P., Dmitriev, A. A., et al. (2016). Expression and DNA methylation alterations of seven cancer-associated 3p genes and their predicted regulator miRNAs (miR-129-2, miR-9-1) in breast and ovarian cancers. Gene, 576(1, Part 3), 483–491. https://doi.org/10.1016/j.gene.2015.10.059.CrossRefPubMed

436.

Gao, J., Wang, G., Wu, J., Zuo, Y., Zhang, J., & Jin, X. (2019). Skp2 expression is inhibited by arsenic trioxide through the upregulation of miRNA-330-5p in pancreatic cancer cells. Mol Ther - Oncolytics, 12, 214–223. https://doi.org/10.1016/j.omto.2019.01.006.CrossRefPubMedPubMedCentral

437.

Gao, L., He, R. Q., Wu, H. Y., Zhang, T. T., Liang, H. W., Ye, Z. H., et al. (2018). Expression signature and role of miR-30d-5p in non-small cell lung cancer: a comprehensive study based on in silico analysis of public databases and in vitro experiments. Cell Physiol Biochem, 50(5), 1964–1987. https://doi.org/10.1159/000494875.CrossRefPubMed

438.

Duan, X., Bai, J., Wei, J., Li, Z., Liu, X., & Xu, G. (2017). MicroRNA-508-5p suppresses metastasis in human gastric cancer by targeting S-phase kinaseassociated protein 2. Mol Med Rep, 16(2), 2163–2171. https://doi.org/10.3892/mmr.2017.6793.CrossRefPubMed

439.

Men, X., Ma, J., Wu, T., Pu, J., Wen, S., Shen, J., et al. (2018). Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer. Oncotarget, 9(3), 4074–4089. https://doi.org/10.18632/oncotarget.23694.CrossRefPubMed

440.

Zuo, T., Liu, R., Zhang, H., Chang, X., Liu, Y., Wang, L., et al. (2007). FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Investig, 117(12), 3765–3773. https://doi.org/10.1172/jci32538.CrossRefPubMedPubMedCentral

441.

Gee, H. E., Buffa, F. M., Harris, A. L., Toohey, J. M., Carroll, S. L., Cooper, C. L., et al. (2015). MicroRNA-related DNA repair/cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer. Int J Radiat Oncol Biol Physics, 93(5), 1104–1114. https://doi.org/10.1016/j.ijrobp.2015.08.046.CrossRef

442.

Dobson, J. R., Taipaleenmäki, H., Hu, Y.-J., Hong, D., van Wijnen, A. J., Stein, J. L., et al. (2014). hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. Cancer Cell Int, 14(1), 73. https://doi.org/10.1186/s12935-014-0073-0.CrossRefPubMedPubMedCentral

443.

Ouellet, V., Tiedemann, K., Mourskaia, A., Fong, J. E., Tran-Thanh, D., Amir, E., et al. (2011). CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone. Am J Pathol, 178(5), 2377–2388. https://doi.org/10.1016/j.ajpath.2011.01.033.CrossRefPubMedPubMedCentral

444.

Brigstock, D. R. (2003). The CCN family: a new stimulus package. J Endocrinol, 178(2), 169–175. https://doi.org/10.1677/joe.0.1780169.CrossRefPubMed

445.

Jiang, W. G., Watkins, G., Fodstad, O., Douglas-Jones, A., Mokbel, K., & Mansel, R. E. (2004). Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer, 11(4), 781. https://doi.org/10.1677/erc.1.00825.CrossRefPubMed

446.

Ghayad, S. E., Vendrell, J. A., Bieche, I., Spyratos, F., Dumontet, C., Treilleux, I., et al. (2009). Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol, 42(2), 87–103. https://doi.org/10.1677/jme-08-0076.CrossRefPubMed

447.

Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y. Y. (2014). Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer. Mol Cancer, 13, 256. https://doi.org/10.1186/1476-4598-13-256.CrossRefPubMedPubMedCentral

448.

Cittelly, D. M., Finlay-Schultz, J., Howe, E. N., Spoelstra, N. S., Axlund, S. D., Hendricks, P., et al. (2013). Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. [Original article]. Oncogene, 32(20), 2555–2564. https://doi.org/10.1038/onc.2012.275.CrossRefPubMed

449.

Garofalo, M., & Croce, C. M. (2015). Role of microRNAs in maintaining cancer stem cells. Adv Drug Deliv Rev, 81, 53–61. https://doi.org/10.1016/j.addr.2014.11.014.CrossRefPubMed

450.

Yu, F., Li, J., Chen, H., Fu, J., Ray, S., Huang, S., et al. (2011). Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene, 30(18), 2161–2172. https://doi.org/10.1038/onc.2010.591.CrossRefPubMedPubMedCentral

451.

Jia, Y., Zhou, J., Luo, X., Chen, M., Chen, Y., Wang, J., et al. (2018). KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer. Cell Signal, 42, 165–175. https://doi.org/10.1016/j.cellsig.2017.09.025.CrossRefPubMed

452.

Cai, W., Xu, Y., Yin, J., Zuo, W., & Su, Z. (2018). miR-590-5p suppresses osteosarcoma cell proliferation and invasion via targeting KLF5. Mol Med Rep, 18(2), 2328–2334. https://doi.org/10.3892/mmr.2018.9173.CrossRefPubMed

453.

Shi, P., Liu, W., Tala, Wang, H., Li, F., Zhang, H., et al. (2017). Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov, 3(1), 17010. https://doi.org/10.1038/celldisc.2017.10.CrossRefPubMedPubMedCentral

454.

Tong, D., Czerwenka, K., Heinze, G., Ryffel, M., Schuster, E., Witt, A., et al. (2006). Expression of KLF5 is a prognostic factor for disease-free survival and overall survival in patients with breast cancer. Clin Cancer Res, 12(8), 2442. https://doi.org/10.1158/1078-0432.CCR-05-0964.CrossRefPubMed

455.

Takagi, K., Miki, Y., Onodera, Y., Nakamura, Y., Ishida, T., Watanabe, M., et al. (2012). Kruppel-like factor 5 in human breast carcinoma: a potent prognostic factor induced by androgens. Endocr Relat Cancer, 19(6), 741–750. https://doi.org/10.1530/erc-12-0017.CrossRefPubMed

456.

Gu, C., Xu, Y., Zhang, S., Guan, H., Song, S., Wang, X., et al. (2016). miR-27a attenuates adipogenesis and promotes osteogenesis in steroid-induced rat BMSCs by targeting PPARγ and GREM1. Sci Rep, 6(1), 38491. https://doi.org/10.1038/srep38491.CrossRefPubMedPubMedCentral

457.

Ren, J., Smid, M., Iaria, J., Salvatori, D. C. F., van Dam, H., Zhu, H. J., et al. (2019). Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Res, 21(1), 109. https://doi.org/10.1186/s13058-019-1194-0.CrossRefPubMedPubMedCentral

458.

Neckmann, U., Wolowczyk, C., Hall, M., Almaas, E., Ren, J., Zhao, S., et al. (2019). GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Commun Sign, 17(1), 140. https://doi.org/10.1186/s12964-019-0467-7.CrossRef

459.

Deng, X., Zhao, Y., & Wang, B. (2015). miR-519d-mediated downregulation of STAT3 suppresses breast cancer progression. Oncol Rep, 34(4), 2188–2194. https://doi.org/10.3892/or.2015.4160.CrossRefPubMed

460.

Shi, P., Chen, C., Li, X., Wei, Z., Liu, Z., & Liu, Y. (2019). MicroRNA124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep, 19(5), 3667–3675. https://doi.org/10.3892/mmr.2019.10044.CrossRefPubMedPubMedCentral

461.

Hughes, K., & Watson, C. J. (2018). The multifaceted role of STAT3 in mammary gland involution and breast cancer. Int J Mol Sci, 19(6). https://doi.org/10.3390/ijms19061695.

462.

Lin, Y., Liu, A. Y., Fan, C., Zheng, H., Li, Y., Zhang, C., et al. (2015). MicroRNA-33b inhibits breast cancer metastasis by targeting HMGA2, SALL4 and Twist1. Sci Rep, 5, 9995. https://doi.org/10.1038/srep09995.CrossRefPubMedPubMedCentral

463.

Dirican, E., & Akkiprik, M. (2016). Functional and clinical significance of SALL4 in breast cancer. Tumor Biol, 37(9), 11701–11709. https://doi.org/10.1007/s13277-016-5150-7.CrossRef

464.

Wang, M., Li, C., Nie, H., Lv, X., Qu, Y., Yu, B., et al. (2012). Down-regulated miR-625 suppresses invasion and metastasis of gastric cancer by targeting ILK. FEBS Lett, 586(16), 2382–2388. https://doi.org/10.1016/j.febslet.2012.05.050.CrossRefPubMed

465.

Noguchi, S., Yasui, Y., Iwasaki, J., Kumazaki, M., Yamada, N., Naito, S., et al. (2013). Replacement treatment with microRNA-143 and -145 induces synergistic inhibition of the growth of human bladder cancer cells by regulating PI3K/Akt and MAPK signaling pathways. Cancer Lett, 328(2), 353–361. https://doi.org/10.1016/j.canlet.2012.10.017.CrossRefPubMed

466.

Cortez, V., Nair, B. C., Chakravarty, D., & Vadlamudi, R. K. (2011). Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed), 3, 788–796. https://doi.org/10.2741/s187.CrossRef

467.

Wendt, M. K., Allington, T. M., & Schiemann, W. P. (2009). Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol, 5(8), 1145–1168. https://doi.org/10.2217/fon.09.90.CrossRefPubMed

468.

Pang, M.-F., Siedlik, M. J., Han, S., Stallings-Mann, M., Radisky, D. C., & Nelson, C. M. (2016). Tissue stiffness and hypoxia modulate the integrin-linked kinase ILK to control breast cancer stem-like cells. Cancer Res, 76(18), 5277. https://doi.org/10.1158/0008-5472.CAN-16-0579.CrossRefPubMedPubMedCentral

469.

Zhao, D., & Cui, Z. (2019). MicroRNA-361-3p regulates retinoblastoma cell proliferation and stemness by targeting hedgehog signaling. Exp Ther Med, 17(2), 1154–1162. https://doi.org/10.3892/etm.2018.7062.CrossRefPubMed

470.

Bhateja, P., Cherian, M., Majumder, S., & Ramaswamy, B. (2019). The Hedgehog signaling pathway: a viable target in breast cancer? Cancers (Basel), 11(8), 1126. https://doi.org/10.3390/cancers11081126.CrossRef

471.

Sirkisoon, S. R., Carpenter, R. L., Rimkus, T., Anderson, A., Harrison, A., Lange, A. M., et al. (2018). Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer. Oncogene, 37(19), 2502–2514. https://doi.org/10.1038/s41388-018-0132-4.CrossRefPubMedPubMedCentral

472.

Katoh, Y., & Katoh, M. (2009). Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, TGFbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol, 35(1), 187–192. https://doi.org/10.3892/ijo_00000328.CrossRefPubMed

473.

Kurebayashi, J., Kanomata, N., Koike, Y., Ohta, Y., Saitoh, W., & Kishino, E. (2018). Comprehensive immunohistochemical analyses on expression levels of hedgehog signaling molecules in breast cancers. [Journal article]. Breast Cancer, 25(6), 759–767. https://doi.org/10.1007/s12282-018-0884-2.CrossRefPubMed

474.

Rudolph, M., Sizemore, S. T., Lu, Y., Teng, K. Y., Basree, M. M., Reinbolt, R., et al. (2018). A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer. [Journal article]. Breast Cancer Res Treat, 169(3), 457–467. https://doi.org/10.1007/s10549-018-4718-x.CrossRefPubMed

475.

Xu, D., Takeshita, F., Hino, Y., Fukunaga, S., Kudo, Y., Tamaki, A., et al. (2011). miR-22 represses cancer progression by inducing cellular senescence. J Cell Biol, 193(2), 409–424. https://doi.org/10.1083/jcb.201010100.CrossRefPubMedPubMedCentral

476.

Eades, G., Yao, Y., Yang, M., Zhang, Y., Chumsri, S., & Zhou, Q. (2011). miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem, 286(29), 25992–26002. https://doi.org/10.1074/jbc.M111.229401.CrossRefPubMedPubMedCentral

477.

Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci, 105(36), 13421–13426. https://doi.org/10.1073/pnas.0801613105.CrossRefPubMedPubMedCentral

478.

Yarahmadi, S., Abdolvahabi, Z., Hesari, Z., Tavakoli-Yaraki, M., Yousefi, Z., Seiri, P., et al. (2019). Inhibition of sirtuin 1 deacetylase by miR-211-5p provides a mechanism for the induction of cell death in breast cancer cells. Gene, 711, 143939. https://doi.org/10.1016/j.gene.2019.06.029.CrossRefPubMed

479.

Menssen, A., Hydbring, P., Kapelle, K., Vervoorts, J., Diebold, J., Lüscher, B., et al. (2012). The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci, 109(4), E187–E196. https://doi.org/10.1073/pnas.1105304109.CrossRefPubMed

480.

Gollavilli, P. N., Kanugula, A. K., Koyyada, R., Karnewar, S., Neeli, P. K., & Kotamraju, S. (2015). AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation. FEBS J, 282(20), 3971–3985. https://doi.org/10.1111/febs.13391.CrossRefPubMed

481.

Santolla, M. F., Avino, S., Pellegrino, M., De Francesco, E. M., De Marco, P., Lappano, R., et al. (2015). SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer. Cell Death Dis, 6, e1834. https://doi.org/10.1038/cddis.2015.201.CrossRefPubMedPubMedCentral

482.

Wang, C., Yang, W., Dong, F., Guo, Y., Tan, J., Ruan, S., et al. (2017). The prognostic role of Sirt1 expression in solid malignancies: a meta-analysis. Oncotarget, 8(39), 66343–66351. https://doi.org/10.18632/oncotarget.18494.CrossRefPubMedPubMedCentral

483.

Shi, L., Tang, X., Qian, M., Liu, Z., Meng, F., Fu, L., et al. (2018). A SIRT1-centered circuitry regulates breast cancer stemness and metastasis. Oncogene, 37(49), 6299–6315. https://doi.org/10.1038/s41388-018-0370-5.CrossRefPubMedPubMedCentral

484.

Latifkar, A., Ling, L., Hingorani, A., Johansen, E., Clement, A., Zhang, X., et al. (2019). Loss of sirtuin 1 alters the secretome of breast cancer cells by impairing lysosomal integrity. Dev Cell. https://doi.org/10.1016/j.devcel.2019.03.011.

485.

Capparelli, C., Whitaker-Menezes, D., Guido, C., Balliet, R., Pestell, T. G., Howell, A., et al. (2012). CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle, 11(12), 2272–2284. https://doi.org/10.4161/cc.20717.CrossRefPubMedPubMedCentral

486.

Lipson, K. E., Wong, C., Teng, Y., & Spong, S. (2012). CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair, 5(1), S24. https://doi.org/10.1186/1755-1536-5-S1-S24.CrossRefPubMedPubMedCentral

487.

Wu, W., Zaal, E. A., Berkers, C. R., Lemeer, S., & Heck, A. J. R. (2018). CTGF/VEGFA-activated fibroblasts promote tumor migration through micro-environmental modulation. Mol Cell Proteomics, 17(8), 1502–1514. https://doi.org/10.1074/mcp.RA118.000708.CrossRefPubMedPubMedCentral

488.

Jain, K., & Basu, A. (2014). The multifunctional protein kinase C-epsilon in cancer development and progression. Cancers (Basel), 6(2), 860–878. https://doi.org/10.3390/cancers6020860.CrossRef

489.

Wang, H., Gutierrez-Uzquiza, A., Garg, R., Barrio-Real, L., Abera, M. B., Lopez-Haber, C., et al. (2014). Transcriptional regulation of oncogenic protein kinase Cϵ (PKCϵ) by STAT1 and Sp1 proteins. J Biol Chem, 289(28), 19823–19838. https://doi.org/10.1074/jbc.M114.548446.CrossRefPubMedPubMedCentral

490.

Kim, K., Madak-Erdogan, Z., Ventrella, R., & Katzenellenbogen, B. S. (2013). A microRNA196a2* and TP63 circuit regulated by estrogen receptor-alpha and ERK2 that controls breast cancer proliferation and invasiveness properties. Horm Cancer, 4(2), 78–91. https://doi.org/10.1007/s12672-012-0129-3.CrossRefPubMed

491.

Ørom, U. A., Lim, M. K., Savage, J. E., Jin, L., Saleh, A. D., Lisanti, M. P., et al. (2012). MicroRNA-203 regulates caveolin-1 in breast tissue during caloric restriction. Cell Cycle, 11(7), 1291–1295. https://doi.org/10.4161/cc.19704.CrossRefPubMedPubMedCentral

492.

Chen, Y., Peng, Y., Fan, S., Li, Y., Xiao, Z. X., & Li, C. (2018). A double dealing tale of p63: an oncogene or a tumor suppressor. Cell Mol Life Sci, 75(6), 965–973. https://doi.org/10.1007/s00018-017-2666-y.CrossRefPubMed

493.

Gatti, V., Bongiorno-Borbone, L., Fierro, C., Annicchiarico-Petruzzelli, M., Melino, G., & Peschiaroli, A. (2019). p63 at the crossroads between stemness and metastasis in breast cancer. Int J Mol Sci, 20(11), 2683. https://doi.org/10.3390/ijms20112683.CrossRefPubMedCentral

494.

Coates, P. J., Nenutil, R., Holcakova, J., Nekulova, M., Podhorec, J., Svoboda, M., et al. (2018). p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Arch, 472(3), 351–359. https://doi.org/10.1007/s00428-018-2324-2.CrossRefPubMed

495.

Matos, I., Dufloth, R., Alvarenga, M., Zeferino, L. C., & Schmitt, F. (2005). p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch, 447(4), 688–694. https://doi.org/10.1007/s00428-005-0010-7.CrossRefPubMed

496.

Iliopoulos, D., Lindahl-Allen, M., Polytarchou, C., Hirsch, H. A., Tsichlis, P. N., & Struhl, K. (2010). Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell, 39(5), 761–772. https://doi.org/10.1016/j.molcel.2010.08.013.CrossRefPubMedPubMedCentral

497.

Comet, I., Riising, E. M., Leblanc, B., & Helin, K. (2016). Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer, 16(12), 803–810. https://doi.org/10.1038/nrc.2016.83.CrossRefPubMed

498.

Hu, J., Su, P., Jiao, M., Bai, X., Qi, M., Liu, H., et al. (2018). TRPS1 suppresses breast cancer epithelial-mesenchymal transition program as a negative regulator of SUZ12. Transl Oncol, 11(2), 416–425. https://doi.org/10.1016/j.tranon.2018.01.009.CrossRefPubMedPubMedCentral

499.

Zhao, S., Han, J., Zheng, L., Yang, Z., Zhao, L., & Lv, Y. (2015). MicroRNA-203 regulates growth and metastasis of breast cancer. Cell Physiol Biochem, 37(1), 35–42. https://doi.org/10.1159/000430331.CrossRefPubMed

500.

Xin, Y., Wang, X., Meng, K., Ni, C., Lv, Z., & Guan, D. (2019). Identification of exosomal miR-455-5p and miR-1255a as therapeutic targets for breast cancer. Biosci Rep. https://doi.org/10.1042/bsr20190303.

501.

Schöndorf, T., Göhring, U. J., Becker, M., Hoopmann, M., Schmidt, T., Rützel, S., et al. (2004). High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis. Pathobiology, 71(4), 217–222. https://doi.org/10.1159/000078676.CrossRefPubMed

502.

Kurozumi, S., Inoue, K., Takei, H., Matsumoto, H., Kurosumi, M., Horiguchi, J., et al. (2015). ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer, 15, 622. https://doi.org/10.1186/s12885-015-1641-y.CrossRefPubMedPubMedCentral

503.

Xie, F., Hosany, S., Zhong, S., Jiang, Y., Zhang, F., Lin, L., et al. (2017). MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1. PLoS One, 12(10), e0185565. https://doi.org/10.1371/journal.pone.0185565.CrossRefPubMedPubMedCentral

504.

Toska, E., & Roberts, S. G. E. (2014). Mechanisms of transcriptional regulation by WT1 (Wilms’ tumour 1). Biochem J, 461(1), 15–32. https://doi.org/10.1042/bj20131587.CrossRefPubMed

505.

Silberstein, G. B., Van Horn, K., Strickland, P., Roberts Jr., C. T., & Daniel, C. W. (1997). Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci U S A, 94(15), 8132–8137.PubMedPubMedCentral

506.

Miyoshi, Y., Ando, A., Egawa, C., Taguchi, T., Tamaki, Y., Tamaki, H., et al. (2002). High expression of Wilms’ tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res, 8(5), 1167–1171.PubMed

507.

Qi, X. W., Zhang, F., Yang, X. H., Fan, L. J., Zhang, Y., Liang, Y., et al. (2012). High Wilms’ tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer. Oncol Rep, 28(4), 1231–1236. https://doi.org/10.3892/or.2012.1906.CrossRefPubMed

508.

McGregor, R. J., Chau, Y.-Y., Kendall, T. J., Artibani, M., Hastie, N., & Hadoke, P. W. F. (2018). WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer. Br J Cancer, 119(12), 1508–1517. https://doi.org/10.1038/s41416-018-0317-1.CrossRefPubMedPubMedCentral

509.

Wu, M.-Y., Fu, J., Xiao, X., Wu, J., & Wu, R.-C. (2014). MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer. Cancer Lett, 354(2), 311–319. https://doi.org/10.1016/j.canlet.2014.08.031.CrossRefPubMed

510.

Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., et al. (2005). Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat, 94(1), 11–16. https://doi.org/10.1007/s10549-005-6001-1.CrossRefPubMed

511.

Browne, G., Dragon, J. A., Hong, D., Messier, T. L., Gordon, J. A., Farina, N. H., et al. (2016). MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol, 37(7), 8825–8839. https://doi.org/10.1007/s13277-015-4710-6.CrossRefPubMed

512.

Teng, H., Wang, P., Xue, Y., Liu, X., Ma, J., Cai, H., et al. (2016). Role of HCP5-miR-139-RUNX1 feedback loop in regulating malignant behavior of glioma cells. Mol Ther, 24(10), 1806–1822. https://doi.org/10.1038/mt.2016.103.CrossRefPubMedPubMedCentral

513.

Chimge, N. O., & Frenkel, B. (2013). The RUNX family in breast cancer: relationships with estrogen signaling. [Review]. Oncogene, 32(17), 2121–2130. https://doi.org/10.1038/onc.2012.328.CrossRefPubMed

514.

Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet, 33(1), 49–54. https://doi.org/10.1038/ng1060.CrossRefPubMed

515.

Zhang, N., Zhang, H., Liu, Y., Su, P., Zhang, J., Wang, X., et al. (2019). SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ, 26(5), 843–859. https://doi.org/10.1038/s41418-018-0158-8.CrossRefPubMed

516.

Bertolio, R., Napoletano, F., Mano, M., Maurer-Stroh, S., Fantuz, M., Zannini, A., et al. (2019). Sterol regulatory element binding protein 1 couples mechanical cues and lipid metabolism. Nat Commun, 10(1), 1326. https://doi.org/10.1038/s41467-019-09152-7.CrossRefPubMedPubMedCentral

517.

Perone, Y., Farrugia, A. J., Meira, A. R., Győrffy, B., Ion, C., Uggetti, A., et al. (2019). SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer. Nat Commun, 10(1), 2115. https://doi.org/10.1038/s41467-019-09676-y.CrossRefPubMedPubMedCentral

518.

Bao, J., Zhu, L., Zhu, Q., Su, J., Liu, M., & Huang, W. (2016). SREBP-1 is an independent prognostic marker and promotes invasion and migration in breast cancer. Oncol Lett, 12(4), 2409–2416. https://doi.org/10.3892/ol.2016.4988.CrossRefPubMedPubMedCentral

519.

Puts, G. S., Leonard, M. K., Pamidimukkala, N. V., Snyder, D. E., & Kaetzel, D. M. (2018). Nuclear functions of NME proteins. Lab Investig, 98(2), 211–218. https://doi.org/10.1038/labinvest.2017.109.CrossRefPubMed

520.

McCorkle, J. R., Leonard, M. K., Kraner, S. D., Blalock, E. M., Ma, D., Zimmer, S. G., et al. (2014). The metastasis suppressor NME1 regulates expression of genes linked to metastasis and patient outcome in melanoma and breast carcinoma. Cancer Genomics Proteomics, 11(4), 175–194.PubMed

521.

Toulas, C., Mihura, J., de Balincourt, C., Marques, B., Marek, E., Soula, G., et al. (1996). Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody. Br J Cancer, 73(5), 630–635. https://doi.org/10.1038/bjc.1996.109.CrossRefPubMedPubMedCentral

522.

Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., et al. (2008). MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression. Mol Cell Biol, 28(7), 2167–2174. https://doi.org/10.1128/mcb.01977-07.CrossRefPubMedPubMedCentral

523.

Zohny, S. F., Al-Malki, A. L., Zamzami, M. A., & Choudhry, H. (2019). p21Waf1/Cip1: its paradoxical effect in the regulation of breast cancer. Breast Cancer, 26(2), 131–137. https://doi.org/10.1007/s12282-018-0913-1.CrossRefPubMed

524.

Pellikainen, M. J., Pekola, T. T., Ropponen, K. M., Kataja, V. V., Kellokoski, J. K., Eskelinen, M. J., et al. (2003). p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol, 56(3), 214–220. https://doi.org/10.1136/jcp.56.3.214.CrossRefPubMedPubMedCentral

525.

Winters, Z. E., Hunt, N. C., Bradburn, M. J., Royds, J. A., Turley, H., Harris, A. L., et al. (2001). Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer: association with prognosis. Eur J Cancer, 37(18), 2405–2412. https://doi.org/10.1016/S0959-8049(01)00327-6.CrossRefPubMed

526.

Lee, J. J., Drakaki, A., Iliopoulos, D., & Struhl, K. (2012). MiR-27b targets PPARgamma to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene, 31(33), 3818–3825. https://doi.org/10.1038/onc.2011.543.CrossRefPubMed

527.

Asukai, K., Kawamoto, K., Eguchi, H., Konno, M., Asai, A., Iwagami, Y., et al. (2017). Micro-RNA-130a-3p regulates gemcitabine resistance via PPARG in cholangiocarcinoma. Ann Surg Oncol, 24(8), 2344–2352. https://doi.org/10.1245/s10434-017-5871-x.CrossRefPubMed

528.

Grygiel-Górniak, B. (2014). Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review. Nutr J, 13(1), 17. https://doi.org/10.1186/1475-2891-13-17.CrossRefPubMedPubMedCentral

529.

Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., et al. (1998). Terminal differentiation of human breast cancer through PPARγ. Mol Cell, 1(3), 465–470. https://doi.org/10.1016/S1097-2765(00)80047-7.CrossRefPubMed

530.

Rubin, G. L., Zhao, Y., Kalus, A. M., & Simpson, E. R. (2000). Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer Res, 60(6), 1604–1608.PubMed

531.

Qin, C., Burghardt, R., Smith, R., Wormke, M., Stewart, J., & Safe, S. (2003). Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res, 63(5), 958–964.PubMed

532.

Jiang, W. G., Douglas-Jones, A., & Mansel, R. E. (2003). Expression of peroxisome-proliferator activated receptor-gamma (PPARgamma) and the PPARgamma co-activator, PGC-1, in human breast cancer correlates with clinical outcomes. Int J Cancer, 106(5), 752–757.PubMed

533.

Chen, J., Shin, V. Y., Siu, M. T., Ho, J. C. W., Cheuk, I., & Kwong, A. (2016). miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. BMC Cancer, 16(1), 887. https://doi.org/10.1186/s12885-016-2916-7.CrossRefPubMedPubMedCentral

534.

Lu, P., Gu, Y., Li, L., Wang, F., & Qiu, X. (2016). miR-544a promotes breast cancer cell migration and invasion reducing cadherin 1 expression. Oncol Res, 23(4), 165–170. https://doi.org/10.3727/096504016x14519157902726.CrossRefPubMedPubMedCentral

535.

Huang, S., Cai, M., Zheng, Y., Zhou, L., Wang, Q., & Chen, L. (2014). miR-888 in MCF-7 side population sphere cells directly targets E-cadherin. J Gen Genomics, 41(1), 35–42. https://doi.org/10.1016/j.jgg.2013.12.002.CrossRef

536.

Zhang, W., Shi, S., Jiang, J., Li, X., Lu, H., & Ren, F. (2017). LncRNA MEG3 inhibits cell epithelial-mesenchymal transition by sponging miR-421 targeting E-cadherin in breast cancer. Biomed Pharmacother, 91, 312–319. https://doi.org/10.1016/j.biopha.2017.04.085.CrossRefPubMed

537.

Roberts, T. C. (2014). The microRNA biology of the mammalian nucleus. Mol Ther Nucleic Acids, 3, e188. https://doi.org/10.1038/mtna.2014.40.CrossRefPubMedPubMedCentral

538.

Christiansen, J. J., & Rajasekaran, A. K. (2006). Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res, 66(17), 8319–8326. https://doi.org/10.1158/0008-5472.can-06-0410.CrossRefPubMed

539.

Liu, Y.-N., Lee, W.-W., Wang, C.-Y., Chao, T.-H., Chen, Y., & Chen, J. H. (2005). Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene, 24(56), 8277–8290. https://doi.org/10.1038/sj.onc.1208991.CrossRefPubMed

540.

Charpin, C., Garcia, S., Bonnier, P., Martini, F., Andrac, L., Choux, R., et al. (1998). Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlates with 10-year survival. Am J Clin Pathol, 109(4), 431–438. https://doi.org/10.1093/ajcp/109.4.431.CrossRefPubMed

541.

Gould Rothberg, B. E., & Bracken, M. B. (2006). E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast: a systematic review and meta-analysis. Breast Cancer Res Treat, 100(2), 139–148. https://doi.org/10.1007/s10549-006-9248-2.CrossRefPubMed

542.

Furuta, M., Kozaki, K.-I., Tanaka, S., Arii, S., Imoto, I., & Inazawa, J. (2010). miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 31(5), 766–776. https://doi.org/10.1093/carcin/bgp250.CrossRefPubMed

543.

Shan, S. W., Fang, L., Shatseva, T., Rutnam, Z. J., Yang, X., Du, W., et al. (2013). Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci, 126(6), 1517–1530. https://doi.org/10.1242/jcs.122895.CrossRefPubMed

544.

Deng, Z., Du, W. W., Fang, L., Shan, S. W., Qian, J., Lin, J., et al. (2013). The intermediate filament vimentin mediates microRNA miR-378 function in cellular self-renewal by regulating the expression of the Sox2 transcription factor. J Biol Chem, 288(1), 319–331. https://doi.org/10.1074/jbc.M112.418830.CrossRefPubMed

545.

Yamasaki, T., Seki, N., Yamada, Y., Yoshino, H., Hidaka, H., Chiyomaru, T., et al. (2012). Tumor suppressive microRNA138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol, 41(3), 805–817. https://doi.org/10.3892/ijo.2012.1543.CrossRefPubMedPubMedCentral

546.

Kokkinos, M. I., Wafai, R., Wong, M. K., Newgreen, D. F., Thompson, E. W., & Waltham, M. (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer--observations in vitro and in vivo. Cells Tissues Organs, 185(1-3), 191–203. https://doi.org/10.1159/000101320.CrossRefPubMed

547.

Satelli, A., & Li, S. (2011). Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci, 68(18), 3033–3046. https://doi.org/10.1007/s00018-011-0735-1.CrossRefPubMedPubMedCentral

548.

Snider, N. T., & Omary, M. B. (2014). Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol, 15(3), 163–177. https://doi.org/10.1038/nrm3753.CrossRefPubMedPubMedCentral

549.

Cattoretti, G., Andreola, S., Clemente, C., D’Amato, L., & Rilke, F. (1988). Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer, 57(4), 353–357. https://doi.org/10.1038/bjc.1988.81.CrossRefPubMedPubMedCentral

550.

Sethi, S., Sarkar, F. H., Ahmed, Q., Bandyopadhyay, S., Nahleh, Z. A., Semaan, A., et al. (2011). Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol, 4(4), 222–226. https://doi.org/10.1593/tlo.10244.CrossRefPubMedPubMedCentral

551.

Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.PubMedPubMedCentral

552.

Nagai, M. A., Gerhard, R., Fregnani, J. H. T. G., Nonogaki, S., Rierger, R. B., Netto, M. M., et al. (2011). Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat, 126(1), 1–14. https://doi.org/10.1007/s10549-010-0867-2.CrossRefPubMed

553.

Lin, R. J., Lin, Y. C., & Yu, A. L. (2010). miR-149* induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Carcinog, 49(8), 719–727. https://doi.org/10.1002/mc.20647.CrossRefPubMed

554.

Liao, X. H., Lu, D. L., Wang, N., Liu, L. Y., Wang, Y., Li, Y. Q., et al. (2014). Estrogen receptor α mediates proliferation of breast cancer MCF–7 cells via a p21/PCNA/E2F1-dependent pathway. FEBS J, 281(3), 927–942. https://doi.org/10.1111/febs.12658.CrossRefPubMed

555.

Feng, T., Shao, F., Wu, Q., Zhang, X., Xu, D., Qian, K., et al. (2016). miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget, 7(13), 16205–16216. https://doi.org/10.18632/oncotarget.7578.CrossRefPubMedPubMedCentral

556.

Gandellini, P., Folini, M., Longoni, N., Pennati, M., Binda, M., Colecchia, M., et al. (2009). miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase C. Cancer Res, 69(6), 2287–2295. https://doi.org/10.1158/0008-5472.can-08-2894.CrossRefPubMed

557.

Piovan, C., Palmieri, D., Di Leva, G., Braccioli, L., Casalini, P., Nuovo, G., et al. (2012). Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol, 6(4), 458–472. https://doi.org/10.1016/j.molonc.2012.03.003.CrossRefPubMedPubMedCentral

558.

Bell, L. A., & Ryan, K. M. (2004). Life and death decisions by E2F-1. Cell Death Differ, 11(2), 137–142. https://doi.org/10.1038/sj.cdd.4401324.CrossRefPubMed

559.

Ofir, M., Hacohen, D., & Ginsberg, D. (2011). miR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E. Mol Cancer Res, 9(4), 440–447. https://doi.org/10.1158/1541-7786.mcr-10-0344.CrossRefPubMed

560.

Vuaroqueaux, V., Urban, P., Labuhn, M., Delorenzi, M., Wirapati, P., Benz, C. C., et al. (2007). Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome. Breast Cancer Res, 9(3), R33. https://doi.org/10.1186/bcr1681.CrossRefPubMedPubMedCentral

561.

Hudson, J., Duncavage, E., Tamburrino, A., Salerno, P., Xi, L., Raffeld, M., et al. (2013). Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma. Exp Mol Pathol, 95(1), 62–67. https://doi.org/10.1016/j.yexmp.2013.05.001.CrossRefPubMedPubMedCentral

562.

Kang, W., Tong, J. H., Lung, R. W., Dong, Y., Zhao, J., Liang, Q., et al. (2015). Targeting of YAP1 by microRNA-15a and microRNA-16-1 exerts tumor suppressor function in gastric adenocarcinoma. Mol Cancer, 14, 52. https://doi.org/10.1186/s12943-015-0323-3.CrossRefPubMedPubMedCentral

563.

Totaro, A., Panciera, T., & Piccolo, S. (2018). YAP/TAZ upstream signals and downstream responses. Nat Cell Biol, 20(8), 888–899. https://doi.org/10.1038/s41556-018-0142-z.CrossRefPubMedPubMedCentral

564.

Lehmann, W., Mossmann, D., Kleemann, J., Mock, K., Meisinger, C., Brummer, T., et al. (2016). ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat Commun, 7(1), 10498. https://doi.org/10.1038/ncomms10498.CrossRefPubMedPubMedCentral

565.

Wu, Y., Hou, Y., Xu, P., Deng, Y., Liu, K., Wang, M., et al. (2019). The prognostic value of YAP1 on clinical outcomes in human cancers. Aging (Albany NY), 11(19), 8681–8700. https://doi.org/10.18632/aging.102358.CrossRef

566.

Tian, F., Shen, Y., Chen, Z., Li, R., Lu, J., & Ge, Q. (2016). Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene, 591(2), 338–343. https://doi.org/10.1016/j.gene.2016.06.014.CrossRefPubMed

567.

Burbee, D. G., Forgacs, E., Zöchbauer-Müller, S., Shivakumar, L., Fong, K., Gao, B., et al. (2001). Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. JNCI: Journal of the National Cancer Institute, 93(9), 691–699. https://doi.org/10.1093/jnci/93.9.691.CrossRefPubMed

568.

Matallanas, D., Romano, D., Yee, K., Meissl, K., Kucerova, L., Piazzolla, D., et al. (2007). RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell, 27(6), 962–975. https://doi.org/10.1016/j.molcel.2007.08.008.CrossRefPubMedPubMedCentral

569.

Chatzifrangkeskou, M., Pefani, D.-E., Eyres, M., Vendrell, I., Fischer, R., Pankova, D., et al. (2019). RASSF1A is required for the maintenance of nuclear actin levels. EMBO J, 38(16), e101168. https://doi.org/10.15252/embj.2018101168.CrossRefPubMedPubMedCentral

570.

Vennin, C., Spruyt, N., Dahmani, F., Julien, S., Bertucci, F., Finetti, P., et al. (2015). H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b. Oncotarget, 6(30), 29209–29223. https://doi.org/10.18632/oncotarget.4976.CrossRefPubMedPubMedCentral

571.

Pan, Q., Luo, X., & Chegini, N. (2008). Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med, 12(1), 227–240. https://doi.org/10.1111/j.1582-4934.2007.00207.x.CrossRefPubMed

572.

Wang, S., Huang, M., Wang, Z., Wang, W., Zhang, Z., Qu, S., et al. (2019). MicroRNA133b targets TGFbeta receptor I to inhibit TGFbetainduced epithelialtomesenchymal transition and metastasis by suppressing the TGFbeta/SMAD pathway in breast cancer. Int J Oncol, 55(5), 1097–1109. https://doi.org/10.3892/ijo.2019.4879.CrossRefPubMedPubMedCentral

573.

Yu, G., Wan, L., Li, Y., Xiang, Y., Song, Y., & Tan, L. (2019). Dysregulated miR-142, -33b, and -423 in granulosa cells target TGFBR1 and SMAD7: a possible role in polycystic ovary syndrome. Mol Hum Reprod, 25(10), 368–346. https://doi.org/10.1093/molehr/gaz014.CrossRef

574.

Dijke, P. t., & Hill, C. S. (2004). New insights into TGF-β–Smad signalling. Trends Biochem Sci, 29(5), 265–273. https://doi.org/10.1016/j.tibs.2004.03.008.CrossRefPubMed

575.

Ghellal, A., Li, C., Hayes, M., Byrne, G., Bundred, N., & Kumar, S. (2000). Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res, 20(6b), 4413–4418.PubMed

576.

Zhang, Y., Jiang, F., He, H., Ye, J., Mao, X., Guo, Q., et al. (2018). Identification of a novel microRNA-mRNA regulatory biomodule in human prostate cancer. Cell Death Dis, 9(3), 301. https://doi.org/10.1038/s41419-018-0293-7.CrossRefPubMedPubMedCentral

577.

Westfall, M. D., & Pietenpol, J. A. (2004). p63: molecular complexity in development and cancer. Carcinogenesis, 25(6), 857–864. https://doi.org/10.1093/carcin/bgh148.CrossRefPubMed

578.

Gomez, L. C., Sottile, M. L., Guerrero-Gimenez, M. E., Zoppino, F. C. M., Redondo, A. L., Gago, F. E., et al. (2018). TP73DNA methylation and upregulation of ΔNp73 are associated with an adverse prognosis in breast cancer. J Clin Pathol, 71(1), 52–58. https://doi.org/10.1136/jclinpath-2017-204499.CrossRefPubMed

579.

Dominguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sanchez, A., Navarro, A., et al. (2001). Wild type p73 overexpression and high-grade malignancy in breast cancer. Breast Cancer Res Treat, 66(3), 183–190. https://doi.org/10.1023/A:1010624717311.CrossRefPubMed

580.

Wang, X., Tong, Z., & Liu, H. (2019). MiR-223-3p targeting epithelial cell transforming sequence 2 oncogene inhibits the activity, apoptosis, invasion and migration of MDA-MB-468 breast cancer cells. Onco Targets Ther, 12, 7675–7684. https://doi.org/10.2147/ott.S217019.CrossRefPubMedPubMedCentral

581.

Li, M., Bian, C., & Yu, X. (2014). Poly(ADP-ribosyl)ation is recognized by ECT2 during mitosis. Cell Cycle, 13(18), 2944–2951. https://doi.org/10.4161/15384101.2014.947197.CrossRefPubMedPubMedCentral

582.

Wang, H. K., Liang, J. F., Zheng, H. X., & Xiao, H. (2018). Expression and prognostic significance of ECT2 in invasive breast cancer. J Clin Pathol, 71(5), 442–445. https://doi.org/10.1136/jclinpath-2017-204569.CrossRefPubMed

583.

Wang, Y., Jiaqi, C., Zhaoying, C., & Huimin, C. (2016). MicroRNA-506-3p regulates neural stem cell proliferation and differentiation through targeting TCF3. Gene, 593(1), 193–200. https://doi.org/10.1016/j.gene.2016.08.026.CrossRefPubMed

584.

Slyper, M., Shahar, A., Bar-Ziv, A., Granit, R. Z., Hamburger, T., Maly, B., et al. (2012). Control of breast cancer growth and initiation by the stem cell–associated transcription factor TCF3. Cancer Res, 72(21), 5613–5624. https://doi.org/10.1158/0008-5472.can-12-0119.CrossRefPubMed

585.

Buffa, F. M., Camps, C., Winchester, L., Snell, C. E., Gee, H. E., Sheldon, H., et al. (2011). microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res, 71(17), 5635–5645. https://doi.org/10.1158/0008-5472.can-11-0489.CrossRefPubMed

586.

Kwak, H. J., Kim, Y. J., Chun, K. R., Woo, Y. M., Park, S. J., Jeong, J. A., et al. (2011). Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas. Oncogene, 30(21), 2433–2442. https://doi.org/10.1038/onc.2010.620.CrossRefPubMed

587.

Lo, T. L., Yusoff, P., Fong, C. W., Guo, K., McCaw, B. J., Phillips, W. A., et al. (2004). The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res, 64(17), 6127–6136.PubMed

588.

Faratian, D., Sims, A. H., Mullen, P., Kay, C., Um, I., Langdon, S. P., et al. (2011). Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy. PLoS One, 6(8), e23772. https://doi.org/10.1371/journal.pone.0023772.CrossRefPubMedPubMedCentral

589.

Imani, S., Wei, C., Cheng, J., Khan, M. A., Fu, S., Yang, L., et al. (2017). MicroRNA-34a targets epithelial to mesenchymal transition-inducing transcription factors (EMT-TFs) and inhibits breast cancer cell migration and invasion. Oncotarget, 8(13), 21362–21379. https://doi.org/10.18632/oncotarget.15214.CrossRefPubMedPubMedCentral

590.

Zhang, H. D., Jiang, L. H., Sun, D. W., Li, J., & Tang, J. H. (2017). miR-30a inhibits the biological function of breast cancer cells by targeting Notch1. Int J Mol Med, 40(4), 1235–1242. https://doi.org/10.3892/ijmm.2017.3084.CrossRefPubMed

591.

Li, H.-C., Chen, Y.-F., Feng, W., Cai, H., Mei, Y., Jiang, Y.-M., et al. (2017). Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. Gene, 603, 1–8. https://doi.org/10.1016/j.gene.2016.11.046.CrossRefPubMed

592.

Kong, P., Chen, L., Yu, M., Tao, J., Liu, J., Wang, Y., et al. (2018). miR-3178 inhibits cell proliferation and metastasis by targeting Notch1 in triple-negative breast cancer. Cell Death Dis, 9(11), 1059. https://doi.org/10.1038/s41419-018-1091-y.CrossRefPubMedPubMedCentral

593.

Zhang, P., Hong, H., Sun, X., Jiang, H., Ma, S., Zhao, S., et al. (2016). MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells. Am J Cancer Res, 6(2), 141–156.PubMedPubMedCentral

594.

Yang, X., Ni, W., & Lei, K. (2013). miR-200b suppresses cell growth, migration and invasion by targeting Notch1 in nasopharyngeal carcinoma. Cell Physiol Biochem, 32(5), 1288–1298. https://doi.org/10.1159/000354527.CrossRefPubMed

595.

Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., et al. (2010). Targeting Notch to target cancer stem cells. Clin Cancer Res, 16(12), 3141–3152. https://doi.org/10.1158/1078-0432.Ccr-09-2823.CrossRefPubMedPubMedCentral

596.

Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., et al. (2015). Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol, 12(8), 445–464. https://doi.org/10.1038/nrclinonc.2015.61.CrossRefPubMedPubMedCentral

597.

Tsuyada, A., Chow, A., Wu, J., Somlo, G., Chu, P., Loera, S., et al. (2012). CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res, 72(11), 2768–2779. https://doi.org/10.1158/0008-5472.can-11-3567.CrossRefPubMedPubMedCentral

598.

Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., et al. (2005). High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res, 65(18), 8530–8537.PubMed

599.

Zhou, W., He, L., Dai, Y., Zhang, Y., Wang, J., & Liu, B. (2018). MicroRNA-124 inhibits cell proliferation, invasion and migration by targeting CAV1 in bladder cancer. Exp Ther Med, 16(4), 2811–2820. https://doi.org/10.3892/etm.2018.6537.CrossRefPubMedPubMedCentral

600.

Bouras, T., Lisanti, M. P., & Pestell, R. G. (2004). Caveolin in breast cancer. Cancer Biol Ther, 3(10), 931–941. https://doi.org/10.4161/cbt.3.10.1147.CrossRefPubMed

601.

Ma, X., Liu, L., Nie, W., Li, Y., Zhang, B., Zhang, J., et al. (2013). Prognostic role of caveolin in breast cancer: a meta-analysis. Breast, 22(4), 462–469. https://doi.org/10.1016/j.breast.2013.03.005.CrossRefPubMed

602.

Eliyatkin, N., Aktas, S., Diniz, G., Ozgur, H. H., Ekin, Z. Y., & Kupelioglu, A. (2018). Expression of stromal caveolin-1 may be a predictor for aggressive behaviour of breast cancer. Pathol Oncol Res, 24(1), 59–65. https://doi.org/10.1007/s12253-017-0212-8.CrossRefPubMed

603.

Cai, J., Guan, H., Fang, L., Yang, Y., Zhu, X., Yuan, J., et al. (2013). MicroRNA-374a activates Wnt/beta-catenin signaling to promote breast cancer metastasis. J Clin Investig, 123(2), 566–579. https://doi.org/10.1172/jci65871.CrossRefPubMedPubMedCentral

604.

Serra, R., Easter, S. L., Jiang, W., & Baxley, S. E. (2011). Wnt5a as an effector of TGFbeta in mammary development and cancer. J Mammary Gland Biol Neoplasia, 16(2), 157–167. https://doi.org/10.1007/s10911-011-9205-5.CrossRefPubMedPubMedCentral

605.

Prasad, C. P., Manchanda, M., Mohapatra, P., & Andersson, T. (2018). WNT5A as a therapeutic target in breast cancer. Cancer Metastasis Rev, 37(4), 767–778. https://doi.org/10.1007/s10555-018-9760-y.CrossRefPubMedPubMedCentral

606.

Lejeune, S., Huguet, E. L., Hamby, A., Poulsom, R., & Harris, A. L. (1995). Wnt5a cloning, expression, and up-regulation in human primary breast cancers. Clin Cancer Res, 1(2), 215.PubMed

607.

Leris, A. C. A., Roberts, T. R., Jiang, W. G., Newbold, R. F., & Mokbel, K. (2005). WNT5A expression in human breast cancer. Anticancer Res, 25(2A), 731–734.PubMed

608.

Dejmek, J., Leandersson, K., Manjer, J., Bjartell, A., Emdin, S. O., Vogel, W. F., et al. (2005). Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival. Clin Cancer Res, 11(2), 520.PubMed

609.

Zhong, Z., Shan, M., Wang, J., Liu, T., Shi, Q., & Pang, D. (2016). Decreased Wnt5a expression is a poor prognostic factor in triple-negative breast cancer. Med Sci Monit, 22, 1–7. https://doi.org/10.12659/msm.894821.CrossRefPubMedPubMedCentral

610.

Cascio, S., D’Andrea, A., Ferla, R., Surmacz, E., Gulotta, E., Amodeo, V., et al. (2010). miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol, 224(1), 242–249. https://doi.org/10.1002/jcp.22126.CrossRefPubMed

611.

Hu, Y., Qiu, Y., Yague, E., Ji, W., Liu, J., & Zhang, J. (2016). miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis, 7(6), e2291. https://doi.org/10.1038/cddis.2016.194.CrossRefPubMedPubMedCentral

612.

Wang, R., Tian, S., Wang, H. B., Chu, D. P., Cao, J. L., Xia, H. F., et al. (2014). MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett, 588(23), 4438–4447. https://doi.org/10.1016/j.febslet.2014.09.045.CrossRefPubMed

613.

Zhu, N., Zhang, D., Xie, H., Zhou, Z., Chen, H., Hu, T., et al. (2011). Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem, 351(1-2), 157–164. https://doi.org/10.1007/s11010-011-0723-7.CrossRefPubMed

614.

Lu, Y., Qin, T., Li, J., Wang, L., Zhang, Q., Jiang, Z., et al. (2017). MicroRNA-140-5p inhibits invasion and angiogenesis through targeting VEGF-A in breast cancer. Cancer Gene Ther, 24(9), 386–392. https://doi.org/10.1038/cgt.2017.30.CrossRefPubMedPubMedCentral

615.

Favaro, E., Lord, S., Harris, A. L., & Buffa, F. M. (2011). Gene expression and hypoxia in breast cancer. Genome Med, 3(8), 55. https://doi.org/10.1186/gm271.CrossRefPubMedPubMedCentral

616.

Kim, M., Jang, K., Miller, P., Picon-Ruiz, M., Yeasky, T. M., El-Ashry, D., et al. (2017). VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. [Original Article]. Oncogene, 36(36), 5199–5211. https://doi.org/10.1038/onc.2017.4.CrossRefPubMedPubMedCentral

617.

Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., et al. (2001). The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res, 61(5), 2256–2260.PubMed

618.

Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., et al. (2009). Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol, 20(10), 1639–1646. https://doi.org/10.1093/annonc/mdp062.CrossRefPubMed

619.

Zou, Q., Wu, H., Fu, F., Yi, W., Pei, L., & Zhou, M. (2016). RKIP suppresses the proliferation and metastasis of breast cancer cell lines through up-regulation of miR-185 targeting HMGA2. Arch Biochem Biophys, 610(Supplement C), 25–32. https://doi.org/10.1016/j.abb.2016.09.007.CrossRefPubMed

620.

Yoo, J.-O., Kwak, S.-Y., An, H.-J., Bae, I.-H., Park, M.-J., & Han, Y.-H. (2016). miR-181b-3p promotes epithelial–mesenchymal transition in breast cancer cells through Snail stabilization by directly targeting YWHAG. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1863(7, Part A), 1601–1611. https://doi.org/10.1016/j.bbamcr.2016.04.016.CrossRef

621.

Hiraoka, E., Mimae, T., Ito, M., Kadoya, T., Miyata, Y., Ito, A., et al. (2019). Breast cancer cell motility is promoted by 14-3-3γ. Breast Cancer, 26(5), 581–593. https://doi.org/10.1007/s12282-019-00957-4.CrossRefPubMed

622.

Song, Y., Yang, Z., Ke, Z., Yao, Y., Hu, X., Sun, Y., et al. (2012). Expression of 14-3-3γ in patients with breast cancer: correlation with clinicopathological features and prognosis. Cancer Epidemiol, 36(6), 533–536. https://doi.org/10.1016/j.canep.2012.05.003.CrossRefPubMed

623.

Nairismagi, M. L., Vislovukh, A., Meng, Q., Kratassiouk, G., Beldiman, C., Petretich, M., et al. (2012). Translational control of TWIST1 expression in MCF-10A cell lines recapitulating breast cancer progression. Oncogene, 31(47), 4960–4966. https://doi.org/10.1038/onc.2011.650.CrossRefPubMed

624.

Haga, C. L., & Phinney, D. G. (2012). MicroRNAs in the imprinted DLK1-DIO3 region repress the epithelial-to-mesenchymal transition by targeting the TWIST1 protein signaling network. J Biol Chem, 287(51), 42695–42707. https://doi.org/10.1074/jbc.M112.387761.CrossRefPubMedPubMedCentral

625.

Li, L. Z., Zhang, C. Z., Liu, L. L., Yi, C., Lu, S. X., Zhou, X., et al. (2014). miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis, 35(2), 469–478. https://doi.org/10.1093/carcin/bgt330.CrossRefPubMed

626.

Yeh, T. C., Huang, T. T., Yeh, T. S., Chen, Y. R., Hsu, K. W., Yin, P. H., et al. (2016). miR-151-3p targets TWIST1 to repress migration of human breast cancer cells. PLoS One, 11(12), e0168171. https://doi.org/10.1371/journal.pone.0168171.CrossRefPubMedPubMedCentral

627.

De, S., Das, S., Mukherjee, S., Das, S., & Sengupta, S. (2017). Establishment of twist-1 and TGFBR2 as direct targets of microRNA-20a in mesenchymal to epithelial transition of breast cancer cell-line MDA-MB-231. Exp Cell Res, 361(1), 85–92. https://doi.org/10.1016/j.yexcr.2017.10.005.CrossRefPubMed

628.

Tao, W., Sun, W., Zhu, H., & Zhang, J. (2018). Knockdown of long non-coding RNA TP73-AS1 suppresses triple negative breast cancer cell vasculogenic mimicry by targeting miR-490-3p/TWIST1 axis. Biochem Biophys Res Commun, 504(4), 629–634. https://doi.org/10.1016/j.bbrc.2018.08.122.CrossRefPubMed

629.

Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S., & Yang, J. (2012). Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell, 22(6), 725–736. https://doi.org/10.1016/j.ccr.2012.09.022.CrossRefPubMedPubMedCentral

630.

Drasin, D. J., Guarnieri, A. L., Neelakantan, D., Kim, J., Cabrera, J. H., Wang, C.-A., et al. (2015). TWIST1-induced miR-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. Cancer Res, 75(9), 1908. https://doi.org/10.1158/0008-5472.CAN-14-2394.CrossRefPubMedPubMedCentral

631.

Riaz, M., Sieuwerts, A. M., Look, M. P., Timmermans, M. A., Smid, M., Foekens, J. A., et al. (2012). High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes. Breast Cancer Res, 14(5), R123. https://doi.org/10.1186/bcr3317.CrossRefPubMedPubMedCentral

632.

Martin, T. A., Goyal, A., Watkins, G., & Jiang, W. G. (2005). Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol, 12(6), 488–496.PubMed

633.

Moes, M., Le Béchec, A., Crespo, I., Laurini, C., Halavatyi, A., Vetter, G., et al. (2012). A novel network integrating a miRNA-203/SNAI1 feedback loop which regulates epithelial to mesenchymal transition. PLoS One, 7(4), e35440. https://doi.org/10.1371/journal.pone.0035440.CrossRefPubMedPubMedCentral

634.

Yu, Y., Zhao, Y., Sun, X. H., Ge, J., Zhang, B., Wang, X., et al. (2015). Down-regulation of miR-129-5p via the Twist1-Snail feedback loop stimulates the epithelial-mesenchymal transition and is associated with poor prognosis in breast cancer. Oncotarget, 6(33), 34423–34436. https://doi.org/10.18632/oncotarget.5406.CrossRefPubMedPubMedCentral

635.

Phillips, S., & Kuperwasser, C. (2014). SLUG: critical regulator of epithelial cell identity in breast development and cancer. Cell Adhes Migr, 8(6), 578–587. https://doi.org/10.4161/19336918.2014.972740.CrossRef

636.

Martinez-Estrada, O. M., Culleres, A., Soriano, F. X., Peinado, H., Bolos, V., Martinez, F. O., et al. (2005). The transcription factors Slug and Snail act as repressors of Claudin-1 expression in epithelial cells. Biochem J, 394, 449–457.

637.

Dong, C., Yuan, T., Wu, Y., Wang, Y., Fan, T. W. M., Miriyala, S., et al. (2013). Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell, 23(3), 316–331.PubMedPubMedCentral

638.

Chang, C. W., Yu, J. C., Hsieh, Y. H., Yao, C. C., Chao, J. I., Chen, P. M., et al. (2016). MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer. Oncotarget, 7(13), 16462–16478. https://doi.org/10.18632/oncotarget.7656.CrossRefPubMedPubMedCentral

639.

Wu, Z., Li, X., Cai, X., Huang, C., & Zheng, M. (2016). miR-497 inhibits epithelial mesenchymal transition in breast carcinoma by targeting Slug. Tumour Biol, 37(6), 7939–7950. https://doi.org/10.1007/s13277-015-4665-7.CrossRefPubMed

640.

Liang, Y.-J., Wang, Q.-Y., Zhou, C.-X., Yin, Q.-Q., He, M., Yu, X.-T., et al. (2012). MiR-124 targets Slug to regulate epithelial–mesenchymal transition and metastasis of breast cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgs383.

641.

Ye, Y., Xiao, Y., Wang, W., Yearsley, K., Gao, J. X., & Barsky, S. H. (2008). ERalpha suppresses slug expression directly by transcriptional repression. Biochem J, 416(2), 179–187. https://doi.org/10.1042/bj20080328.CrossRefPubMed

642.

Alves, C. L., Elias, D., Lyng, M. B., Bak, M., & Ditzel, H. J. (2018). SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res, 20(1), 60. https://doi.org/10.1186/s13058-018-0988-9.CrossRefPubMedPubMedCentral

643.

Liu, T., Zhang, X., Shang, M., Zhang, Y., Xia, B., Niu, M., et al. (2013). Dysregulated expression of Slug, vimentin, and E-cadherin correlates with poor clinical outcome in patients with basal-like breast cancer. J Surg Oncol, 107(2), 188–194. https://doi.org/10.1002/jso.23240.CrossRefPubMed

644.

Rajabi, H., Jin, C., Ahmad, R., McClary, C., Joshi, M. D., & Kufe, D. (2010). MUCIN 1 oncoprotein expression is suppressed by the miR-125b oncomir. Genes Cancer, 1(1), 62–68. https://doi.org/10.1177/1947601909357933.CrossRefPubMedPubMedCentral

645.

Sachdeva, M., & Mo, Y.-Y. (2010). MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res, 70(1), 378–387. https://doi.org/10.1158/0008-5472.can-09-2021.CrossRefPubMed

646.

Ma, J., Yang, Y., Huo, D., Wang, Z., Zhai, X., Chen, J., et al. (2018). LincRNA-RoR/miR-145 promote invasion and metastasis in triple-negative breast cancer via targeting MUC1. Biochem Biophys Res Commun, 500(3), 614–620. https://doi.org/10.1016/j.bbrc.2018.04.119.CrossRefPubMed

647.

Jin, C., Rajabi, H., & Kufe, D. (2010). miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. Int J Oncol, 37(1), 61–69.PubMed

648.

Li, X. Y., Zhou, L. Y., Luo, H., Zhu, Q., Zuo, L., Liu, G. Y., et al. (2019). The long noncoding RNA MIR210HG promotes tumor metastasis by acting as a ceRNA of miR-1226-3p to regulate mucin-1c expression in invasive breast cancer. Aging (Albany NY), 11(15), 5646–5665. https://doi.org/10.18632/aging.102149.CrossRef

649.

Kufe, D. W. (2009). Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer, 9(12), 874–885. https://doi.org/10.1038/nrc2761.CrossRefPubMedPubMedCentral

650.

Kufe, D. W. (2013). MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 32(9), 1073–1081. https://doi.org/10.1023/a:1011379725811.CrossRefPubMed

651.

Hata, T., Rajabi, H., Yamamoto, M., Jin, C., Ahmad, R., Zhang, Y., et al. (2019). Targeting MUC1-C inhibits TWIST1 signaling in triple-negative breast cancer. Mol Cancer Ther, 18(10), 1744. https://doi.org/10.1158/1535-7163.MCT-19-0156.CrossRefPubMedPubMedCentral

652.

Hata, T., Rajabi, H., Takahashi, H., Yasumizu, Y., Li, W., Jin, C., et al. (2019). MUC1-C activates the NuRD complex to drive dedifferentiation of triple-negative breast cancer cells. Cancer Res, 79(22), 5711. https://doi.org/10.1158/0008-5472.CAN-19-1034.CrossRefPubMedPubMedCentral

653.

Rajabi, H., & Kufe, D. (2017). MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1868(1), 117–122. https://doi.org/10.1016/j.bbcan.2017.03.003.CrossRef

654.

Park, S.-M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev, 22(7), 894–907. https://doi.org/10.1101/gad.1640608.CrossRefPubMedPubMedCentral

655.

Deng, S., Li, X., Niu, Y., Zhu, S., Jin, Y., Deng, S., et al. (2015). MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget, 6(37), 39661–39675. https://doi.org/10.18632/oncotarget.5350.CrossRefPubMedPubMedCentral

656.

Zeng, Y., Gao, T., Huang, W., Yang, Y., Qiu, R., Hou, Y., et al. (2019). MicroRNA-455-3p mediates GATA3 tumor suppression in mammary epithelial cells by inhibiting TGF-β signaling. J Biol Chem, 294(43), 15808–15825. https://doi.org/10.1074/jbc.RA119.010800.CrossRefPubMedPubMedCentral

657.

Chen, B., Chen, B., Zhu, Z., Ye, W., Zeng, J., Liu, G., et al. (2019). Prognostic value of ZEB-1 in solid tumors: a meta-analysis. BMC Cancer, 19(1), 635. https://doi.org/10.1186/s12885-019-5830-y.CrossRefPubMedPubMedCentral

658.

Katsura, A., Tamura, Y., Hokari, S., Harada, M., Morikawa, M., Sakurai, T., et al. (2017). ZEB1-regulated inflammatory phenotype in breast cancer cells. Mol Oncol, 11(9), 1241–1262. https://doi.org/10.1002/1878-0261.12098.CrossRefPubMedPubMedCentral

659.

Soini, Y., Tuhkanen, H., Sironen, R., Virtanen, I., Kataja, V., Auvinen, P., et al. (2011). Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer, 11(1), 73. https://doi.org/10.1186/1471-2407-11-73.CrossRefPubMedPubMedCentral

660.

Alkatout, I., Wiedermann, M., Bauer, M., Wenners, A., Jonat, W., & Klapper, W. (2013). Transcription factors associated with epithelial–mesenchymal transition and cancer stem cells in the tumor centre and margin of invasive breast cancer. Exp Mol Pathol, 94(1), 168–173. https://doi.org/10.1016/j.yexmp.2012.09.003.CrossRefPubMed

661.

Jang, M. H., Kim, H. J., Kim, E. J., Chung, Y. R., & Park, S. Y. (2015). Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome. Hum Pathol, 46(9), 1267–1274. https://doi.org/10.1016/j.humpath.2015.05.010.CrossRefPubMed

662.

Brown, C. Y., Dayan, S., Wong, S. W., Kaczmarek, A., Hope, C. M., Pederson, S. M., et al. (2018). FOXP3 and miR-155 cooperate to control the invasive potential of human breast cancer cells by down regulating ZEB2 independently of ZEB1. Oncotarget, 9(45), 27708–27727. https://doi.org/10.18632/oncotarget.25523.CrossRefPubMedPubMedCentral

663.

Ji, H., Sang, M., Liu, F., Ai, N., & Geng, C. (2019). miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. Pathol Res Pract, 215(4), 697–704. https://doi.org/10.1016/j.prp.2018.12.039.CrossRefPubMed

664.

di Gennaro, A., Damiano, V., Brisotto, G., Armellin, M., Perin, T., Zucchetto, A., et al. (2018). A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ, 25(12), 2165–2180. https://doi.org/10.1038/s41418-018-0103-x.CrossRefPubMedPubMedCentral

665.

Dimitrova, Y., Gruber, A. J., Mittal, N., Ghosh, S., Dimitriades, B., Mathow, D., et al. (2017). TFAP2A is a component of the ZEB1/2 network that regulates TGFB1-induced epithelial to mesenchymal transition. Biol Direct, 12(1), 8. https://doi.org/10.1186/s13062-017-0180-7.CrossRefPubMedPubMedCentral

666.

Wang, H., An, X., Yu, H., Zhang, S., Tang, B., Zhang, X., et al. (2017). MiR-29b/TET1/ZEB2 signaling axis regulates metastatic properties and epithelial-mesenchymal transition in breast cancer cells. Oncotarget, 8(60), 102119–102133. https://doi.org/10.18632/oncotarget.22183.CrossRefPubMedPubMedCentral

667.

Georgess, D., Padmanaban, V., Sirka, O. K., Coutinho, K., Choi, A., Frid, G., et al. (2020). Twist1-induced epithelial dissemination requires Prkd1 signaling. Cancer Res, 80(2), 204–218. https://doi.org/10.1158/0008-5472.Can-18-3241.CrossRefPubMed

668.

Iorio, M. V., & Croce, C. M. (2012). microRNA involvement in human cancer. Carcinogenesis, 33(6), 1126–1133. https://doi.org/10.1093/carcin/bgs140.CrossRefPubMedPubMedCentral

669.

Stacy, A. J., Craig, M. P., Sakaram, S., & Kadakia, M. (2017). DeltaNp63alpha and microRNAs: leveraging the epithelial-mesenchymal transition. Oncotarget, 8(2), 2114–2129. https://doi.org/10.18632/oncotarget.13797.CrossRefPubMed

670.

Exposito-Villen, A., Aránega, A. E., & Franco, D. (2018). Functional role of non-coding RNAs during epithelial-to-mesenchymal transition. Noncoding RNA, 4(2), 14. https://doi.org/10.3390/ncrna4020014.CrossRefPubMedCentral

671.

LaFoya, B., Munroe, J. A., Mia, M. M., Detweiler, M. A., Crow, J. J., Wood, T., et al. (2016). Notch: a multi-functional integrating system of microenvironmental signals. Dev Biol, 418(2), 227–241. https://doi.org/10.1016/j.ydbio.2016.08.023.CrossRefPubMedPubMedCentral

672.

Kar, R., Jha, N. K., Jha, S. K., Sharma, A., Dholpuria, S., Asthana, N., et al. (2019). A “NOTCH” deeper into the epithelial-to-mesenchymal transition (EMT) program in breast cancer. Genes (Basel), 10(12), 961. https://doi.org/10.3390/genes10120961.CrossRef

673.

Zabuawala, T., Taffany, D. A., Sharma, S. M., Merchant, A., Adair, B., Srinivasan, R., et al. (2010). An Ets2-driven transcriptional program in tumor-associated macrophages promotes tumor metastasis. Cancer Res, 70(4), 1323–1333. https://doi.org/10.1158/0008-5472.Can-09-1474.CrossRefPubMedPubMedCentral

674.

Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., et al. (2015). CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene, 34(28), 3651–3661. https://doi.org/10.1038/onc.2014.294.CrossRefPubMed

675.

Mondal, T., Subhash, S., Vaid, R., Enroth, S., Uday, S., Reinius, B., et al. (2015). MEG3 long noncoding RNA regulates the TGF-beta pathway genes through formation of RNA-DNA triplex structures. Nat Commun, 6, 7743. https://doi.org/10.1038/ncomms8743.CrossRefPubMed

676.

Chang, C.-J., Yang, J.-Y., Xia, W., Chen, C.-T., Xie, X., Chao, C.-H., et al. (2011). EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell, 19(1), 86–100. https://doi.org/10.1016/j.ccr.2010.10.035.CrossRefPubMedPubMedCentral

677.

Mahara, S., Lee, P. L., Feng, M., Tergaonkar, V., Chng, W. J., & Yu, Q. (2016). HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci, 113(26), E3735–E3744. https://doi.org/10.1073/pnas.1602079113.CrossRefPubMedPubMedCentral

678.

Cirillo, L. A., & Zaret, K. S. (2007). Specific interactions of the wing domains of FOXA1 transcription factor with DNA. J Mol Biol, 366(3), 720–724. https://doi.org/10.1016/j.jmb.2006.11.087.CrossRefPubMed

679.

Yang, J., Li, T., Gao, C., Lv, X., Liu, K., Song, H., et al. (2014). FOXO1 3′UTR functions as a ceRNA in repressing the metastases of breast cancer cells via regulating miRNA activity. FEBS Lett, 588(17), 3218–3224. https://doi.org/10.1016/j.febslet.2014.07.003.CrossRefPubMed

680.

Xin, F., Li, M., Balch, C., Thomson, M., Fan, M., Liu, Y., et al. (2009). Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics, 25(4), 430–434. https://doi.org/10.1093/bioinformatics/btn646.CrossRefPubMed

681.

Johansson, P., Jeffery, J., Al-Ejeh, F., Schulz, R. B., Callen, D. F., Kumar, R., et al. (2014). SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication. J Biol Chem, 289(26), 18514–18525. https://doi.org/10.1074/jbc.M114.559930.CrossRefPubMedPubMedCentral

682.

Li, C., Du, L., Ren, Y., Liu, X., Jiao, Q., Cui, D., et al. (2019). SKP2 promotes breast cancer tumorigenesis and radiation tolerance through PDCD4 ubiquitination. J Exp Clin Cancer Res, 38(1), 76. https://doi.org/10.1186/s13046-019-1069-3.CrossRefPubMedPubMedCentral

683.

Kossatz, U., Dietrich, N., Zender, L., Buer, J., Manns, M. P., & Malek, N. P. (2004). Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. Genes Dev, 18(21), 2602–2607. https://doi.org/10.1101/gad.321004.CrossRefPubMedPubMedCentral

684.

Brandão, M., Caparica, R., Eiger, D., & de Azambuja, E. (2019). Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol, 30, x27–x42. https://doi.org/10.1093/annonc/mdz280.CrossRefPubMedPubMedCentral

685.

Clement, E., Inuzuka, H., Nihira, N. T., Wei, W., & Toker, A. (2018). Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors. Sci Signal, 11(521), eaao3810. https://doi.org/10.1126/scisignal.aao3810.CrossRefPubMedPubMedCentral

686.

Croset, M., Pantano, F., Kan, C. W. S., Bonnelye, E., Descotes, F., Alix-Panabières, C., et al. (2018). MicroRNA-30 family members inhibit breast cancer invasion, osteomimicry, and bone destruction by directly targeting multiple bone metastasis-associated genes. [10.1158/0008-5472.CAN-17-3058]. Cancer Res, 78(18), 5259–5273.PubMed

687.

Akaogi, K., Nakajima, Y., Ito, I., Kawasaki, S., Oie, S. h., Murayama, A., et al. (2009). KLF4 suppresses estrogen-dependent breast cancer growth by inhibiting the transcriptional activity of ER[alpha]. Oncogene, 28(32), 2894–2902.PubMed

688.

Quintana, A., Liu, F., O'Rourke, J., & Ness, S. (2011). Identification and regulation of c-Myb target genes in MCF-7 cells. BMC Cancer, 11(1), 30.PubMedPubMedCentral

689.

Hilakivi-Clarke, L., Wärri, A., Bouker, K. B., Zhang, X., Cook, K. L., Jin, L., et al. (2017). Effects of in utero exposure to ethinyl estradiol on tamoxifen resistance and breast cancer recurrence in a preclinical model. JNCI: Journal of the National Cancer Institute, 109(1), 1–11. https://doi.org/10.1093/jnci/djw188.CrossRef

690.

Jia, X., Shi, L., Wang, X., Luo, L., Ling, L., Yin, J., et al. (2019). KLF5 regulated lncRNA RP1 promotes the growth and metastasis of breast cancer via repressing p27kip1 translation. Cell Death Dis, 10(5), 373. https://doi.org/10.1038/s41419-019-1566-5.CrossRefPubMedPubMedCentral

691.

Vafaizadeh, V., Graab, U., Darvishi, T., Machado, R., & Groner, B. (2012). Transforming growth factor beta signaling regulates the invasiveness of normal mammary epithelial cells and the metastasis formation of tumor cells. Horm Mol Biol Clin Invest, 10(1), 227–239. https://doi.org/10.1515/hmbci-2012-0016.CrossRef

692.

Chang, C.-C., Wu, M.-J., Yang, J.-Y., Camarillo, I. G., & Chang, C.-J. (2015). Leptin–STAT3–G9a signaling promotes obesity-mediated breast cancer progression. Cancer Res, 75(11), 2375. https://doi.org/10.1158/0008-5472.CAN-14-3076.CrossRefPubMedPubMedCentral

693.

Balanis, N., & Carlin, C. R. (2017). Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer. Mol Cell Endocrinol, 451, 24–30. https://doi.org/10.1016/j.mce.2017.01.013.CrossRefPubMedPubMedCentral

694.

McDaniel, J. M., Varley, K. E., Gertz, J., Savic, D. S., Roberts, B. S., Bailey, S. K., et al. (2017). Genomic regulation of invasion by STAT3 in triple negative breast cancer. Oncotarget, 8(5), 8226–8238. https://doi.org/10.18632/oncotarget.14153.CrossRefPubMed

695.

Böhm, J., Sustmann, C., Wilhelm, C., & Kohlhase, J. (2006). SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. Biochem Biophys Res Commun, 348(3), 898–907. https://doi.org/10.1016/j.bbrc.2006.07.124.CrossRefPubMed

696.

Matsumoto, Y., Itou, J., Sato, F., & Toi, M. (2018). SALL4 - KHDRBS3 network enhances stemness by modulating CD44 splicing in basal-like breast cancer. Cancer Med, 7(2), 454–462. https://doi.org/10.1002/cam4.1296.CrossRefPubMedPubMedCentral

697.

Olmos, Y., Brosens, J. J., & Lam, E. W. F. (2011). Interplay between SIRT proteins and tumour suppressor transcription factors in chemotherapeutic resistance of cancer. Drug Resist Updat, 14(1), 35–44. https://doi.org/10.1016/j.drup.2010.12.001.CrossRefPubMed

698.

Bayele, H. K. (2019). A conserved mechanism of sirtuin signalling through steroid hormone receptors. Biosci Rep, 39(12), BSR20193535. https://doi.org/10.1042/bsr20193535.CrossRefPubMedPubMedCentral

699.

Huang, H., & Tindall, D. J. (2007). Dynamic FoxO transcription factors. J Cell Sci, 120(15), 2479–2487. https://doi.org/10.1242/jcs.001222.CrossRefPubMed

700.

Liarte, S., Alonso-Romero, J. L., & Nicolás, F. J. (2018). SIRT1 and estrogen signaling cooperation for breast cancer onset and progression. [Mini review]. Front Endocrinol, 9, 552. https://doi.org/10.3389/fendo.2018.00552.CrossRef

701.

Brooks, C. L., & Gu, W. (2009). How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer, 9(2), 123–128. https://doi.org/10.1038/nrc2562.CrossRefPubMed

702.

Ma, W., Xiao, G. G., Mao, J., Lu, Y., Song, B., Wang, L., et al. (2015). Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget, 6(12), 10432–10444

703.

Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., et al. (2001). Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev, 15(1), 50–65. https://doi.org/10.1101/gad.828901.CrossRefPubMedPubMedCentral

704.

Simic, P., Williams, E. O., Bell, E. L., Gong, J. J., Bonkowski, M., & Guarente, L. (2013). SIRT1 suppresses the epithelial-to-mesenchymal transition in cancer metastasis and organ fibrosis. Cell Rep, 3(4), 1175–1186. https://doi.org/10.1016/j.celrep.2013.03.019.CrossRefPubMed

705.

Jiang, C. G., Lv, L., Liu, F. R., Wang, Z. N., Liu, F. N., Li, Y. S., et al. (2011). Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer, 10, 122. https://doi.org/10.1186/1476-4598-10-122.CrossRefPubMedPubMedCentral

706.

Edwards, L. A., Woolard, K., Son, M. J., Li, A., Lee, J., Ene, C., et al. (2011). Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst, 103(15), 1162–1178. https://doi.org/10.1093/jnci/djr224.CrossRefPubMedPubMedCentral

707.

Chang, C. C., Shih, J. Y., Jeng, Y. M., Su, J. L., Lin, B. Z., Chen, S. T., et al. (2004). Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst, 96(5), 364–375. https://doi.org/10.1093/jnci/djh059.CrossRefPubMed

708.

de Kruijf, E. M., van Nes, J. G., van de Velde, C. J., Putter, H., Smit, V. T., Liefers, G. J., et al. (2011). Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat, 125(3), 687–696. https://doi.org/10.1007/s10549-010-0855-6.CrossRefPubMed

709.

Zhu, X., Zhong, J., Zhao, Z., Sheng, J., Wang, J., Liu, J., et al. (2015). Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition. Oncotarget, 6(28), 25320–25338. https://doi.org/10.18632/oncotarget.4659.CrossRefPubMedPubMedCentral

710.

Santolla, M. F., Lappano, R., Cirillo, F., Rigiracciolo, D. C., Sebastiani, A., Abonante, S., et al. (2018). miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. J Exp Clin Cancer Res, 37(1), 94. https://doi.org/10.1186/s13046-018-0767-6.CrossRefPubMedPubMedCentral

711.

Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., et al. (1994). p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev, 8(1), 9–22. https://doi.org/10.1101/gad.8.1.9.CrossRefPubMed

712.

Kim, G. J., Kim, D.-H., Min, K.-W., Kim, Y. H., & Oh, Y. H. (2018). Loss of p27kip1 expression is associated with poor prognosis in patients with taxane-treated breast cancer. Pathol Res Pract, 214(4), 565–571. https://doi.org/10.1016/j.prp.2018.02.004.CrossRefPubMed

713.

Berton, S., Cusan, M., Segatto, I., Citron, F., D’Andrea, S., Benevol, S., et al. (2017). Loss of p27kip1 increases genomic instability and induces radio-resistance in luminal breast cancer cells. Sci Rep, 7(1), 595. https://doi.org/10.1038/s41598-017-00734-3.CrossRefPubMedPubMedCentral

714.

Wang, D. D., Yang, S. J., Chen, X., Shen, H. Y., Luo, L. J., Zhang, X. H., et al. (2016). miR-222 induces adriamycin resistance in breast cancer through PTEN/Akt/p27(kip1) pathway. Tumour Biol, 37(11), 15315–15324. https://doi.org/10.1007/s13277-016-5341-2.CrossRefPubMed

715.

Cheng, H., Wang, S., & Feng, R. (2016). STIM1 plays an important role in TGF-beta-induced suppression of breast cancer cell proliferation. Oncotarget, 7(13), 16866–16878. https://doi.org/10.18632/oncotarget.7619.CrossRefPubMedPubMedCentral

716.

Reizner, N., Maor, S., Sarfstein, R., Abramovitch, S., Welshons, W. V., Curran, E. M., et al. (2005). The WT1 Wilms’ tumor suppressor gene product interacts with estrogen receptor-{alpha} and regulates IGF-I receptor gene transcription in breast cancer cells. J Mol Endocrinol, 35(1), 135–144.PubMed

717.

Tsai, K.-W., Leung, C.-M., Lo, Y.-H., Chen, T.-W., Chan, W.-C., Yu, S.-Y., et al. (2016). Arm selection preference of microRNA-193a varies in breast cancer. Sci Rep, 6, 28176. https://doi.org/10.1038/srep28176.CrossRefPubMedPubMedCentral

718.

Markiewicz, A., Welnicka-Jaskiewicz, M., Seroczynska, B., Skokowski, J., Majewska, H., Szade, J., et al. (2014). Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation. Am J Transl Res, 6(6), 793–808.PubMedPubMedCentral

719.

Evans, M. F., Vacek, P. M., Sprague, B. L., Stein, G. S., Stein, J. L., & Weaver, D. L. (2020). Microarray and RNA in situ hybridization assay for recurrence risk markers of breast carcinoma and ductal carcinoma in situ: Evidence supporting the use of diverse pathways panels. J Cell Biochem, 121(2), 1736–1746. https://doi.org/10.1002/jcb.29409.CrossRefPubMed

720.

Buck, M. B., & Knabbe, C. (2006). TGF-beta signaling in breast cancer. Ann N Y Acad Sci, 1089, 119–126. https://doi.org/10.1196/annals.1386.024.CrossRefPubMed

721.

Winbanks, C. E., Wang, B., Beyer, C., Koh, P., White, L., Kantharidis, P., et al. (2011). TGF-β regulates miR-206 and miR-29 to control myogenic differentiation through regulation of HDAC4. J Biol Chem, 286(16), 13805–13814. https://doi.org/10.1074/jbc.M110.192625.CrossRefPubMedPubMedCentral

722.

Wang, B., Komers, R., Carew, R., Winbanks, C. E., Xu, B., Herman-Edelstein, M., et al. (2012). Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol, 23(2), 252–265. https://doi.org/10.1681/asn.2011010055.CrossRefPubMedPubMedCentral

723.

Wang, Y., Liu, J., Chen, J., Feng, T., & Guo, Q. (2015). MiR-29 mediates TGFbeta 1-induced extracellular matrix synthesis through activation of Wnt/beta-catenin pathway in human pulmonary fibroblasts. Technol Health Care, 23(Suppl 1), S119–S125. https://doi.org/10.3233/thc-150943.CrossRefPubMed

724.

Zanetti, A., Affatato, R., Centritto, F., Fratelli, M., Kurosaki, M., Barzago, M. M., et al. (2015). All-trans-retinoic acid modulates the plasticity and inhibits the motility of breast cancer cells: role of NOTCH1 and transforming growth factor (TGFβ). J Biol Chem, 290(29), 17690–17709. https://doi.org/10.1074/jbc.M115.638510.CrossRefPubMedPubMedCentral

725.

Balamurugan, K., Mendoza-Villanueva, D., Sharan, S., Summers, G. H., Dobrolecki, L. E., Lewis, M. T., et al. (2018). C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes. Oncogene, 38(20), 3765–3780. https://doi.org/10.1038/s41388-018-0516-5.CrossRefPubMedPubMedCentral

726.

Guarnieri, A. L., Towers, C. G., Drasin, D. J., Oliphant, M. U. J., Andrysik, Z., Hotz, T. J., et al. (2018). The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene, 37(28), 3879–3893. https://doi.org/10.1038/s41388-018-0239-7.CrossRefPubMedPubMedCentral

727.

Carson, D. D. (2008). The cytoplasmic tail of MUC1: a very busy place. Sci Signal, 1(27), pe35. https://doi.org/10.1126/scisignal.127pe35.CrossRefPubMed

728.

Gendler, S. J. (2001). MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia, 6(3), 339–353.PubMed

729.

Panchamoorthy, G., Jin, C., Raina, D., Bharti, A., Yamamoto, M., Adeebge, D., et al. (2018). Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight, 3(12), e99880. https://doi.org/10.1172/jci.insight.99880.CrossRefPubMedCentral

730.

Ahmad, R., Raina, D., Joshi, M. D., Kawano, T., Ren, J., Kharbanda, S., et al. (2009). MUC1-C oncoprotein functions as a direct activator of the nuclear factor-{kappa}B p65 transcription factor. Cancer Res, 69(17), 7013–7021. https://doi.org/10.1158/0008-5472.can-09-0523.CrossRefPubMedPubMedCentral

731.

Rajabi, H., Alam, M., Takahashi, H., Kharbanda, A., Guha, M., Ahmad, R., et al. (2014). MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition. [Original article]. Oncogene, 33(13), 1680–1689. https://doi.org/10.1038/onc.2013.114.CrossRefPubMed

732.

Alam, M., Ahmad, R., Rajabi, H., Kharbanda, A., & Kufe, D. (2013). MUC1-C oncoprotein activates ERK→C/EBPβ signaling and induction of aldehyde dehydrogenase 1A1 in breast cancer cells. J Biol Chem, 288, 30892–30903. https://doi.org/10.1074/jbc.M113.477158.CrossRefPubMedPubMedCentral

733.

Wei, X., Xu, H., & Kufe, D. (2006). MUC1 oncoprotein stabilizes and activates estrogen receptor [alpha]. Mol Cell, 21(2), 295–305. https://doi.org/10.1016/j.molcel.2005.11.030.CrossRefPubMed

734.

Rajabi, H., Hiraki, M., Tagde, A., Alam, M., Bouillez, A., Christensen, C. L., et al. (2017). MUC1-C activates EZH2 expression and function in human cancer cells. Sci Rep, 7(1), 7481. https://doi.org/10.1038/s41598-017-07850-0.CrossRefPubMedPubMedCentral

735.

Derynck, R., & Zhang, Y. E. (2003). Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature, 425(6958), 577–584. https://doi.org/10.1038/nature02006.CrossRefPubMed

736.

Gulei, D., Mehterov, N., Ling, H., Stanta, G., Braicu, C., & Berindan-Neagoe, I. (2017). The “good-cop bad-cop” TGF-beta role in breast cancer modulated by non-coding RNAs. Biochim Biophys Acta Gen Subj, 1861(7), 1661–1675. https://doi.org/10.1016/j.bbagen.2017.04.007.CrossRefPubMed

737.

Dumont, N., & Arteaga, C. L. (2003). Targeting the TGFβ signaling network in human neoplasia. Cancer Cell, 3(6), 531–536. https://doi.org/10.1016/S1535-6108(03)00135-1.CrossRefPubMed

738.

Wang, J., Liang, S., & Duan, X. (2019). Molecular mechanism of miR-153 inhibiting migration, invasion and epithelial-mesenchymal transition of breast cancer by regulating transforming growth factor beta (TGF-β) signaling pathway. J Cell Biochem, 120(6), 9539–9546. https://doi.org/10.1002/jcb.28230.CrossRefPubMed

739.

Keklikoglou, I., Koerner, C., Schmidt, C., Zhang, J. D., Heckmann, D., Shavinskaya, A., et al. (2012). MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways. Oncogene, 31(37), 4150–4163. https://doi.org/10.1038/onc.2011.571.CrossRefPubMed

740.

Heldin, C.-H., Vanlandewijck, M., & Moustakas, A. (2012). Regulation of EMT by TGFβ in cancer. FEBS Lett, 586(14), 1959–1970. https://doi.org/10.1016/j.febslet.2012.02.037.CrossRefPubMed

741.

Hao, Y., Baker, D., & ten Dijke, P. (2019). TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci, 20(11), 2767. https://doi.org/10.3390/ijms20112767.CrossRefPubMedCentral

742.

Yu, Y., Luo, W., Yang, Z.-J., Chi, J.-R., Li, Y.-R., Ding, Y., et al. (2018). miR-190 suppresses breast cancer metastasis by regulation of TGF-β-induced epithelial–mesenchymal transition. Mol Cancer, 17(1), 70. https://doi.org/10.1186/s12943-018-0818-9.CrossRefPubMedPubMedCentral

743.

Thuault, S., Valcourt, U., Petersen, M., Manfioletti, G., Heldin, C.-H., & Moustakas, A. (2006). Transforming growth factor-β employs HMGA2 to elicit epithelial–mesenchymal transition. J Cell Biol, 174(2), 175–183. https://doi.org/10.1083/jcb.200512110.CrossRefPubMedPubMedCentral

744.

Hinz, N., & Jücker, M. (2019). Distinct functions of AKT isoforms in breast cancer: a comprehensive review. Cell Commun Sign, 17(1), 154. https://doi.org/10.1186/s12964-019-0450-3.CrossRef

745.

Zeltz, C., Primac, I., Erusappan, P., Alam, J., Noel, A., & Gullberg, D. (2019). Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins. Semin Cancer Biol, in press, corrected proof. https://doi.org/10.1016/j.semcancer.2019.08.004.

746.

Jiang, Y., Zhao, X., Xiao, Q., Liu, Q., Ding, K., Yu, F., et al. (2014). Snail and Slug mediate tamoxifen resistance in breast cancer cells through activation of EGFR-ERK independent of epithelial-mesenchymal transition. J Mol Cell Biol, 6(4), 352–354. https://doi.org/10.1093/jmcb/mju019.CrossRefPubMed

747.

Manavalan, T. T., Teng, Y., Appana, S. N., Datta, S., Kalbfleisch, T. S., Li, Y., et al. (2011). Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett, 313(1), 26–43. https://doi.org/10.1016/j.canlet.2011.08.018.CrossRefPubMedPubMedCentral

748.

Park, S. M., Gaur, A. B., Lengyel, E., & Peter, M. E. (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. Genes Dev, 22(7), 894–907. https://doi.org/10.1101/gad.1640608.CrossRefPubMedPubMedCentral

749.

Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020). Epigenetic polypharmacology: a new frontier for epi-drug discovery. Med Res Rev, 40(1), 190–244. https://doi.org/10.1002/med.21600.CrossRefPubMed

750.

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. CA Cancer J Clin, 69(1), 7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Springer Medizin

Regulation of breast cancer metastasis signaling by miRNAs

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

RNA-biology ruling cancer progression? Focus on 3′UTRs and splicing

CDK7 inhibitors as anticancer drugs

Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis

Wnts and the hallmarks of cancer